

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934
(Amendment No. 20)

China Cord Blood Corporation

(Name of Issuer)

Ordinary Shares, par value \$0.0001 per share
(Title of Class of Securities)

G21107100

(CUSIP Number)

Yuen Kam
48th Floor, Bank of China Tower
1 Garden Road, Central
Hong Kong S.A.R.
(852) 3605-8180

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

With a copy to:

Paul Strecker, Esq.
Shearman & Sterling
12th Floor, Gloucester Tower
The Landmark
15 Queen's Road Central
Hong Kong
(852) 2978 8000

January 6, 2016

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box o.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. G21107100

13D/A

1	Name of Reporting Persons Golden Meditech Stem Cells (BVI) Company Limited
2	Check the Appropriate Box if a Member of a Group (a) <input type="radio"/> (b) <input checked="" type="radio"/>
3	SEC Use Only
4	Source of Funds (See Instructions) OO

5	Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) <input type="radio"/>	
6	Citizenship or Place of Organization British Virgin Islands	
Number of Shares Beneficially Owned by Each Reporting Person With	7	Sole Voting Power 78,874,106
	8	Shared Voting Power 0
	9	Sole Dispositive Power 78,874,106
	10	Shared Dispositive Power 0
11	Aggregate Amount Beneficially Owned by Each Reporting Person 78,874,106	
12	Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) <input type="radio"/>	
13	Percent of Class Represented by Amount in Row (11) 65.4%	
14	Type of Reporting Person (See Instructions) CO	

2

CUSIP No. G21107100	13D/A	
---------------------	-------	--

1	Name of Reporting Persons Golden Meditech Holdings Limited	
2	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="radio"/> (b) <input checked="" type="checkbox"/>	
3	SEC Use Only	
4	Source of Funds (See Instructions) OO	
5	Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) <input type="radio"/>	
6	Citizenship or Place of Organization Cayman Islands	
Number of Shares Beneficially Owned by Each Reporting Person With	7	Sole Voting Power 78,874,106
	8	Shared Voting Power 0
	9	Sole Dispositive Power 78,874,106
	10	Shared Dispositive Power 0
11	Aggregate Amount Beneficially Owned by Each Reporting Person 78,874,106	
12	Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) <input type="radio"/>	

13	Percent of Class Represented by Amount in Row (11) 65.4%
14	Type of Reporting Person (See Instructions) CO

3

CUSIP No. G21107100	13D/A	
---------------------	-------	--

1	Name of Reporting Persons Excellent China Healthcare Investment Limited		
2	Check the Appropriate Box if a Member of a Group (a) <input type="radio"/> (b) <input checked="" type="radio"/>		
3	SEC Use Only		
4	Source of Funds (See Instructions) OO		
5	Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) <input type="radio"/>		
6	Citizenship or Place of Organization Cayman Islands		
Number of Shares Beneficially Owned by Each Reporting Person With	7	Sole Voting Power 0	
	8	Shared Voting Power 0	
	9	Sole Dispositive Power 0	
	10	Shared Dispositive Power 0	
11	Aggregate Amount Beneficially Owned by Each Reporting Person 0		
12	Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) <input type="radio"/>		
13	Percent of Class Represented by Amount in Row (11) 0.00%		
14	Type of Reporting Person (See Instructions) CO		

4

CUSIP No. G21107100	13D/A	
---------------------	-------	--

1	Name of Reporting Persons Magnum Opus 2 International Holdings Limited		
2	Check the Appropriate Box if a Member of a Group (a) <input type="radio"/>		

	(b) <input checked="" type="checkbox"/> x	
3	SEC Use Only	
4	Source of Funds (See Instructions) OO	
5	Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) <input type="checkbox"/> o	
6	Citizenship or Place of Organization British Virgin Islands	
Number of Shares Beneficially Owned by Each Reporting Person With	7	Sole Voting Power 0
	8	Shared Voting Power 0
	9	Sole Dispositive Power 0
	10	Shared Dispositive Power 0
11	Aggregate Amount Beneficially Owned by Each Reporting Person 0	
12	Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) <input type="checkbox"/> o	
13	Percent of Class Represented by Amount in Row (11) 0.00%	
14	Type of Reporting Person (See Instructions) CO	

5

CUSIP No. G21107100	13D/A
---------------------	-------

1	Name of Reporting Persons Bio Garden Inc.	
2	Check the Appropriate Box if a Member of a Group (a) <input type="checkbox"/> o (b) <input checked="" type="checkbox"/> x	
3	SEC Use Only	
4	Source of Funds (See Instructions) OO	
5	Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) <input type="checkbox"/> o	
6	Citizenship or Place of Organization British Virgin Islands	
Number of Shares Beneficially Owned by Each Reporting Person With	7	Sole Voting Power 0
	8	Shared Voting Power 29,736,465
	9	Sole Dispositive Power 0

	10	Shared Dispositive Power 29,736,465
11	Aggregate Amount Beneficially Owned by Each Reporting Person 29,736,465	
12	Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) <input type="radio"/>	
13	Percent of Class Represented by Amount in Row (11) 24.7%	
14	Type of Reporting Person (See Instructions) CO	

6

CUSIP No. G21107100	13D/A
---------------------	-------

1	Name of Reporting Persons Yuen Kam	
2	Check the Appropriate Box if a Member of a Group (a) <input type="radio"/> (b) <input checked="" type="checkbox"/>	
3	SEC Use Only	
4	Source of Funds (See Instructions) OO	
5	Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) <input type="radio"/>	
6	Citizenship or Place of Organization Hong Kong S.A.R.	
Number of Shares Beneficially Owned by Each Reporting Person With	7	Sole Voting Power 0
	8	Shared Voting Power 29,772,843
	9	Sole Dispositive Power 0
	10	Shared Dispositive Power 29,772,843
11	Aggregate Amount Beneficially Owned by Each Reporting Person 29,772,843	
12	Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) <input type="radio"/>	
13	Percent of Class Represented by Amount in Row (11) 24.7%	
14	Type of Reporting Person (See Instructions) IN	

7

This Amendment No. 20 amends and supplements the statement on Schedule 13D jointly filed with the Securities and Exchange Commission on July 9, 2009 by GM Stem Cells and Golden Meditech, as previously amended and supplemented by amendments to Schedule 13D filed on June 23, 2011, September 30, 2011, April 12, 2012, May 2, 2012, October 4, 2012, July 11, 2013, August 25, 2014, April 27, 2015, May 4, 2015, May 8, 2015, July 27, 2015, August 6, 2015, August 26, 2015, October 26, 2015, November 3, 2015, November 5, 2015, November 13, 2015, November 30, 2015 and December 7, 2015 (as so amended, the “Original Schedule 13D”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Original Schedule 13D.

Item 3. Source and Amount of Funds or Other Consideration.

Item 3 of the Original Schedule 13D is hereby amended and supplemented by adding the following at the end thereof:

As of January 4, 2016, Golden Meditech completed the purchases of the ECHIL Notes, the Magnum Note and the Kam Sale Shares. In addition, as of January 4, 2016, Golden Meditech transferred (a) the ECHIL Notes, (b) the Magnum-GM Note, (c) the Kam Sale Shares, (d) the CGL-GM Note, and (e) 7,314,015 Ordinary Shares held by Golden Meditech to GM Stem Cells. As a result of such transfers, GM Stem Cells became the beneficial owner of an aggregate of 78,874,106 Ordinary Shares, comprising (i) 38,352,612 Ordinary Shares directly held by GM Stem Cells, (ii) 22,903,454 Ordinary Shares issuable upon conversion in full of the ECHIL Notes, (iii) 8,809,020 Ordinary Shares issuable upon conversion in full of the Magnum-GM Note, and (iv) 8,809,020 Ordinary Shares issuable upon conversion in full of the CGL-GM Note (collectively, the “GM Shares”), representing in the aggregate approximately 65.4% of the outstanding Ordinary Shares of the Company on a fully diluted basis.

On January 6, 2016, Golden Meditech (as the guarantor), GM Stem Cells (as the seller) and Nanjing Xinjiekou Department Store Co., Ltd. (“Nanjing Xinjiekou”) entered into an agreement to purchase assets by share issuance and cash payment (the “GM Sale Agreement”), pursuant to which GM Stem Cells agreed to sell to Nanjing Xinjiekou and Nanjing Xinjiekou agreed to acquire from GM Stem Cells (a) the GM Shares or (b) such number of Ordinary Shares held by GM Stem Cells in the Company as the surviving company after the completion of the Acquisition (as defined below) equivalent to the number of GM Shares (each of (a) or (b), the “GM Sale Shares”). The “Acquisition” refers to the proposed acquisition by GM Stem Cells of the outstanding Ordinary Shares not currently owned by GM Stem Cells pursuant to a merger of the Company with a wholly-owned subsidiary of GM Stem Cells, resulting in a delisting of the Company from the New York Stock Exchange.

Pursuant to the GM Sale Agreement, the purchase price for the GM Sale Shares will be RMB5,764 million, of which RMB2,500 million will be settled by the allotment and issuance of ordinary shares of Nanjing Xinjiekou to GM Stem Cells, and the remaining RMB3,264 million will be settled by Nanjing Xinjiekou in cash through the payment in U.S. Dollars of US\$504.8 million to GM Stem Cells.

The GM Sale Agreement will come into effect upon the satisfaction of certain conditions specified therein, including but not limited to the following: (a) Nanjing Xinjiekou, Golden Meditech and GM Stem Cells having obtained the appropriate corporate approvals to proceed with the sale and purchase of the GM Sale Shares; (b) the sale and purchase of the GM Sale Shares having been approved by the relevant regulatory authorities, including the Ministry of Commerce of the PRC and the China Securities Regulatory Commission; and (c) GM Stem Cells and Golden Meditech having obtained consents or waivers from certain third parties with respect to the execution and performance of the GM Sale Agreement.

The completion of the sale and purchase of the GM Sale Shares is conditional upon, among other things, (a) for a period commencing from September 30, 2015 and ending on the date the sale and purchase of the GM Sale Shares is completed (the “First Completion Date”), the Company and Nanjing Xinjiekou having conducted their respective businesses normally, and there being no material adverse change to the legal person status, shareholding structure, financial status or substantial assets of the Company or Nanjing Xinjiekou, respectively; (b) Nanjing Xinjiekou having maintained its listing status on the Shanghai Stock Exchange; (c) the Profit Compensation Agreement (as defined below) having been executed by GM Stem Cells and Nanjing Xinjiekou; (d) Nanjing Xinjiekou having agreed, for a period commencing from the First Completion Date and ending on December 31, 2018, not to (x) change the number or composition of the key management members, scope of principal business, development plan, operating strategy, investment plan or business model of the Company or (y) unreasonably interfere with the daily operation of the Company; and (e) the First Share Charge (as defined below) having been executed by Nanjing Xinjiekou and GM Stem Cells.

The GM Sale Agreement may be terminated by either GM Stem Cells or Nanjing Xinjiekou unilaterally in the circumstances specified therein, including in the event of any material breach of the GM Sale Agreement by Nanjing Xinjiekou or GM Stem Cells or the failure by Nanjing Xinjiekou or GM Stem Cells to satisfy the applicable conditions precedent by December 31, 2016. Upon such termination, the non-defaulting party shall be entitled to receive a termination fee of US\$30 million from the defaulting party; provided, however, in the event that the sale and purchase of the GM Sale Shares has not been approved by the relevant regulatory authorities or the shareholders of Golden Meditech or Nanjing Xinjiekou, the non-defaulting party will not be entitled to such a termination fee.

In connection with the GM Sale Agreement, on January 6, 2016, GM Stem Cells and Nanjing Xinjiekou also entered into a profit compensation agreement (the “Profit Compensation Agreement”), pursuant to which GM Stem Cells agreed to provide certain undertakings to Nanjing Xinjiekou with respect to the financial performance of the Company for each of the calendar year ending 31 December 2016, 2017 and 2018 (the “Guaranteed Period”), and to provide compensation to Nanjing Xinjiekou under certain circumstances in the event that the Company does not meet the net profit targets specified in the Profit Compensation Agreement during the Guaranteed Period.

In connection with the GM Sale Agreement, Nanjing Xinjiekou also agreed to execute a share charge (the “First Share Charge”) with GM Stem Cells, pursuant to which Nanjing Xinjiekou will, upon acquiring ownership of the GM Sale Shares, grant a charge over the GM Sale Shares in favor of GM Stem Cells to secure (a) all the present and future payment obligations of Nanjing Xinjiekou to GM Stem Cells under the GM Sale Agreement and (b) all the present and future payment and other obligations of Nanjing Xinjiekou under the First Share Charge.

Concurrently with the execution of the GM Sale Agreement, Golden Meditech (as the guarantor), GM Stem Cells (as the seller) and Nanjing Xinjiekou also entered into a share sale and purchase agreement (the “Minority Share Sale Agreement”), pursuant to which GM Stem Cells agreed to sell to Nanjing Xinjiekou and Nanjing Xinjiekou agreed to acquire from GM Stem Cells, 41,730,636 Ordinary Shares to be issued to GM Stem Cells by the Company as the surviving company after the completion of the Acquisition (the “Minority Sale Shares”). Pursuant to the Minority Share Sale Agreement, the purchase price for the Minority Sale Shares will be US\$267,076,070, which will be settled by Nanjing Xinjiekou in cash paid to GM Stem Cells.

The Minority Share Sale Agreement will come into effect upon the satisfaction of certain conditions specified therein, including but not limited to the following: (a) Nanjing Xinjiakou, Golden Meditech and GM Stem Cells having obtained the appropriate corporate approvals to proceed with the sale and purchase of the Minority Sale Shares; (b) the sale and purchase of the Minority Sale Shares having been approved by the relevant regulatory authorities; (c) GM Stem Cells and Golden Meditech having obtained consents or waivers from certain third parties with respect to the execution and performance of the Minority Share Sale Agreement; (d) the GM Sale Agreement having come into effect; and (e) the Acquisition having been completed and GM Stem Cells having acquired ownership of the Minority Sale Shares.

The completion of the sale and purchase of the Minority Sale Shares is conditional upon, among other things, (a) for a period commencing from the date of the Minority Share Sale Agreement and ending on the date the sale and purchase of the Minority Sale Shares is completed, the Company and Nanjing Xinjiakou having conducted their respective businesses normally, and there being no material adverse change to the legal person status, shareholding structure, financial status or substantial assets of the Company or Nanjing Xinjiakou, respectively; (b) Nanjing Xinjiakou having maintained its listing status on the Shanghai Stock Exchange, and (c) the Second Share Charge (as defined below) having been executed by Nanjing Xinjiakou and GM Stem Cells.

The Minority Share Sale Agreement may be terminated by either GM Stem Cells or Nanjing Xinjiakou unilaterally in the circumstances specified therein, including any material breach of the Minority Share Sale Agreement by Nanjing Xinjiakou or GM Stem Cells or the failure by Nanjing Xinjiakou or GM Stem Cells to satisfy the applicable conditions precedent by December 31, 2016. Upon such termination, the non-defaulting party shall be entitled to receive a termination fee of US\$30 million from the defaulting party; provided, however, in the event that the sale and purchase of the Minority Sale Shares has not been approved by the relevant regulatory authorities or the shareholders of Golden Meditech or Nanjing Xinjiakou, or the Acquisition has not been approved by the special committee of the board of directors of the Company or the relevant regulatory authorities, or the Acquisition has not otherwise been consummated and GM Stem Cells has not acquired ownership of the Minority Sale Shares, the non-defaulting party will not be entitled to such a termination fee.

In connection with the Minority Share Sale Agreement, Nanjing Xinjiakou also agreed to execute a share charge (the “Second Share Charge”) with GM Stem Cells, pursuant to which Nanjing Xinjiakou will, upon acquiring ownership of the Minority Sale Shares, grant a charge over the Minority Sale Shares in favor of GM Stem Cells to secure (a) all the present and future payment obligations of Nanjing Xinjiakou to GM Stem Cells under the Minority Share Sale Agreement and (b) all the present and future payment and other obligations of Nanjing Xinjiakou under the Second Share Charge.

The description of the GM Sale Agreement, the Minority Share Sale Agreement and the Profit Compensation Agreement in this Item 3 is qualified in its entirety by reference to the complete text of the English translations of such documents, copies of which are attached hereto as exhibits 31, 32 and 33, respectively, and are incorporated by reference in their entirety into this Item 3. The description of the First Share Charge and Second Share Charge in this Item 3 is also qualified in its entirety by reference to the complete text of such documents, copies of which are attached hereto as exhibits 34 and 35 and are incorporated by reference in their entirety into this Item 3.

Item 4. Purpose of Transaction.

Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following at the end thereof:

The description of the GM Sale Agreement, the Minority Share Sale Agreement, the Profit Compensation Agreement, the First Share Charge and the Second Share Charge in Item 3 is incorporated herein by reference in its entirety.

Item 5. Interest in Securities of the Issuer.

Item 5 of the Original Schedule 13D is hereby amended and restated in its entirety to read as follows:

(a) — (b) The following table sets forth the beneficial ownership of Ordinary Shares of the Company for each of the Reporting Persons as of the date of this Amendment No. 20.

Name	Shares Beneficially Owned	Percentage of Total ⁽¹⁾	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power
GM Stem Cells ⁽²⁾	78,874,106	65.4%	78,874,106	—	78,874,106	—
Golden Meditech ⁽³⁾	78,874,106	65.4%	78,874,106	—	78,874,106	—
ECHIL	—	—	—	—	—	—
MO2	—	—	—	—	—	—
Bio Garden ⁽⁴⁾	29,736,465	24.7%	—	29,736,465	—	29,736,465
Mr. Kam ⁽⁵⁾	29,772,843	24.7%	—	29,772,843	—	29,772,843

(1) As disclosed in the Form 20-F of the Company filed with the SEC on July 31, 2015, the Company had 80,083,248 Ordinary Shares outstanding as of March 31, 2015.

(2) Includes (i) 38,352,612 Ordinary Shares held by GM Stem Cells, (ii) 22,903,454 Ordinary Shares issuable upon conversion in full of the ECHIL Notes, (iii) 8,809,020 Ordinary Shares issuable upon conversion in full of the Magnum-GM Note, and (iii) 8,809,020 Ordinary Shares issuable upon conversion in full of the CGL-GM Note.

(3) Includes 78,874,106 Ordinary Shares held by GM Stem Cells.

(4) Includes 29,736,465 of the 78,874,106 Ordinary Shares beneficially owned by Golden Meditech. Bio Garden beneficially owns 37.701175% of the ordinary shares of Golden Meditech.

(5) Includes 29,772,843 of the 78,874,106 Ordinary Shares beneficially owned by Golden Meditech. Mr. Kam beneficially owns 37.747296% of the ordinary shares of Golden Meditech assuming the exercise of vested share options held by Mr. Kam to purchase additional ordinary shares of Golden Meditech.

Mr. Kam Yu Kong currently owns 282,193 Ordinary Shares and Ms. Ting Zheng currently owns 1,071,994 Ordinary Shares.

Due to the nature of the transactions described in this Schedule 13D, the Reporting Persons may be deemed to be part of a "group" (within the meaning of Section 13(d)(3) of the Exchange Act) with each other. Except as disclosed in this Schedule 13D, each Reporting Person hereby expressly disclaims beneficial ownership of any Ordinary Shares beneficially owned by any of the other Reporting Persons or any other person, and does not affirm membership in a "group" (within the meaning of Rule 13(d)-5 of the Exchange Act) with any of the other Reporting Persons or any other person.

The description of the GM Sale Agreement, the Minority Share Sale Agreement, the Profit Guarantee Agreement, the First Share Charge and the Second Share Charge in Item 3 is incorporated herein by reference in its entirety.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

Item 6 of the Original Schedule 13D is hereby amended and supplemented by adding the following at the end thereof:

The description of the GM Sale Agreement, the Minority Share Sale Agreement, the Profit Compensation Agreement, the First Share Charge and the Second Share Charge in Item 3 is incorporated herein by reference in its entirety.

11

Item 7. Material to be Filed as Exhibits.

Item 7 of the Original Schedule 13D is hereby amended and supplemented by adding the following at the end thereof:

The following documents are filed as exhibits:

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 31	Agreement to Purchase Assets by Share Issuance and Cash Payment, dated as of January 6, 2016, by and among Nanjing Xinjiekou, GM Stem Cells and Golden Meditech
Exhibit 32	Share Sale and Purchase Agreement, dated as of January 6, 2016, by and among Nanjing Xinjiekou, GM Stem Cells and Golden Meditech
Exhibit 33	Profit Compensation Agreement, dated as of January 6, 2016, by and between Nanjing Xinjiekou and GM Stem Cells
Exhibit 34	Form of Share Charge, to be entered into by Nanjing Xinjiekou in favor of GM Stem Cells
Exhibit 35	Form of Share Charge, to be entered into by Nanjing Xinjiekou in favor of GM Stem Cells

12

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: January 7, 2016

GOLDEN MEDITECH STEM CELLS (BVI) COMPANY LIMITED

By: /s/ Yuen Kam
Name: Yuen Kam
Title: Director

GOLDEN MEDITECH HOLDINGS LIMITED

By: /s/ Yuen Kam
Name: Yuen Kam
Title: Chairman and Chief Executive Officer

BIO GARDEN INC.

By: /s/ Yuen Kam
Name: Yuen Kam
Title: Director

EXCELLENT CHINA HEALTHCARE INVESTMENT LIMITED

By: /s/ Yuen Kam
Name: Yuen Kam
Title: Director

MAGNUM OPUS 2 INTERNATIONAL HOLDINGS LIMITED

By: /s/ Yuen Kam
Name: Yuen Kam
Title: Director

YUEN KAM

/s/ Yuen Kam

Confidential

English Translation of Chinese Original

Agreement to Purchase Assets by Share Issuance and Cash Payment

In relation to

Nanjing Xinjiekou Department Store Co., Ltd.

By and among

Nanjing Xinjiekou Department Store Co., Ltd.

Golden Meditech Stem Cells (BVI) Company Limited

and

Golden Meditech Holdings Limited

January 2016

Confidential

Table of Contents

ARTICLE 1	DEFINITIONS	2
ARTICLE 2	TRANSACTION ARRANGEMENTS	7
ARTICLE 3	CLOSING CONDITIONS	10
ARTICLE 4	REPRESENTATIONS AND WARRANTIES	15
ARTICLE 5	FURTHER COVENANTS	28
ARTICLE 6	CONFIDENTIALITY	33
ARTICLE 7	EFFECTIVENESS AND TERMINATION	34
ARTICLE 8	LIABILITY FOR BREACH AND INDEMNIFICATION	37
ARTICLE 9	CLOSING SECURITY, REMEDIES AND GUARANTEE	39
ARTICLE 10	FORCE MAJEURE	41
ARTICLE 11	GOVERNING LAW AND DISPUTE RESOLUTION	42
ARTICLE 12	NOTICE AND DELIVERY	42
ARTICLE 13	MISCELLANEOUS	43

Confidential

Agreement to Purchase Assets by Share Issuance and Cash Payment

This Agreement to Purchase Assets by Share Issuance and Cash Payment (this “*Agreement*”) is made on the sixth day of January 2016 by and among:

- (1) **Nanjing Xinjiekou Department Store Co., Ltd.**, a joint stock company established and validly existing under the laws of the PRC (the “*Purchaser*” or “*XJK*”);
- (2) **Golden Meditech Stem Cells (BVI) Company Limited**, a limited liability company established and validly existing under the laws of the British Virgin Islands (the “*Seller*”); and

- (3) **Golden Meditech Holdings Limited**, a limited liability company established and validly existing under the laws of the Cayman Islands, and the sole shareholder of the Seller (the “**Guarantor**”).

The parties hereto each individually a “**Party**” or such “**Party**”, and collectively the “**Parties**”; and with respect to each other a “**Party**” or the other “**Party**”.

Whereas,

- (A) The Purchaser is a joint stock company duly established and legally existing, with its RMB-denominated ordinary shares being publicly listed on the Shanghai Stock Exchange under the stock code of 600682, and as of the date of this Agreement, the Purchaser has a registered capital of RMB828,016,327, consisting of 828,016,327 RMB-denominated ordinary shares issued and outstanding;
- (B) China Cord Blood Corporation (the “**Target Company**”) is a limited liability company incorporated in the Cayman Islands and listed on the New York Stock Exchange of the United States of America, being dedicated to the storage of umbilical cord blood stem cells. As of the date of this Agreement, the issued and outstanding share capital of the Target Company consists of 80,083,248 ordinary shares. Upon full conversion of all the Golden Meditech CBs (as defined below) into Target Company ordinary shares, the Target Company will by then have 120,604,742 ordinary shares issued and outstanding;
- (C) As of the date of this Agreement, the Seller owns 38,352,612 Target Company ordinary shares, the CGL-GM CBs (as defined below) that are convertible into 8,809,020 Target Company ordinary shares, the Magnum CBs (as defined below) that are convertible into 8,809,020 Target Company ordinary shares, and the ECHIL CBs (as defined below) that are convertible into 22,903,454 Target Company ordinary shares;
- (D) Upon conversion of all of the Golden Meditech CBs as described above into the Target Company ordinary shares, the Seller will own in aggregate 78,874,106 Target Company ordinary shares, accounting for approximately 65.4% of the issued and outstanding share capital of the Target Company assuming that all the

Confidential

convertible bonds issued by the Target Company have been converted into ordinary shares (the “**Golden Meditech Shares**”);

- (E) As of the date of this Agreement, the Seller and its affiliates are working towards the execution of the “**Merger Agreement**” (as defined below) with the Target Company in relation to the Going-private (as defined below) of the Target Company for the acquisition from the other shareholders of the Target Company of all of the Target Company shares that are not owned by Golden Meditech;
- (F) The Purchaser desires to issue shares and pay a certain amount of cash to the Seller to acquire from the Seller the Golden Meditech Shares held by the Seller.

NOW, THEREFORE, the Parties hereby enter into this Agreement for mutual observance after friendly consultations by adhering to the principle of equality, mutual benefit, integrity and good faith.

Article 1 Definitions

1.1 Unless otherwise specified herein, the following terms shall have the meanings as set forth below:

“**Proposed Transaction**” means the proposed transaction through which the Purchaser shall acquire from the Seller the Golden Meditech Shares (as defined in the recitals) held by the Seller by issuing the Consideration Shares (as defined below) and paying the Cash Consideration (as defined below) in accordance with this Agreement.

“**Target Assets**” means the Golden Meditech Shares, or the Golden Meditech Rollover Shares (as defined below) to be held by the Seller upon consummation of the Going-private.

“**Purchase Price**” or “**Transaction Consideration**” or “**Target Assets Purchase Price**” means the price payable by the Purchaser to the Seller in order to acquire the Target Assets, which shall have a value to be determined in accordance with Section 2.2 and be in the form of a combination of the Consideration Shares to be issued in the Proposed Issuance and the Cash Consideration.

“**Proposed Issuance**” means the proposed issuance by XJK of the Consideration Shares (as defined below) to the Seller through a private placement as part of the consideration for XJK’s acquisition of the Target Assets in accordance with the terms and subject to the conditions set forth in this Agreement.

“**CGL-GM CBs**” means the convertible bonds issued by the Target Company on October 3, 2012, which has a principal amount of US\$25 million, and are convertible into the Target Company ordinary shares at a price of US\$2.838 per share at any time during the five years after the issuance thereof, upon full conversion of which, 8,809,020 Target Company ordinary shares will be issued.

Confidential

“**Long Form Merger**” means a process in which the Seller will establish the Merger Sub under the laws of the Cayman Islands and the Merger Sub will be merged with and into the Target Company by a reverse merger. As a result of such merger, the Merger Sub will be merged into the Target Company, and the Target Company will survive as a wholly-owned subsidiary of the Seller.

“**COM**” means COM COMPANY LIMITED, i.e., the Merger Sub to be established as part of the Going-private (as defined below).

“**ECHIL CBs**” means the convertible bonds issued by the Target Company on April 27, 2012, which has a principal amount of US\$65 million, and are convertible into the Target Company ordinary shares at a price of US\$2.838 per share at any time during the five years after the issuance thereof, upon full conversion of which, 22,903,454 Target Company ordinary shares will be issued.

“**Rollover**” means the process under which, as part of the Going-private, in lieu of any cash consideration that would otherwise be payable to the Seller in consideration of cancellation of the Golden Meditech Shares, the Seller shall roll over the Golden Meditech Shares held by it into the ordinary shares in the Target Company surviving the Long Form Merger on a one-for-one basis in accordance with a method permitted under the laws of the Cayman Islands.

“**HKSFC**” means the Securities and Futures Commission of Hong Kong.

“**HKEx**” means the Stock Exchange of Hong Kong Limited.

“**Company Law**” means the Company Law of the People’s Republic of China.

“**Business Day**” means a day on which banks are generally open for regular banking business in the PRC and the Hong Kong Special Administrative Region, other than Saturdays, Sundays or statutory holidays.

“**Share Registry**” means China Securities Depository & Clearing Corp. Ltd. Shanghai Branch.

“**Affiliate**” means, with respect to a particular natural person, any of the spouse, children, parents, grandparents, grandparents in law, grandchildren, grandchildren in law, siblings, and the spouses thereof, the siblings of the spouse and other close relatives of such natural person; and with respect to a particular entity, any other entity that controls, or is controlled by or is under common control with such entity, whether directly or indirectly.

“**Transitional Period**” means the period from the Reference Date (as defined below) to the Asset Closing Date (as defined below).

“**Merger Agreement**” means the Merger Agreement to be entered into by and among the Seller, certain Affiliates of the Seller, and the Target Company after the date hereof where such parties have reached agreement on the Going-private by then, as

Confidential

amended from time to time after execution thereof.

“**Golden Meditech Rollover Shares**” means upon consummation of the Going-private, the ordinary shares to be held by the Seller in the Target Company surviving the Long Form Merger which shall be rolled over from the Golden Meditech Shares held by the Seller on a one-for-one basis.

“**Golden Meditech CBs**” means collectively the CGL-GM CBs, the ECHIL CBs and the Magnum CBs.

“**Trading Day**” means any day on which shares are tradable on the Shanghai Stock Exchange.

“**Magnum CBs**” means the convertible bonds issued by the Target Company on October 3, 2012, which has a principal amount of US\$25 million, and are convertible into the Target Company ordinary shares at a price of US\$2.838 per share at any time during the five years after the issuance thereof, upon full conversion of which, 8,809,020 Target Company ordinary shares will be issued.

“**Consideration Shares**” means the ordinary shares with a par value of RMB1.00 (A Shares) that will be issued through a private placement by XJK to the Seller for the purpose of the Proposed Transaction as part of the Target Assets Purchase Price, the actual number of which shall be determined in accordance with Section 2.3 herein below.

“**Issuing Price**” means the price per Consideration Share at which XJK will issue to the Seller the Consideration Shares, and which shall be equal to an amount to be determined in accordance with Section 2.3 herein below.

“**Target Company Minority Interest**” means all the Target Company ordinary shares issued and outstanding other than the Golden Meditech Shares, which in aggregate account for 34.6% of the aggregate number of the Target Company shares (taking into account any ordinary shares converted from the convertible bonds) as calculated on a fully-diluted basis and will be cancelled against receipt of the Going-private cash consideration upon consummation of the Going-private.

“**Consideration Shares Registration Date**” means the date on which the Consideration Shares are issued and delivered by the Purchaser to the Seller and are registered with the competent securities registration and clearing authority.

“**NYSE**” means the New York Stock Exchange.

“**Reference Date**” means September 30, 2015.

“**Encumbrance**” means any security interest, pledge, mortgages lien, charge, encumbrance, adverse claim, preferential arrangement, option, right of first refusal, attachment, freezing, entrusted management, or restriction of any kind.

“**Person**” or “**Persons**” shall include any natural person, legal person, enterprise, association of natural persons or enterprises, or group of any of the foregoing.

“**day**” means a calendar day, unless otherwise specified herein to be a Business Day.

“**SSE**” means the Shanghai Stock Exchange.

“**Applicable Law**” means, with respect to a particular Person, any published, valid and applicable law, treaty, regulation, inter-governmental agreement, decision, order, local regulation, regulation on the exercise of autonomy and regulation on the exercise of separate autonomy, rule and local government rule, listing rule of any stock exchange, any rule formulated by any competent regulatory authority, and other code in any other form with a legally binding force, whether of the PRC or any other jurisdiction, which in each case is applicable to such Person or binding upon such Person or any of his/her assets.

“**Taxes**” means any and all mandatory taxes, assessments, duties, fees, or levies of any form or any kind (together with any and all penalties, fines, surcharges or interest imposed with respect thereto) imposed by any central, local or municipal Governmental Authority or organization or institution of the PRC or Hong Kong or any other jurisdiction, and shall include income taxes, business taxes, resource taxes, value-added taxes, stamp duties, tariffs and any other charges.

“**Going-private**” means the process through which the Seller shall take the Target Company private and have the Target Company delisted from NYSE by means of the Long Form Merger, pursuant to which, the Target Company shall survive, the Golden Meditech Shares owned by the Seller shall be cancelled in exchange for the Golden Meditech Rollover Shares, and the Seller shall pay the owners of the Target Company Minority Interest cash consideration in consideration of the cancellation of the Target Company Minority Interest and at the same time receive certain equity interest to be newly issued by the Target Company of an amount equal to the Target Company Minority Interest, upon consummation of which, the Seller will own 100% of the equity interest in the Target Company.

“**Damages**” means any losses, expenses (including reasonable investigation expenses and reasonable attorney fees), damages or harm, or claims against any Person, including without limitation, any liabilities for indemnification determined by any judgment, decision or settlement.

“**Lockup**” or “**Share Lockup**” means the share lockup undertaking made by the Seller in accordance with Applicable Laws, as described in further detail in Section 5.5.

“**Cash Consideration**” the cash amount to be paid by the Purchaser to the Seller as part of the Target Assets Purchase Price for the purpose of the Proposed Transaction, the actual amount of which shall be determined in accordance with Section 2.3.

“**RMB**” means, for the purpose of this Agreement, Renminbi Yuan, the lawful

currency of the PRC, unless otherwise indicated.

“**Securities Law**” means the Securities Law of the People’s Republic of China.

“**Governmental Authority**” means any legislative, administrative, judicial, regulatory or governmental authority, agency, commission, or securities regulatory authority, including any stock exchange, whether in China or any other jurisdiction.

“**China**” or “**PRC**” means the People’s Republic of China, which for the purpose of this Agreement, shall exclude the Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan.

“**MOFCOM**” means the Ministry of Commerce of the People’s Republic of China.

“**CSRC**” means the China Securities Regulatory Commission.

“**Asset Closing Date**” means the date on which the sale and purchase of the Target Assets takes place, or in other words, date on which the Target Assets are transferred to XJK and the registration of such transfer is completed in accordance with the procedures required by Applicable Laws.

“**Seller’s Closing Conditions**” means all the conditions set forth in Section 3.2.

“**Purchaser’s Closing Conditions**” means all the conditions set forth in Section 3.3.

“**Net Profit**” has the same meaning ascribed to it in the Profit Compensation Agreement.

“**Non-recurring Loss/Gain**” has the same meaning ascribed to it in the Profit Compensation Agreement.

1.2 Interpretation

Unless otherwise specified herein, this Agreement shall be interpreted as follows:

- (1) Any reference to any law or regulation in this Agreement shall include a reference to any and all of the laws and regulations as amended or reenacted, that are applicable, published, and publicly available, or revised (whether prior to or after the date hereof) in accordance with any

other law or regulation of the PRC.

- (2) Any reference to any chapter, article, section, item, exhibit or annex shall be a reference to the corresponding chapter, article, section, item, exhibit or annex in or to this Agreement.
- (3) The headings used in this Agreement are for convenience only, and shall not affect the interpretation of this Agreement.

Confidential

- (4) Any annex referred to herein or attached hereto shall constitute an integral part of this Agreement, and shall have the equal legal effect as this Agreement.
- (5) The word “written” or “writing” means any communication transmitted by letter, email or fax.
- (6) The word “including” used herein shall be interpreted to be “including without limitation”.
- (7) Any Party hereto shall include any of its successors and permitted assigns.
- (8) Where the date on which any action, matter or issue shall be taken, done or handled under this Agreement is not a Business Day, such action, matter or issue shall be taken, done or handled on the Business Day immediately following such date.

Article 2 Transaction Arrangements

2.1 Target Assets

The basic information of the Target Assets and the capitalization structure of the Target Company are as set forth in Exhibit 1 hereto.

2.2 Basis for Purchase Price Determination and Purchase Price

After consultations on the principle of equality, the Parties have agreed and determined that the aggregate Purchase Price of the Target Assets shall be RMB5,764 million.

2.3 Purchase Price and Payment

- 2.3.1 The Parties agree that in consideration of the Purchaser’s acquisition of the Target Assets, the Purchaser shall pay the Seller the Purchase Price in the form of a combination of the Consideration Shares to be issued and cash. The Consideration Shares to be issued under the Proposed Issuance shall be RMB-denominated ordinary shares to be listed on the PRC domestic market (A Shares), with a par value of RMB1.00 per share. The share pricing base date for the Proposed Issuance shall be the date on which the public announcement of the board resolutions (adopted at the 36th meeting of the seventh board) of the Purchaser approving the Proposed Issuance is made. The board of directors of the Purchaser has determined that the Issuing Price of the shares to be issued under the Proposed Issuance shall be RMB18.61/share, being no less than 90% of the average trading price of the Purchaser’s shares during the 120 Trading Days prior to the share pricing base date for the Proposed Issuance. In case of any distribution of dividend in cash or shares, grant of shares converted from capital reserve or any other similar ex-rights or ex-dividend event with respect to shares of the Purchaser between the share pricing base date and the issuing date of the Proposed Issuance,

Confidential

the Issuing Price shall be adjusted accordingly in compliance with the applicable SSE rules. The shares to be issued under the Proposed Issuance will be listed on SSE, and become tradable on SSE upon expiration of the applicable Lockup period in accordance with the applicable rules of CSRC, MOFCOM and SSE.

The Parties agree that the Target Assets Purchase Price determined under Section 2.3.1 shall be paid by using a combination of the Consideration Shares and the Cash Consideration as follows:

- (a) The Purchaser will issue to the Seller the Consideration Shares in satisfaction of the payment of a portion of the Purchase Price equal to RMB2,500 million, accounting for approximately 43.37% of the Purchase Price. If calculated on the assumptions that the Issuing Price of the Consideration Shares is RMB18.61/per share, the number of the Consideration Shares to be issued by the Purchaser to the Seller shall be 134,336,378 shares; and
- (b) The Purchaser shall pay the Seller a cash amount equal to RMB3,264 million, accounting for approximately 56.63% of the Purchase Price.

The Parties agree that the Cash Consideration hereunder shall be converted to US dollar equivalent at the exchange rate of US\$1 against RMB6.466 and then paid to the Seller in US dollar. The Cash Consideration payable by the Purchaser to the Seller shall be equal to US\$504.8 million.

- 2.3.2 The Parties acknowledge that the consummation of the Going-private currently conducted by the Seller shall not be a condition precedent to the Proposed Transaction, and they do not exclude the possibility that on the Asset Closing Date the Going-private will have been

consummated and the Purchaser will actually obtain the Golden Meditech Rollover Shares.

- 2.3.3 In the event that any of CSRC, MOFCOM, SSE, HKEx or any other competent regulatory authority imposes any other requirement on the scheme of the Proposed Transaction, the Parties mutually agree that they will make reasonable efforts to modify the Proposed Transaction, including without limitation, the number of the Consideration Shares, and extension of the Share Lockup period, to accommodate such other regulatory requirements; provided however that, each Party shall have the right to terminate this Agreement unilaterally by written notice, where within 20 Business Days as of the date on which any of the regulatory authorities as mentioned above raises such requirement for modification, the Parties fail to reach agreement on the scheme so modified as required by such other regulatory requirement.
- 2.3.4 It is acknowledged that the Seller and the Guarantor shall agree that subject to further agreement among the Parties by then, they will further execute relevant statements and undertakings, and enter into supplementary agreements to specify any matters not covered hereunder in satisfaction of

Confidential

PRC or foreign regulatory requirements.

2.4 Closing

- 2.4.1 Subject to the taking effect of this Agreement in accordance with Section 7.2 and the continuous satisfaction or waiver of each of the Purchaser's Closing Conditions and the Seller's Closing Conditions, the Asset Closing Date shall fall on a date within 20 Business Days as of the fulfillment or waiver in accordance with Article 3 of each and all of the closing conditions set forth under Article 3 (including the Seller's Closing Conditions and the Purchaser's Closing Conditions), or on any other date as otherwise mutually agreed among the Parties.
- 2.4.2 On the Asset Closing Date, the Seller shall register the Target Assets under the name of the Purchaser in accordance with the procedures required by Applicable Laws, and deliver to the Purchaser the following documents:
- (a) The Target Company shall deliver to the Purchaser a copy of its register of members signed for acknowledgement by one director of the Target Company evidencing that the Purchaser has been effectively registered on its shareholder register as owner of the Target Assets, and a copy of a share certificate signed for acknowledgement by one director of the Target Company evidencing that the Purchaser owns the Target Assets;
 - (b) In the event that the Going-private has been consummated by then, the Seller shall or shall cause the Target Company to, deliver to the Purchaser a copy of the Memorandum and Articles of Association of the Target Company adopted immediately after consummation of the Going-private (the "**Post-Going-Private M&A**") and the shareholder resolution of the Target Company approving the Post-Going-Private M&A;
 - (c) In the event that the Going-private has been completed by then, directors of the Target Company nominated by the Seller shall have delivered to the Purchaser letters of resignation to resign from their position as directors of the Target Company, effective immediately as of the Purchaser's full and complete performance of its obligation to pay the Purchase Price; and the shareholder meeting of the Target Company shall have approved that the director candidates nominated by the Purchaser shall be elected as directors of the Target Company and constitute all the directors of the board of the Target Company, the appointment of which directors so elected shall take effect immediately as of the Purchaser's full and complete performance of its obligation to pay the Purchase Price.

For the avoidance of doubt, Section 2.4.2 shall not limit in any way any other agreement among the Parties.

Confidential

- 2.4.3 As of the Asset Closing Date, the Purchaser shall own the Target Assets, and legally own the rights and assume the obligations attached to the Target Assets in proportion to its equity interest in the Target Company.
- 2.4.4 The Purchaser shall complete the payment of the Cash Consideration to the Seller within 40 Trading Days as of the Asset Closing Date or within five Business Days as of the date on which the Purchaser's relevant acquisition financing is consummated, whichever falls earlier. The Parties acknowledge that the Purchaser's relevant acquisition financing arrangement shall not be a condition to the closing or effectiveness of the Proposed Transaction, and the completeness of or the actual amount of the proceeds financed through the relevant acquisition financing shall not have any effect on the Proposed Transaction or the Purchaser's obligation to pay the Cash Consideration under the Proposed Transaction.
- 2.4.5 As required by the procedures related to the Proposed Transaction, unless otherwise agreed among the Parties, in order for the completion of the procedures necessary for the registration of the Consideration Shares, the Seller shall deliver to the Purchaser within 10 Business Days as of the Asset Closing Date the original of the share certificate evidencing that the Purchaser owns the Target Assets.
- 2.4.6 No later than 10 Business Days as of the Asset Closing Date and subject to the Seller's performance of its obligation to render assistance to the Purchaser by delivering to the Purchaser the original of the share certificate of the Target Assets in accordance with Section 2.4.5, the Purchaser shall complete all the procedures required by the Proposed Issuance, including without limitation, engaging an accounting firm to conduct a capital verification and issue the corresponding capital verification report, going through the information disclosure procedures, completing the procedures with SSE and the Share Registry necessary for the issuance, registration and listing of the Consideration Shares,

and registering the Consideration Shares of an agreed number and with the agreed value under the name of the Seller, free from encumbrance or any other restriction on title, so as to complete the closing with respect to the Consideration Shares.

Article 3 Closing Conditions

3.1 Closing Conditions

The closing under this Agreement shall be subject to (a) the satisfaction or waiver of each of the Purchaser's Closing Conditions and the Seller's Closing Conditions on or prior to December 31, 2016 or any other date otherwise agreed in writing among the Parties (the "**Closing Condition Fulfillment Deadline**"), and (b) the fulfillment of each of the conditions to effectiveness of this Agreement set forth in Section 7.2 hereof.

10

Confidential

3.2 Purchaser's Closing Conditions

- 3.2.1 Each of the Seller and the Guarantor shall have disclosed fully and completely to the Purchaser the information relating to the assets, liabilities, interests, security interest provided to third parties, and status of the equity interest of the Target Company which may have a material effect on the Proposed Transaction;
- 3.2.2 Except as disclosed publicly or disclosed to the Purchaser by using an information disclosure letter which refers specifically to Section 3.2.2 or waived by the Purchaser, within the Transitional Period, the Target Company shall have conducted its business normally, no material adverse change shall have occurred to the legal person status, capitalization structure, financial status or substantial assets of the Target Company, and the Target Company shall not have committed any material violation of law or regulation, other than any material adverse change and/or material violation of law or regulation arising from any litigation resulting from and/or any restructuring or recapitalization related to the Going-private;
- 3.2.3 Except as disclosed to or waived by the Purchaser, within the Transitional Period, the Target Company shall not have disposed of its substantial assets or created any security interest or any other encumbrance on its substantial assets, or incurred or assumed any material indebtedness, unless as confirmed by all the Parties as necessary for its ordinary course of business and does not subject the Target Company to any material indebtedness;
- 3.2.4 On the Asset Closing Date, all the representations and warranties made by each of the Seller and the Guarantor hereunder are true, accurate, and complete, free from false records, misleading representations or material omissions;
- 3.2.5 Each of the Seller and the Guarantor shall have performed and complied with in material aspects all the undertakings that are required hereunder to be performed or complied with on or prior to the Asset Closing Date;
- 3.2.6 The Seller shall have entered into with the Purchaser certain Profit Compensation Agreement;
- 3.2.7 The Seller and the Guarantor shall deliver to the Purchaser an undertaking to be issued by the key management team members of the Target Company worded to the effect that (x) the clause in any labor contract of the Target Company regarding the payment of severance pay upon termination of any employee is terminated thereby, and each employee involved therein shall issue an undertaking that he/she shall not bring any dispute or claim against the Target Company by virtue of such clause, and (y) the Seller and the Guarantor shall deliver to the Purchaser the supplementary labor contracts executed by and between the Target Company and its key management team members in form and substance satisfactory to each Party.

11

Confidential

3.3 Seller's Closing Conditions

- 3.3.1 Except as disclosed publicly or disclosed to the Seller by using an information disclosure letter which refers specifically to Section 3.3.1 and waived by the Seller, within the Transitional Period, the Purchaser shall have conducted its business normally, no material adverse change shall have occurred to the legal person status, capitalization structure, financial status or substantial assets of the Purchaser, and the Purchaser shall not have committed any material violation of law or regulation;
- 3.3.2 On the Asset Closing Date, all the representations and warranties made by the Purchaser hereunder are true, accurate, and complete, free from false records, misleading representations or material omissions;
- 3.3.3 The Purchaser shall have performed and complied with in material aspects all the undertakings that are required hereunder to be performed or complied with on or prior to the Asset Closing Date;
- 3.3.4 The Purchaser shall maintain its status as a listed company on SSE, and there shall not exist any circumstances which by common business or legal sense are reasonably expected to result in the Purchaser's loss of the status as a listed company on SSE;
- 3.3.5 As of the date by which any and all of the other Seller's Closing Conditions set forth in Section 3.3 have been satisfied or waived, as long as the Purchaser or any of its directors, senior officers, employees or advisors has not received any oral and/or written decision from CSRC or any other competent regulatory authority ordering a suspension, halt or termination of the Proposed Issuance or revoking any document approving the Proposed Issuance, or any decision by any competent securities registration and clearing authority that it will not register or

will revoke the registration of the Proposed Issuance, or any other administrative decision revoking the approval to the Proposed Transaction, or ordering a termination or revocation of the Proposed Transaction, it shall be deemed that the Seller's Closing Conditions have been satisfied;

- 3.3.6 The board of directors of the Purchaser has validly adopted resolutions, based on which, the Purchaser shall have issued to the Target Company and the Seller an irrevocable confirmation with a term of effectiveness from the Asset Closing Date to the end of fiscal year 2018 worded to the effect that, from the Asset Closing Date to the end of fiscal year 2018, as long as the key management team members of the Target Company as identified on the name list agreed by and between the Seller and the Purchaser normally perform their duties, the Purchaser shall not, whether by exercising its right as shareholder of the Target Company or causing the members of the board of the Target Company appointed by it, and shall have the obligation to procure that the members of the board of the Target Company appointed by

Confidential

it will not, change the number and composition of the key management team members, scope of principal business, any development plan, any operating strategy, any investment plan or business model of the Target Company, nor shall it unreasonably disrupt the daily normal operation of the Target Company. The Purchaser shall, by taking advantage of its shareholder's rights and through the members of the board of directors of the Target Company nominated by it (and the Purchaser shall be obligated to ensure that such directors nominated by it shall) adequately ensure the key management team members of the Target Company shall have the power to decide on (and adjust from time to time) the scope of business, development plans, business strategies and business models in compliance with laws and regulations and based on the internal and external business environment faced by the Target Company from time to time ("Business Decision-Making Power"), and the Purchaser shall not interfere in any manner in the exercise of such Business Decision-making Power;

- 3.3.7 The Target Assets Reverse Pledge Agreement in the form of Annex 1 hereto, together with all the appendices thereto, shall have been executed by the Purchaser and delivered to the Seller.

3.4 Responsibility for Fulfillment of Closing Conditions

- 3.4.1 Each of the Seller and the Guarantor shall make commercially reasonable efforts to maintain or fulfill the conditions set forth in Section 3.2.
- 3.4.2 The Purchaser shall make commercially reasonable efforts to maintain or fulfill the conditions set forth in Section 3.3.
- 3.4.3 For the avoidance of doubt, the Purchaser shall notify both the Seller and the Guarantor in writing, together with all the relevant materials (if any) for the Seller and the Guarantor to do verification, as promptly as practicable on the date immediately following the date on which the Purchaser, including its directors, senior officers, employees or advisers, is aware of the occurrence of any of the events described in Section 3.3.5.

3.5 Other Conditions Imposed by Governmental Authorities

Where in the course of seeking approvals from applicable Governmental Authorities as set forth under Section 7.2, any competent Governmental Authority demands any change to any term of this Agreement or any addition of any term or condition to this Agreement or imposes any additional condition on any Party which has a material adverse effect on the interest of such Party, the Parties shall as soon as practicable and in principle no later than 10 Business Days following the occurrence of such event, have discussions and enter into renegotiations in good faith on the relevant terms and conditions with a view to achieving the commercial objectives originally contemplated by the Parties to the extent permitted by Applicable Laws; provided however that, where the Parties fail to reach agreement on any amendment to this Agreement or to any term or condition of this Agreement within 20 Business

Confidential

Days as of the date on which such competent Governmental Authority makes such demand or any other period mutually agreed among the Parties, any Party shall within 10 Business Days as of expiration of the aforementioned period, have the right to unilaterally terminate this Agreement by written notice.

3.6 Waiver of Closing Conditions

- 3.6.1 On or prior to the Asset Closing Date and no later than December 31, 2016, by giving written notice to the Seller, the Purchaser may waive conditionally or unconditionally, any or all of the conditions set forth in Section 3.2. In the event that the Purchaser gives a written notice that all or any of the conditions set forth in Section 3.2 have or has been fulfilled or waived, such written notice or waiver shall not operate as the Purchaser's nonreliance upon the representations and warranties made by the Seller or release the Seller from any obligation required to be performed by the Seller on or prior to the Asset Closing Date and no later than December 31, 2016, instead, it shall represent only that the Purchaser will proceed with the closing of the transactions under this Agreement in reliance on such representations, warranties and status of the performance of such obligation, and that the Purchaser will reserve its right to hold the Seller liable for the relevant default in accordance with this Agreement.

- 3.6.2 On or prior to the Asset Closing Date and no later than December 31, 2016, by giving written notice to the Purchaser, the Seller and the Guarantor may waive conditionally or unconditionally, any or all of the conditions set forth in Section 3.3. In the event that the Seller and the Guarantor give a written notice that all or any of the conditions set forth in Section 3.3 have or has been fulfilled or waived, such written notice or waiver shall not operate as the nonreliance by the Seller or the Guarantor upon the representations and warranties made by the Purchaser or release the Purchaser from any obligation required to be performed by the Purchaser on or prior to the Asset Closing Date and

no later than December 31, 2016, instead, it shall represent only that the Seller and the Guarantor will proceed with the closing under this Agreement in reliance on such representations, warranties and status of the performance of such obligation, and that each of the Seller and the Guarantor will reserve its right to hold the Purchaser liable for the relevant default in accordance with this Agreement.

3.7 Delay in Fulfillment of the Closing Conditions

- 3.7.1 In the event that any of the Purchaser's Closing Conditions fails to be fully fulfilled and satisfied and the Purchaser has indicated expressly that it will not waive any of such Purchaser's Closing Conditions that fails to be satisfied, the Purchaser shall have the right to terminate this Agreement, in which case, Section 7.5.2 shall apply.
- 3.7.2 In the event that any of the Seller's Closing Conditions fails to be fully fulfilled and satisfied and the Seller has indicated expressly that it will not

14

Confidential

waive any of such Seller's Closing Conditions that fails to be satisfied, the Seller shall have the right to terminate this Agreement, in which case, Section 7.5.1 shall apply.

Article 4 Representations and Warranties

4.1 Common Representations and Warranties

Each Party hereby represents to the other Parties that:

- 4.1.1 It is a company or enterprise duly organized, validly existing and in good standing under the laws of the jurisdiction of its establishment and has full civil rights and civil capacity to independently carry out its obligations to any other parties;
- 4.1.2 It has all the necessary power, authority and approval under Applicable Law to enter into this Agreement and to perform each of its obligations under this agreement. For the avoidance of doubt, each of those stated in Section 7.2 (as applicable) shall be excluded;
- 4.1.3 It has taken all appropriate and necessary corporate actions to authorize the execution and delivery of this Agreement and any other documents hereunder to which it is a party, and has authorized to perform and comply with the terms and conditions set forth in this Agreement and such other documents. For the avoidance of doubt, each of those stated in Section 7.2 (as applicable) shall be excluded;
- 4.1.4 The person acting on behalf of it to enter into this Agreement and any other documents hereunder to which it is a party has been granted irrevocable, legal and full authorization to enter into on its behalf and bound by this Agreement and such other documents; and it shall not defend itself against any other Parties by reason of lack of power of attorney, exceeding the scope of power of attorney or any other defects in the authorization;
- 4.1.5 Its execution of this Agreement and any other documents hereunder to which it is a party does not and will not violate (a) any of its organizational documents, (b) any contracts, agreements, permits or any other instruments to which it is a party or by which it is bound, or (b) any orders, effective judgments, arbitral awards, judicial rulings, administrative decisions, policies, regulations, orders or rules applicable to it. For the avoidance of doubt, each of those stated in Section 7.2 (as applicable) shall be excluded; and
- 4.1.6 There are no actions, arbitrations or any other legal or administrative proceedings or governmental investigations pending against it, which would have a substantial effect on its execution of or ability to perform this Agreement, and to its knowledge, there are no such actions, arbitrations or any other legal or administrative proceedings or governmental investigations

15

Confidential

threatened by any Governmental Authority or other third parties against it for its execution or performance of this Agreement.

4.2 Representation and Warranties of the Seller and the Guarantor

The Seller and the Guarantor hereby jointly and severally represent and warrant to the Purchaser that for purpose of this Section 4.2, any and all references to the Target Company shall include all the subsidiaries subject to the merger, and the following representations and warranties shall be deemed repeated on the Asset Closing Date as if made at such time. As of the date hereof and the Asset Closing Date, except for those disclosed by the Seller publicly or by way of an information disclosure letter as of the date of this Agreement or in this Agreement or any other transaction documents executed by the Purchaser to which it is a party, or disclosed to the Purchaser for purpose of implementation or consummation of the Going-private or the Proposed Transaction or for purpose of this Agreement, or disclosed by the Guarantor on the website of HKEx, or disclosed by the Target Company on the website of US Securities and Exchange Commission:

- 4.2.1 The Seller has legitimate and entire ownership of the Target Assets proposed to be sold, and there is no encumbrance on the Target Assets, nominee shareholding through any trust or under entrustment, or any other dispute in connection with ownership.
- 4.2.2 The Seller and the Guarantor have fully disclosed the capitalization structure of the Target Company as of the date of this Agreement and the Asset Closing Date, as set forth in Exhibit 1 hereto. As of the date of this Agreement and the Asset Closing Date, the Target Assets represent approximately 65.4% of the Target Company's share capital on a fully-diluted basis (assuming all the convertible bonds have been

converted into shares). Except as disclosed, the Target Company has no (i) shares or other voting securities, (ii) corporate securities convertible or exchangeable into shares or voting securities of the Target Company, or (iii) options, warrants, rights or any other commitments or agreements, which may result in the acquisition from or cause the Target Company to issue any shares or any other voting securities, or any corporate securities convertible or exchangeable into the shares or voting securities of the Target Company.

- 4.2.3 The Seller has provided to the Purchaser a complete list of all the subsidiaries of the Target Company and the Seller's shareholding percentage in these subsidiaries. The Target Company legally owns the entire ownership of all the subsidiaries set forth on the list, and with respect to the ownership, there is no encumbrance, nominee shareholding through any trust or under entrustment, or any other dispute in connection therewith.
- 4.2.4 Valid existence. The Target Company is duly established or incorporated in the jurisdiction where it is established or incorporated. There is no circumstance under which it may be cancelled or deregistered. The Target Company has all the necessary power, authority or qualification to

Confidential

own, lease and operate its property and assets and carry out the business it currently conducts, and its articles of association, business license and any other permits, licenses and qualifications are in full force and effect from the date of this Agreement through the Asset Closing Date.

- 4.2.5 Affiliates. Except for the related party transactions that have been disclosed, there is no significant related party transaction or arrangement between the Target Company and any of the other Affiliates that are required to be disclosed under the applicable laws, which includes without limitation, those in connections with possession of funds, financing, procurement, licensing, creditors' rights and liabilities.
- 4.2.6 Finance and Accounting
- (a) The financial statements of the Target Company shall be prepared based on the transactions or events actually incurred and are in compliance with the international Generally Accepted Accounting Principles ("GAAP"), which have fairly reflected the financial conditions, performance results and cash flows of the Target Company in all material respects. An unqualified audit report has been issued by a certified public accountant on the financial statements of the Target Company as of September 30, 2015 (the "**Financial Statements of the Target Company**").
- (b) The Target Company has established an independent financial accounting system which enables it to make financial decision independently, and has set up standard financial accounting policies and financial management policies. The Target Company has no joint bank account with its controlling shareholder, de facto controlling person and any other enterprises under its control.
- 4.2.7 No undisclosed corporate liabilities which should have been disclosed. Except for those that have been disclosed, the Target Company has no significant corporate liabilities, or existing or contingent condition which is reasonably expected to result in such other material corporate liabilities. The Target Company does not provide any guarantee to any other parties with respect to their liabilities.
- 4.2.8 No material changes. Since September 30, 2015, except for those that have been disclosed or unless otherwise agreed in this Agreement or with the written consent of the Purchaser, the Target Company has been conducting its business in the ordinary course of business consistent with the past practice and none of the following has occurred:
- (a) any matter outside the ordinary course of business resulting in material adverse effect on the assets, liabilities, financial condition, operation condition of the Target Company listed on the financial statement of the Target Company;

Confidential

- (b) any significant or contingent liabilities of the Target Company incurred outside the ordinary course of business by way of providing guarantee, indemnification or commitment etc.;
- (c) any losses having material adverse effect on the assets, financial conditions, operation conditions, business prospects and business of the Target Company;
- (d) waiving any rights with significant value to the Target Company which value amounts to over 10% of the sales revenue or the total assets of the Target Company.
- (e) waiving any creditor's rights of the Target Company or discharging any other parties' obligations, unless such waiver or discharge is necessary in the ordinary course of business and does not constitute or result in any material adverse effect;
- (f) unless required by Applicable Law or ordinary operation of business or related to any matters required for the Going-private, entering into or amending any Material Contract (as defined in Section 4.2.11 (a) below) or any other material commercial agreements, or amending or replacing its articles of association;
- (g) any material amendment of the compensation arrangements or agreements entered into with any current employees, consultants or directors;

- (h) any sale or transfer of all or substantially all the property, intangible assets or Intellectual Property of the Target Company, other than required for purpose of the Going-private;
- (i) resignation by or termination of the employment with any key employees, a list of which shall be otherwise determined by the Parties;
- (j) payment, repurchase, redemption, purchase or transfer of the shares of the Target Company, directly or indirectly, other than related to any matters required for the Going-private;
- (k) any substantial change of its scope of business or commercial plans, or failing to conduct its principal business in the ordinary course of business;
- (l) any transactions entered into by it with any shareholders, directors, supervisors, executive officers, employees or any relatives of any of the foregoing persons or any entities controlled thereby, other than related to any matters required for the Going-private;

Confidential

- (m) unless required by Applicable Law or related to any matters required for the Going-private, any amendment of its articles of association;
- (n) any increase or decrease of its registered share capital, other than related to any matters required for the Going-private;
- (o) bankruptcy, liquidation, or dissolution of the Target Company or merger with any other company, other than any reorganization related to the Going-private; or
- (p) any agreement or covenant made by the Target Company or the Seller with respect to any of the above matters.

4.2.9 Compliance of Business Operation. The Target Company has not violated or did not materially violate any Applicable Law. To the reasonable knowledge of the Seller and the Guarantor, the Target Company has been conducting its business in accordance with all the Applicable Law. During the last three calendar years prior to the execution of this Agreement, the Target Company has not committed any material violation of any mandatory provisions or prohibitions under any Applicable Law in its business operation. The Target Company has all the licenses, permits, consents and authorizations required for operating its assets and conducting its business. Such licenses, permits, consents and authorizations do not materially contravene with the mandatory provisions or prohibitions under the Applicable Law and are in full force and effect. None of such licenses, permits, consents or authorizations will be terminated or adversely affected as a result of the Proposed Transaction, and the Target Company has not received any notification, either in writing or orally, from any Governmental Authority regarding the cancelling or revoking any license, permit, consent or authorization obtained by the Target Company.

4.2.10 Administrative Penalties, Administrative Mandatory Measures and Administrative Supervision Measures. No Governmental Authorities have imposed any administrative penalties, administrative mandatory measures or administrative supervision measures that have any material adverse effect on the assets or business of the Target Company. There are no administrative penalties, administrative mandatory measures or administrative supervision measures imposed by any Governmental Authorities that (i) has or has had material adverse effect on the Target Company or its assets, (ii) may affect the validity, effectiveness or enforceability of this Agreement, or (iii) affect the consummation of the Proposed Transaction.

4.2.11 Material Contracts

- (a) Except those that have been disclosed to the Purchaser or the public, the Target Company has not entered into any other contracts or arrangements that cross the threshold of materiality (as defined below) (each contract

Confidential

crossing the threshold of materiality is referred to as a "Material Contract"). For purpose of this Section 4.2.11, if the annual turnover of the subject matters or services under any contract, agreement or arrangement or the costs of the commodities or services obtained thereunder (or the payment or liabilities in connection therewith) for the current year is equal to or exceeds RMB10,000,000, then such contract, agreement or arrangement has crossed the "threshold of materiality". Each Material Contract (i) is duly executed and binding on each party thereto and is in full force and effect, and (ii) shall remain in full force and effect after consummation of the Proposed Transaction and will not result in any penalty or other material adverse effect. The Target Company has not materially breach any Seller's Material Contract. Except for the Material Contracts that have been publicly disclosed, other true and complete copies of other Material Contracts shall have been delivered to the Purchaser or its representative prior to the date of this Agreement.

- (b) Any other parties to any Material Contract have not committed any material breach of such Material Contract. The Target Company does not receive any notice of terminating or cancelling any Target Company's Material Contract or breach of contract thereunder.
- (c) The Target Company has not entered into any contract with any abnormal terms that may have material adverse effect or impose material potential risk on the operation of the Target Company, including any abnormal assumption, limitation, exclusive, non-competition terms and any abnormal market price, joint venture and market share that may have material adverse effect or impose material potential risk on the operation of the Target Company.

4.2.12 Environment, health and safety compliance. The Target Company has obtained and maintains all the environmental, health and safety licenses and permits issued by the Governmental Authorities required for its current use, possession or operation of its business. The Target

Company has conducted its business operation in compliance with the foregoing environmental, health and safety permits, licenses and approvals in all material respects. During the last three calendar years prior to the date of this Agreement, there has not been any material administrative penalty or litigation arising out of environmental, health or safety issues within three calendar years following the date of this Agreement.

4.2.13 Intellectual Property Rights

- (a) The Target Company has used the intellectual property owned, leased or otherwise obtained by it, such as the names, domain names, trademarks, copy rights, patent rights, invention, technical data, process, know-how, drawings, design, etc. (the “**Intellectual Property**”), in compliance with the requirements of PRC law.

20

Confidential

- (b) The Seller and the Guarantor have provided the Purchaser with a complete list of the Intellectual Property owned by the Target Company. The operation of Target Company’s current principal business does not require any other Intellectual Property other than those included in such list. The Target Company has legal, valid and enforceable rights or rights to use with respect to the Intellectual Property disclosed by it, and such rights are free and clear of any encumbrances.
- (c) To the reasonable knowledge of the Seller and the Guarantor, there is no pending or potential material action, dispute, claim or demand affecting the Intellectual Property of the Target Company. None of the Seller, the Guarantor and the Target Company has received any written notice from any person challenging the rights of the Target Company to use the Intellectual Property owned, leased or otherwise obtained by the Target Company, and such right of use is not subject to any governmental orders that may affect the free use by the Target Company of each of the Seller’s Intellectual Property.
- (d) To the best knowledge of the Seller and the Guarantor, no officers, employees, or consultants of the Target Company are subject to any obligations under any agreement, contract (including any permits, covenants and undertakings of any nature) or deed or any judgment, decree or order of any court, which may affect its ability to use their best efforts to promote the interest of the Target Company, result in any conflict with the business currently or proposed to be operated by the Target Company, or prevent it from transferring to the Target Company all the Intellectual Property designed, developed or created by them in connection with their service to the Target Company. The Target Company does not need to use any invention created by its officers or employees (or any persons it currently intends to employ) prior to their employment with the Target Company or beyond the scope of service as stipulated between such officers or employees with the Target Company.

- 4.2.14 Corporate Assets. Except those that have been disclosed to the Purchaser, the Target Company has ownership or legal and valid right of use with respect to all the material assets that are currently used by it, including personal property and real property, and such assets are free and clear of any security interests or any other encumbrances. The Target Company’s rights, title or any rights or interests of any other kinds in the each material corporate asset have been disclosed to the Purchaser, which constitute all the material assets required for the normal operation of the Target Company during the past year, and such assets are currently owned, possessed or used by the Target Company. To the reasonable knowledge of the Seller and the Guarantor, there is no material dispute or claim pending or threatened that will affect the operation, use or possession of such assets by the Target Company.

21

Confidential

- 4.2.15 Insurance. The Target Company has maintained commercially reasonable insurance with respect to all the material insurable assets since the date of this Agreement, with the same coverage as those companies engaged in similar business would generally maintain. In addition, the Target Company has never been refused to be directly insured during the past three (3) years since the date of this Agreement. With respect to all such insurance:
- (a) all premiums have been paid in full in accordance with the requirements of the policies;
- (b) all the policies are valid and will not become void as a result of any action, non-action or failure to disclose by the insured; and
- (c) there are no material claims pending, unsettled or in dispute, and no circumstance or situation that may give rise to any material claims.
- 4.2.16 Employee Welfare Matters. Except the customary social security insurance, housing fund and Welfare Plan (as defined below), the Target Company has no other plans, agreements or covenants for its current or former employees in connection with the pension, severance payment, commercial insurance, housing welfare or any other employee welfare (individually or collectively “Welfare Plan”). To the reasonable knowledge of the Seller and the Guarantor, there is no material dispute or claim against the Target Company pending or threatened in respect of the social security insurance, housing fund or any Welfare Plan, or any fact that have been known which may give rise to such material dispute or claim. All amounts payable by the Target Company and its employees under the social security insurance, housing fund and each of the Seller’s Welfare Plan shall have been paid in full as of the due date. No employee of the Target Company is entitled to obtain any increase or improvement of its salary, welfare or employment terms and conditions or receive any compensation, severance payment or settlement fee from the Target Company based on his employment contract by reason of the share transfer. There is no collective labor contract between the Target Company and its labor union.

4.2.17 Labor Matters

- (a) The Target Company has fully complied with the labor laws of the place of its incorporation and any employment contract to which it is a party. There is no material or pending dispute or controversy between the Target Company and any of its employees or the labor union. No strike, slowdown, work stoppage or plant closure has occurred in the Target Company.
- (b) To the reasonable knowledge of the Seller and the Guarantor, there is no labor dispute, controversy or arbitration pending between its key employees and their former employers, and none of its key employees

Confidential

are subject to any non-compete obligation, and all such key employees work on a full time basis for the Target Company.

4.2.18 Taxes

- (a) Except for those that have been disclosed to the Purchaser, the Target Company has complied with the mandatory provisions or prohibitions under the PRC tax laws in all material respects, paid all the taxes and penalties and fines due and payable, and fully and accurately reported to the Purchaser all the tax liabilities in respect of any period (or a portion thereof) prior to the date of this Agreement.

There is no material civil, administrative or criminal responsibilities resulted from failure by the Target Company to duly make any tax payments, nor any circumstance which, to the knowledge of the Seller and the Guarantor, may give rise to any such responsibilities.

- (b) To the reasonable knowledge of the Seller and the Guarantor, the Target Company is not obligated to refund or repay any tax deductions, tax rebates, tax incentives or any other subsidies in connection with the Target Company, its assets or business that has or will be granted, offered or paid by any Governmental Authority.

4.2.19 Improper Payment

- (a) None of the Seller, the Guarantor or the Target Company has paid or caused any other person to pay or give anything of significant value to or enter into any transaction with any Governmental Authority, governmental officials or officers of any enterprises, for purpose of influencing such persons in official positions in order to obtain or retain business or transfer any business to the Target Company or any other person, except for those that the Seller, the Guarantor or the Target Company is not aware of.
- (b) Throughout the negotiation and execution of this Agreement, to the knowledge of the Seller and the Guarantor, neither the Seller nor its Affiliates, including the directors, officers, business personnel, representatives and intermediaries (the “**Project Representatives**”) have provided any commercial bribery to the Purchaser’s project representatives by any way or by any reason in the form of cash, anything of value, consumption or otherwise. For purpose of this Section 4.2.19, any benefit such as work meal, accommodation, transportation or any gift with insignificant value publicly provided by the Seller to the project representatives of the Purchaser based on business reception etiquette and for purpose of completion of the share transfer contemplated under this Agreement, shall not be deemed commercial bribery.

Confidential

4.2.20 Non-competition. None of the Seller, the Guarantor, any key members of the management (to the best knowledge of the Seller and the Guarantor), or their respective Affiliates have, at any time, directly or indirectly,

- (a) engaged in any activities that are the same or similar as or directly or indirectly compete with the business of the Target Company (“**Competing Business**”) or invested in any company engaged in the Competing Business (whether by equity investments or contractual arrangements), other than purchasing or holding any tradable securities or warrants of any company listed in any securities market (excluding over-the-counter market), but excluding any acquisition by which they may obtain the power to affect the decision making of such listed company;
- (b) solicited or encouraged any employees of the Target Company to accept their or their Affiliates’ or any other third party’s offer for employment or recruited any employees of the Target Company by any other means; or
- (c) provided any advices, assistances or funding with respect to any Competing Business.

4.2.21 Litigations; Claims. Except for those that have been disclosed or frequently incurred as the result of the customary commercial or legal practices of the jurisdiction where the Target Company is listed or registered, there is no potential litigation, arbitration, mediation, administrative or criminal proceeding to which the Target Company is the plaintiff, defendant, appellant, respondent, claimant or otherwise that is ongoing or reasonably expected to happen, which may have material adverse effect on the continuous operation of the Target Company. To the reasonable knowledge of the Seller and the Guarantor, they are not aware of any matter which may give rise to any litigation, arbitration, mediation, administrative or criminal proceeding against its directors, supervisors, senior management or the Seller that may have material adverse effect on the continuous operation of the Target Company. There is no event that may result in any challenge or objection brought by any third party against this Agreement or the Proposed Transaction, invalidity of this Agreement or the Proposed Transaction or any material adverse effect on or change of control of the Target Company, or any other event that may affect the consummation of the Proposed Transaction by the Purchaser. There is no litigation, arbitration or administrative investigation proceeding against the Target Company or any Seller alleging that it has violated any securities laws and regulations, anti-corruption, anti-bribery, antitrust laws or any other Applicable Law that may have material adverse effect on the Target Company.

4.2.22 No Proceedings or Litigations. To the reasonable knowledge of the Seller and the Guarantor, there is no investigation, penalty, mandatory measure or supervision measure initiated by any Governmental Authority or

24

Confidential

non-Governmental Authority against the Seller, the Guarantor or the Target Company for enjoining or materially changing the Proposed Transaction.

- 4.2.23 No Related-party Transaction or Affiliation. Except those that have been disclosed, there is neither affiliation nor any related-party transaction of any form between the Seller, the Guarantor or their respective Affiliates, on the one hand, and the Purchaser or its controlled subsidiaries, on the other hand. For the avoidance of doubt, any affiliation that is expected to be formed within the next 12 months in accordance with Applicable Law (including without limitation, CSRC and SSE listing rules) shall be excluded.
- 4.2.24 Insider Trading. Without the prejudice of any other provisions hereunder, none of the Seller, the Guarantor and their controlling shareholders, de facto controlling persons and their respective Affiliates, and the directors and the executive officers of the Seller or the Guarantor, have disclosed any inside information obtained in the Proposed Transaction to any other person in any manner or take advantage of the inside information to gain any illegal interests. The Seller and the Guarantor further undertakes that they will cause their respective Affiliates, directors and executive officers not to disclose in any manner any inside information related to the Proposed Transaction prior to the announcement of such inside information, or take advantage of the inside information to gain any illegal interests directly or indirectly in any manner. The Seller and the Guarantor further represent and warrant that:
- (a) there is no administrative or criminal investigation due to any alleged insider trading in connection with the Proposed Transaction;
 - (b) there is no administrative penalty imposed by CSRC or criminal punishment pursued by any judicial authority due to insider trading;
 - (c) there is no circumstance described under Article 13 of “the Interim Provision on Strengthening Supervision of Unusual Stock Trading Related to the Material Asset Restructuring of Listed Company” that would prevent their participation in the material asset restructuring of the listed company.
- 4.2.25 No Administrative Penalty or Large Amount of Overdue Debt. The Seller and the Guarantor further represent and warrant that:
- (a) None of the Seller, the Guarantor or their major officers have been subject to any administrative penalties (excluding any penalty obviously unrelated to the securities market), criminal punishments or involved in any material civil litigations or arbitrations in connection with economic disputes during the last five calendar years prior to the date of this Agreement, and there is no large amount of overdue debts that have not been repaid, unperformed commitments or administrative

25

Confidential

supervision measures taken by CSRC or disciplinary actions taken by any stock exchange against them;

- (b) Neither the Seller nor the Guarantor is subject to any material penalty imposed by either domestic or foreign regulatory authority during the last three calendar years prior to the date of this Agreement;
 - (c) None of the following circumstances, as described under Article 6 of the Administrative Measures on Acquisition of Listed Companies enjoining the acquisition of a listed company, exists with respect to the Seller:
 - (i) owing large amount overdue and unpaid debt which remains unpaid;
 - (ii) committing or allegedly committing material violations of law during the last three calendar years prior to the date of this Agreement;
 - (iii) committing serious acts of dishonesty in the securities market within the last three calendar years prior to the date of this Agreement;
 - (iv) any other circumstances where acquisition of listed companies is enjoined by laws or administrative regulations or determined by CSRC.
- 4.2.26 The forms filed and information disclosed by the Target Company to the US Securities and Exchange Commission each year did not include any false representations, misleading statements or significant omissions in all material respects;
- 4.2.27 COM is duly established and valid existing under the laws of Cayman Islands ;
- 4.2.28 The Seller owns 100% of the equity of COM. Except for those that have been disclosed, such equity is free and clear of any encumbrances and is not subject to any other title disputes, and there is no circumstances in respect of such equity which would affect COM’s Going-private as the Merger Sub;

4.2.29 COM is established solely for purpose of acting as the Merger Sub for the Going-private. It does not have any subsidiary or any equity in any other person and it does not have any assets or engage in any business or trading.

4.2.30 COM does not and will not have any claims, liabilities or debts.

Confidential

4.2.31 Full Disclosure. Any matters related to the Seller, the Target Company, COM and the Proposed Transaction that may have material adverse effect on the Proposed Transaction have been fully disclosed in this Agreement and the appendices hereto, the information disclosure letter, the materials or information provided during the due diligence, audit and appraisal by the Purchaser (and the professional agency retained by it) and the information disclosure documents filed by the Target Company with NYSE and provided to the Purchaser. Any representations, warranties or materials provided by the Seller to the Purchaser under this Agreement in connection with the Proposed Transaction are true, accurate and complete in all material respects without any false representation, misleading statement or significant omission in all material respects. The Seller further warrants to the Purchaser that all the materials provided to the Purchaser and the agents engaged by the Purchaser are true, accurate and complete original written materials or duplicates of the same without any false representation, misleading statement or material omission and the duplicates or copies are consistent with the originals. All the signatures and seals of all the documents are true and are not false, forged or tampered. The Seller further undertakes that it will indemnify the Purchase against any losses suffered by the Purchaser or its investors arising out of any false representation, misleading representation or significant omission in any material respect of the information provided by the Seller in accordance with the law. If the Proposed Transaction is subject to investigation by any judicial authority or the CSRC due to any alleged false representation, misleading statement or material omission existing in the information so provided or disclosed, before any conclusion for such investigation is made, the Seller shall suspend any transfer of the shares direct or directly held by it in the Purchaser.

4.2.32 As the Target Company is listed on NYSE on the date of this Agreement, therefore, the risks and information disclosed by the Target Company in the information disclosure materials to the NYSE, including without limitation, [20-F], shall constitute and be deemed an integral part of the information disclosure letter provided by the Seller and the Guarantor to the Purchaser.

4.2.33 As the Guarantor is a company listed in HKEx, the risks and information disclosed in the information disclosure materials to the HKEx shall constitute and be deemed an integral part of the information disclosure letter provided by the Seller and the Guarantor to the Purchaser.

4.3 Representations and Warranties of the Purchaser

The Purchaser makes additional representations and warranties to the Seller and the Guarantor in Exhibit 2 hereto. For purpose of this Section 4.3 and Exhibit 2, any reference to the Purchaser shall include its subsidiaries subject to the merger, and the following representations and warranties shall be deemed to be repeated on the Asset Closing Date as if they were made on such date.

Confidential

4.4 Reliance on the Representations and Warranties

One Party acknowledges that the other parties have considered the representations and warranties made by such Party in entering into this Agreement, which representations and warranties are factors considered by the other Parties determined to execute this Agreement.

4.5 Further Statement

Each representation and warranty made in this Agreement shall be deemed a separate representation and warranty, unless otherwise agreed in this Agreement, and each forgoing representation and warranty shall not be subject to any restriction or limitation due to reference to or be quoted by any other clauses of representations or warranties or any other clauses of this Agreement.

4.6 Effectiveness

The representations and warranties under Sections 4.2 of this Agreement shall continue to be effective from the execution of this Agreement throughout the Asset Closing Date. The representations and warranties under Section 4.3 of this Agreement shall continue to be effective from the execution of this Agreement throughout the Consideration Shares Registration Date. Each Party undertakes that it shall promptly notify the other Parties in writing if it becomes aware of anything occurring during the period from the date of this Agreement throughout the Asset Closing Date or the Consideration Shares Registration Date (as the case maybe) that would make any representation or warranty become untrue, inaccurate or misleading in any material respect.

Article 5 Further Covenants

5.1 Transitional Period and Losses and Profits in the Transitional Period

5.1.1 The Seller covenants and agrees, during the Transitional Period, to procure the Target Company:

- (a) to conduct business in the ordinary course of business consistent with the past operating practice, make efforts to maintain the existing relationship with its material clients and persons with whom it has maintained a material business relationship, and maintain the validity of all licenses, permits, and certificated as required to conduct business;

- (b) not to adopt any board resolutions or shareholder meeting resolutions in relation to matters not in the ordinary course of business, other than the resolutions adopted at the board meeting or shareholder meeting for the purpose of performance of the transactions contemplated under this Agreement or the Going-private;

Confidential

- (c) not to provide or borrow any loan with the principal amount over RMB3 million to or from any third party, not to create any material security over any of its assets, business, or equity interest, not to sell, assign or otherwise dispose of any material assets or business of the Target Company, not to reach any compromise, settlement, waiver, or satisfaction of thereof in relation to any material action, demand or dispute, or not to waive any right in connection with any material lawsuit or arbitration proceeding, unless in the ordinary course of business and for the purpose of performance of this Agreement and consummation of the Going-private;
- (d) not to increase or reduce the authorized share capital or issued share capital, or not to issue, sell, or redeem any shares, debentures or other securities other than for the purpose of the Going-private;
- (e) not to repay or make payment of any amount to its shareholders;
- (f) not to declare or distribute any profits to its shareholders;
- (g) not to enter into, amend, or terminate any material contracts or amend the articles of association, unless as required by Applicable Laws, in the ordinary course of business, and for the purpose of the Going-private (including without limitation, execution and performance of the Merger Agreement and the relevant ancillary agreements) and performance of this Agreement;
- (h) not to take any action as set forth in Section 4.2.8, which shall otherwise be disclosed if incurred prior to the date of this Agreement;

provided that, the Target Company has obtained the prior written consent of the Purchaser which shall not be withheld by it without reasonable and sufficient causes, or in emergency cases and for the purpose of preventing the Target Company from incurring material losses (in such cases the Purchaser shall be notified as soon as possible).

- 5.1.2 The Parties agree and acknowledge, the Purchaser and the Seller shall jointly engage an accounting firm acceptable to the Parties and satisfying the requirements of regulatory authorities, and such accounting firm shall conduct a closing audit on the Target Assets within 20 Business Days after the Asset Closing Date, to determine the profit and loss to be enjoyed or assumed during the period. During the period from the Reference Date to the reference date of the closing audit, any increase in equity interest of Target Assets attributable to increase in net profits shall be enjoyed by the Purchaser; any reduction in equity interest of Target Assets attributable to decrease in net profits or net losses shall be made up by the Seller in cash, and the Guarantor shall be jointly and severally liable for the obligation of the Seller to make up the losses in cash. Any increase

Confidential

or reduction in equity interest shall be determined based on the difference of owners' equity of the Target Company as of the Reference Date and as of the reference date of the closing audit. In the event of reduction in equity interest, the Seller and the Guarantor shall make up the losses in cash on a lump-sum basis within 10 days after the issuance of the closing audit report in relation to the Target Assets. Each of the Purchaser and the Seller shall bear 50% of the costs of auditing mentioned above.

5.2 Taxes

- 5.2.1 Unless otherwise agreed herein, any and all taxes in connection with performance of this Agreement and consummation of the Proposed Transaction shall be borne by the taxpayers as required by Applicable Laws, including taxes payable pursuant to the *Announcement of the State Administration of Taxation on Certain Issues in relation to Corporate Income Tax Arising from Indirect Transfer of Properties among Non-Resident Enterprises* [SAT Announcement [2015] No. 7] that is applicable to the Seller. The Seller shall submit information in relation to the Proposed Transaction in a timely manner and make representations in relation thereof pursuant to the *Announcement of the State Administration of Taxation on Certain Issues in relation to Corporate Income Tax Arising from Indirect Transfer of Properties among Non-Resident Enterprises* [SAT Announcement [2015] No. 7]. The Purchaser shall provide assistance to the Seller in the provision of relevant information in order to obtain fair and appropriate tax treatment. If the competent tax authority renders any enforceable decision in relation to imposition of taxes, and no condition is available to initiate any remedial measures, the Seller shall make payment of such taxes.

- 5.2.2 Each Party shall be responsible for its respective taxes due and payable in connection with performance of this Agreement pursuant to the relevant laws and regulations.

5.3 Notice of Development

- 5.3.1 Prior to the closing and subject to Applicable Laws, any Party shall notify the other Parties of (i) any matters that occur after the date of this Agreement and may be reasonably expected to constitute a breach of the representations, warranties, and undertakings made by such breaching Party hereunder; (ii) any significant progress that may have material effect on the assets, liabilities, financial position, operations, relationship with clients, suppliers, and employees, and prospects of the Target Company or the Purchaser; (iii) any progress

5.4 Assumption of Liabilities

30

Confidential

- 5.4.1 The Seller shall be liable for any liabilities of the Target Company not specifically disclosed in its financial statements or this Agreement, and for any liabilities of the Target Company incurring after the Asset Closing Date attributable to the omission of act to disclose such liabilities existing prior to the Asset Closing Date in its financial statements or this Agreement, other than the liabilities incurred in the ordinary course of business or operation and liabilities otherwise provide by the Parties. The Seller undertakes the Target Company and the Purchaser will not suffer any financial losses in connection therewith.
- 5.4.2 The Seller and the Guarantor undertake that, no financing will be undertaken on COM, including equity financing, debt financing, and financing in form of other convertible securities, and undertake that, after consummation of the Going-private, the Target Company and its surviving entity will not be liable for any debts in connection with the Going-private. The Seller and the Guarantor shall be responsible for any costs (including, without limitation, costs to legal counsel, financial advisor, etc.) in connection with the Going-private incurred by the Target Company and its surviving entity.

5.5 Lockup Period of the Consideration Shares

Upon consummation of the Proposed Transaction, the Seller shall undertake that within 36 months as of the consummation of the Proposed Issuance, it may not transfer any of the Consideration Shares acquired by it pursuant to the Proposed Issuance and thereafter it shall act in compliance with the applicable rules of the CSRC, MOFCOM and SSE in respect of the Lockup period of the Consideration Shares.

5.6 Treatment of Creditor's Rights and Debts and Settlement of Employees

- 5.6.1 The Proposed Transaction is for the purpose of acquiring the equity interest in the Target Company and does not involve the substitution of the Target Company with a new party with respect to the existing creditor's rights or debts of the Target Company, and the existing creditor's rights and debts of the Target shall remain the creditor's rights and debts of the Target Company after the Asset Closing Date.
- 5.6.2 The Proposed Transaction does not involve the settlement of employees at the Target Company. After the Asset Closing Date, employees currently in the employment of the Target Company shall remain in the employment of the Target Company in accordance with the relevant labor contracts that have been signed as of the date hereof.

5.7 Arrangements with respect to the Retained Profit Carried forward from Previous Periods

31

Confidential

- 5.7.1 Any undistributed profit, surplus reserve, and any other reserve (if any) of the Target Company shall be vested in the shareholders of the Target Company after the consummation of the Proposed Transaction, or in other words, the Target Company will not distribute profit prior to the consummation or termination of the Proposed Transaction. However, the profit declared as of the Asset Closing Date that is payable but not paid shall be vested in, and paid to, the Seller, prior to the Asset Closing Date of the Target Assets.
- 5.7.2 Any undistributed profit, surplus reserve, and any other reserve (if any) of the Purchaser accumulated prior to the Consideration Shares Registration Date, shall be distributed by both new shareholders and original shareholders (including the Seller acquiring the Consideration Shares) in proportion to their shareholding percentage then existing upon consummation of the Proposed Issuance.

5.8 Merger Sub

- 5.8.1 The Seller and the Guarantor undertake to maintain and use COM as the Merger Sub for the Going-private.
- 5.8.2 In the event that the Seller elects at any time not to use COM as the Merger Sub for the Going-private, the Seller shall form a new Merger Sub and notify the Purchaser in a timely manner. Any and all references to COM hereunder shall be automatically substituted by, and shall be applicable to, the new Merger Sub.

5.9 Exchange Rate and Calculation

Unless otherwise agreed in this Agreement (including ancillary documents attached hereto) and subject to any other terms contained herein, any conversion or settlement between RMB and a foreign currency in relation to the Proposed Transaction under this Agreement, shall be made at the central parity rate of RMB against such foreign currency published by the China Foreign Exchange Trade System on the date on which the payment or the conversion is actually made, or on the date of settlement or determination under the authorization by the People's Bank of China.

5.10 Purchase of Foreign Exchange

The Purchaser and the Seller shall, in compliance with law, complete the procedures in connection with foreign exchange registration, opening of special foreign exchange account, and review of purchase of foreign exchanges in relation to the payment of the Consideration Shares and Cash Consideration.

5.11 Going-private

The Seller and the Guarantor undertake that in the event that any amendments to the

Confidential

relevant matters in connection with the Going-private would result in failure of the Purchaser to obtain the Target Assets subject to its compliance with this Agreement on a continuous basis, the Seller and the Guarantor shall obtain the prior consent from the Purchaser for such amendments. For the avoidance of doubt, any amendments to the relevant matters in connection with the Going-private for which the Purchaser's consent that is otherwise required pursuant to this Article is not obtained shall be deemed a violation of Section 3.2.5. For the avoidance of doubt, this Article shall not in any event be interpreted: a) as if the Seller, the Guarantor, and the Purchaser would act in concert or have similar relationship; b) as if the Seller or the Guarantor would be liable to the Purchaser for driving or consummating the Going-private; c) the Going-private (including any plan thereof), or its implementation, consummation or termination as condition to give effect, the closing conditions or conditions precedent to this Agreement; or d) as if the Purchaser would have any independent rights to claim or other interests (including without limitation, property interests or non-property interests) in the Going-private. This Article shall not in any way limit any other agreements among the Parties.

Article 6 Confidentiality

6.1 Obligation of Confidentiality

Other than circumstances set forth in Section 6.2 hereof, any Party hereto shall not, and shall cause any of its Affiliates, directors, senior officers, employees, shareholders, agents or the directors, senior officers, employees, agents, financial advisor or accounting advisor of the Target Company not to, disclose information set forth below to any third parties, without the prior written consent of other Parties: (a) any discussions and assessments among the Parties in relation to the assignment contemplated hereunder, and any terms and conditions thereof; (b) the existence of this Agreement and any of its terms and conditions; and (c) any private, secretive, or confidential data and information obtained by any Party from other Parties in connection with the execution of this Agreement or performance of the assignment contemplated hereunder (collectively "**Confidential Information**"), and shall keep the Confidential Information in strict confidence, provided that the obligation of confidentiality shall not apply to any information that, at the time of disclosure, (i) is or has been available publicly, other than for the reason of disclosure directly or indirectly by the receiving party; or (ii) has been made available to the receiving party and not bound by the obligation of confidentiality, or Confidential Information obtained independently by the receiving party without assistance, utilization, or use of Confidential Information.

6.2 Exceptions

Each Party agree, it may disclose or divulge the Confidential Information only to the extent that:

- 6.2.1 for the purpose of the performance of the assignment contemplated hereunder, it may disclose to the senior officers, directors, legal counsel, financial advisor, accounting advisor on a need to know basis in connection with the

Confidential

performance of duties and only to the extent of such basis. The disclosing party shall procure that any person receiving Confidential Information shall be fully aware of the confidential nature of Confidential Information and the obligation of confidentiality assumed by such disclosing party, and shall procure that any person receiving Confidential Information shall abide by the same obligation of confidentiality; or

- 6.2.2 it is permitted to make disclosures to the person otherwise agreed in writing by other Parties hereto; or

- 6.2.3 it is required by Applicable Laws to make disclosures or announcements to any stock exchange or Governmental Authority, in which case it shall give other Parties reasonable written notice in advance and make accurate disclosure with the content being determined by the Parties jointly to the extent as required by Applicable Laws.

6.3 Duties

Each Party shall be liable for any breach of terms set forth in Section 6.1 by any of its Affiliates, directors, senior officers, employees, shareholders, agents, and its legal counsel, financial advisor and/or accounting advisor.

Article 7 Effectiveness and Termination

7.1 Formation

This Agreement shall be formed after being executed by the Parties.

7.2 Effectiveness

This Agreement shall take effect on the date when all conditions set forth below are satisfied:

- 7.2.1 The matters under the Proposed Transaction have been approved by the board of directors and the shareholder meeting of Purchaser;

- 7.2.2 The matters under the Proposed Transaction have been approved by the board of directors of the Seller;
- 7.2.3 This Agreement and the matters under the Proposed Transaction have been approved by the board of directors and the shareholder meeting of the Guarantor;
- 7.2.4 The Guarantor has fulfilled applicable requirements of HKEx, and other regulatory authorities, all of which grant approval in relation to the Proposed Transaction;

Confidential

- 7.2.5 The Seller and the Guarantor have obtained consents and/or waivers from the sponsors that will provide financing to the Going-private in relation to the execution/performance by the Seller and the Guarantor of this Agreement and the Proposed Transaction;
- 7.2.6 The matters under the Proposed Transaction have been filed with the National Development and Reform Commission of the People's Republic of China ("NDRC") in relation to offshore investment;
- 7.2.7 The matters under the Proposed Transaction have been filed with the Department of Commerce of Jiangsu Province in relation to offshore investment;
- 7.2.8 The matters under the Proposed Transaction have been approved by MOFCOM in relation to strategic offshore investors;
- 7.2.9 The matters under the Proposed Transaction have been approved by MOFCOM in relation to concentrations of business operators; and
- 7.2.10 The Proposed Transaction has been approved by CSRC.

7.3 Termination

This Agreement may be terminated:

- 7.3.1 by mutual written consent of the Parties;
- 7.3.2 This Agreement fails to take effect on or prior to the first anniversary of the date hereof;
- 7.3.3 Any permanent injunction, regulation, rules or order rendered by the competent Governmental Authority that makes restrictions on, bans or terminates the assignment contemplated hereunder has become final and non-appealable, then any Party is entitled to terminate this Agreement by giving a written notice; where a Party terminate this Agreement by giving a notice, the termination date shall be the date as set forth in such notice, or the day when the notice is given, in case no date contained therein.
- 7.3.4 under the circumstances as set forth in Article 10 (Force Majeure) hereof;
- 7.3.5 The Purchaser fails to complete the issue, registration, and registration under the name of the Seller, of entire Consideration Shares, within the prescribed period set forth in this Agreement; or the Purchaser fails to pay the entire Cash Consideration in full within the prescribed period set forth in this Agreement, and continues to fail to perform the obligation of payment of the Cash Consideration within thirty (30) days after the Seller

Confidential

gives a written notice to the Purchaser, the Seller has the right to terminate this Agreement unilaterally in writing;

- 7.3.6 by any Party pursuant to Section 3.7 hereof;
- 7.3.7 In the event any Party commits material breach of the terms of this Agreement which affects the specific performance of this Agreement, and such Party fails to remedy such breaches within thirty (30) days after receipt of the written notice given by the non-breaching party that requests an immediate remedy, the non-breaching party shall have the right to terminate this Agreement unilaterally by written notice; or
- 7.3.8 by any Party after giving other Parties the written notice of termination in accordance with other terms of this Agreement (including supplementary agreement hereof).

7.4 Effect of Termination

- 7.4.1 All rights and obligations of each Party under this Agreement shall become void upon termination of this Agreement, provided that:
- (a) any terms that shall survive the termination of this Agreement in accordance with provisions of this Agreement, or determined based on the nature of the terms or in the context of this Agreement, and any terms that are required for the interpretation or implementation of this Agreement, shall survive the termination of this Agreement; and

- (b) termination of this Agreement shall not affect any rights and obligations of any Party incurred prior to such termination and, without prejudicing the generality of such provisions, termination of this Agreement shall not cancel or affect any rights of a Party to seek liquidated damages in respect of any violations by other Party of this Agreement, unless otherwise specified in this Agreement.
- 7.4.2 None of the Parties shall be liable for any breach in case this Agreement is terminated in accordance with Sections 7.3.1 to 7.3.4;
- 7.4.3 If this Agreement is terminated in accordance with Sections 7.3.5 to Section 7.3.7, the breaching party shall be liable for breach and indemnify other Parties of any losses that are actually incurred. For the avoidance of doubt, none of the Parties shall be liable for any breach in case this Agreement is terminated due to the matters under Section 8.5 and Section 8.6;
- 7.4.4 Each of the Parties shall assume liabilities arising from termination of this Agreement pursuant to Section 7.5 in case this Agreement is terminated in accordance with Section 7.3.6;

Confidential

- 7.4.5 The terms in relation to confidentiality, liability of breach, governing law and dispute resolution shall survive the termination of this Agreement.

7.5 Termination Fee

- 7.5.1 The Purchaser shall pay the Seller an amount equal to US\$30 million as termination fee within 20 Business Days upon receipt of the written notice of the Seller, in the event that the Seller shall dissolve this Agreement unilaterally in accordance with this Agreement, if:
- (a) Any circumstances set forth in Section 3.7.2;
 - (b) Subject to other covenants contained herein, upon full satisfaction (or waiver in accordance of this Agreement) of the closing conditions, the Purchaser refuses to close or accept the closing conditions, and continue to refuses to close or accept the closing conditions within 30 days following the notice of the Seller, then the Seller shall dissolve this Agreement unilaterally; or
 - (c) Subject to other covenants contained herein, upon closing of the Target Assets, the Purchaser fails to perform or unduly perform the obligation of payment in relation to the Consideration Shares and/or Cash Consideration, and continues to fail to perform the obligation of payment within thirty (30) days after the Seller gives a formal written notice to the Purchaser, then the Seller shall dissolve this Agreement unilaterally.

For the avoidance of doubt, the Purchaser is not required to pay any termination fee in case the Seller dissolves this Agreement in accordance with Section 8.6.

- 7.5.2 The Seller shall pay the Purchaser a termination fee equal to US\$30 million within 20 Business Days following receipt of the written notice from the Purchaser, in the event that the Purchaser shall dissolve this Agreement unilaterally in any of the circumstances as set forth in Section 3.7.1.

For the avoidance of doubt, the Seller is not required to pay any termination fee arising from the matters set forth in Section 8.5.

Article 8 Liability for Breach and Indemnification

- 8.1** Any breach by a Party hereto of its representations, warranties, covenants, or any false representations, non-performance of any rights and obligations hereunder shall constitute a breach, and upon request of the non-breaching party, the breaching party shall continue to perform its obligations, take remedy measures, or make any indemnification that shall be comprehensive, timely, adequate, and effective.
- 8.2** In case that any non-performance, delay in performance, or unduly performance of any obligations hereunder by any Party results in any failure to achieve the purposes of this Agreement, the non-breaching party shall have the right to dissolve this

Confidential

Agreement, and the breaching party shall indemnify any other parties of the losses on a full indemnity basis, provided that, the maximum amount of damages to be made by the breaching party to other Parties shall not exceed the Transaction Consideration. Such maximum amount of Damages shall not in any way conflict with, and shall be subject to, the terms in relation to the termination fee set forth in Section 7.5. Where any Party is liable for payment of both Damages and the termination fee, such party shall make payment of both Damages and the termination fee, and shall not seek defenses or refuse to perform such obligation by the excuse of the maximum amount of Damages.

- 8.3** None of the Parties shall be liable for any breach in case the Proposed Transaction does not take effect or consummate with no fault of the Parties hereto.

- 8.4** Without prejudicing any other rights and remedies to which the Purchaser is entitled hereunder, the Seller and the Guarantor shall, jointly and severally, indemnify the Purchaser from and against any liabilities and losses (including without limitation, any damages, penalties, fines, and any costs of investigation, legal costs, professional fees, accountant fees, and other costs that are reasonably incurred in relation to any action, or asset or value impairment of the Target Company), arising out of, or in connection with matters set forth below; the Seller shall, jointly and severally, indemnify the Purchaser from and against any liabilities and losses (including without limitation, any damages, penalties, fines, and any costs of

investigation, legal costs, professional fees, accountant fees, and other costs that are reasonably incurred in relation to any action, or asset or value impairment of the Target Company), arising out of, or in connection with any matters set forth below, which include, without limitation: (i) any action or arbitration against the Target Company, the Purchaser and its Affiliates arising from Going-private; (ii) the appraisal rights under the Merger Agreement to be exercised by the shareholders of the Target Company pursuant to Companies Law of Cayman Islands Cap 22 (Law 3 of 1961, as revised) — Section 238, and any costs to be borne by the Target Company (including without limitation, costs in lawsuit, costs to shareholders who exercise the appraisal rights); and (iii) all indemnification paid by the Target Company or its surviving entity under the Merger Agreement for Going-private, and all costs arising from Going-private (including without limitation, costs to legal counsel, financial advisor, payment agent, etc.)

8.5 For the avoidance of doubt, subject to the good faith and great efforts of the Seller and the Guarantor to promote satisfaction of the transactional conditions, any of the cases set forth below shall not constitute a breach and the Seller or Guarantor is not obliged to assume any liability of breach, liability of compensation, other financial liability or corresponding guarantee liability:

- (a) No approval or verification is obtained at the shareholder meeting of the Guarantor and/or from the HKEx and/or other regulatory authorities (if applicable) in relation to the Proposed Transaction;
- (b) No approval is obtained from the power authority of the Target Company in relation to the Proposed Transaction.

Confidential

8.6 For the avoidance of doubt, subject to the good faith and great efforts of the Purchaser to promote satisfaction of the transactional conditions, any of the cases set forth below shall not constitute a breach and the Purchaser is not obliged to assume any liability of breach, liability of compensation, other financial liability or corresponding guarantee liability:

- (a) No approval or verification is obtained at the shareholder meeting of the Purchaser and/or from the SSE and/or CSRC in relation to the Proposed Transaction;
- (b) No approval is obtained from the MOFCOM in relation to the Proposed Transaction.

Article 9 Closing Security, Remedies and Guarantee

9.1 Closing Security and Remedies Available to the Purchaser

- 9.1.1 In the event that the Seller fails to duly perform its obligation to conduct the closing of the sale and purchase of the Target Assets on the Asset Closing Date, the Purchaser shall be entitled to liquidated damages for delayed closing in accordance with Section 9.1.2. In order to exercise such remedy mentioned above, the Purchaser shall notify the Seller in writing. Whether the Purchaser terminates this Agreement or not, it shall have the right to claim and receive liquidated damages for delayed payment in accordance with this Agreement.
- 9.1.2 For each day the Seller delays the closing of the sale and purchase of any Target Assets past the Asset Closing Date, the Seller shall pay the Purchaser daily liquidated damages which shall be equal to the value of such Target Assets as of such day multiplied by 0.05% (the “*Seller Daily Liquidated Damages Rate*”). The aggregate liquidated damages for delayed closing payable by the Seller shall be equal to the Seller daily liquidated damages multiplied by the number of calendar days elapsed from the date on which the delay in the closing commences and to the date on which the liquidated damages are determined. The Seller Daily Liquidated Damages Rate shall be doubled on the basis of compounding whenever a delay amounts to 30 consecutive days or an integral multiple thereof.

9.2 Closing Security and Remedies Available to the Seller

- 9.2.1 In the event that the Purchaser fails to duly perform its obligation to issue the Consideration Shares or pay the Cash Consideration after the closing of the sale and purchase of the Target Assets, the Seller shall be entitled to liquidated damages for delayed payment in accordance with Section 9.2.4. In order to exercise such remedy, the Seller shall notify the Purchaser in writing. Whether the Seller terminates this Agreement or not, the Seller shall have the right to claim and receive the liquidated damages for delayed payment in accordance with this Agreement.

Confidential

- 9.2.2 Where the Purchaser fails to perform properly its obligation to issue the Consideration Shares or pay the Cash Consideration for more than 30 consecutive days, the Seller shall have the right (but no obligation) to exercise any one or more of the following remedies and the security right, all at its own discretion: a) to terminate this Agreement; b) to enforce the pledge created on the relevant Target Company shares set forth in Section 9.3; c) to receive liquidated damages so as to hold the Seller and/or the Target Company harmless from any loss in accordance with the other terms of this Agreement; and d) to claim the payment of liquidated damages for delayed payment set forth under Section 9.2.4.
- 9.2.3 Any exercise of any remedy or security right by the Seller set forth under Section 9.2 shall not in any way operate as or be interpreted as a waiver of any other remedy or security right.
- 9.2.4 For each day the Purchaser delays the payment of any portion of the Purchase Price, the Purchaser shall pay the Seller the daily liquidated damages which shall be equal to the value of such portion of the Purchase Price as of such day multiplied by 0.05% (the “*Purchaser Daily Liquidated Damages Rate*”). The aggregate liquidated damages payable by the Purchaser shall be equal to the Purchaser daily liquidated damages multiplied by the number of calendar days elapsed from the date on which the delay in the payment

commences and to the date on which the liquidated damages are determined. The term "Value of such portion of the Purchase Price" referred to above shall mean the sum of (i) the amount equal to product of the number of the delayed Consideration Shares multiplied by the agreed Issuing Price plus, (ii) amount of the delayed Cash Consideration. The Purchaser Daily Liquidated Damages Rate shall be doubled on the basis of compounding whenever a delay amounts to 30 consecutive days or an integral multiple thereof.

9.3 Reverse Pledge of the Target Assets

9.3.1 Prior to the Closing Condition Fulfillment Deadline, the Purchaser and the Seller shall, in accordance with the laws of Cayman Islands, enter into a Share Pledge Agreement in the form of Annex 1 hereto, together with all the appendices thereto (including without limitation, a share transfer instrument) (the "**Target Assets Reverse Pledge Agreement**"). The Target Assets Reverse Pledge Agreement shall take effect upon satisfaction of certain conditions, including, the actual performance and consummation by the Parties of the closing of the sale and purchase of the Target Assets, and shall provide that, assuming that the Parties have consummated the closing of the sale and purchase of the Target Assets in accordance with this Agreement, until the Purchaser has actually performed fully its obligation to pay the Purchase Price and any other amount payable by it under this Agreement and relevant transaction documents, including without limitation, liquidated damages, Damages, termination fee, and any other amount, the Purchaser shall pledge to the Seller the Target Assets obtained by it

40

Confidential

hereunder to secure the Purchaser's performance of its obligation to pay all or any portion of the Purchase Price and any other amount payable by it under this Agreement and relevant transaction documents. Promptly within 10 Business Days as of the payment in full by the Purchaser of the Purchase Price and any other amount payable by it in accordance with the foregoing provisions, the Seller shall have such pledge so created over the Target Assets released and return to the Purchaser any and all of the documents and share certificates that should be returned.

9.3.2 At the same time, the Purchaser undertakes that it shall bear the reasonable expenses and fees incurred by the Seller in the exercise or enforcement of the security interest, including without limitation, the expenses and fees to be incurred in the pursuit of litigations, obtaining of writs, enforcement, evaluation (to the extent necessary), engagement of intermediary agencies.

Article 10 Force Majeure

10.1 If any Party hereto fails to perform all or part of its obligations hereunder affected by a force majeure event, performance of such obligations may be suspended for a period when such force majeure event lasts. An force majeure event means any event which is beyond the reasonable control of the affected Party, unforeseeable, or even if foreseeable is unavoidable or insurmountable, and occurs after the date of this Agreement, and such events render the performance of all or part of this Agreement impossible or impracticable. Such events include, without limitation, flood, fire, drought, typhoon, earthquake, or other natural disaster, traffic accident, strikes, turbulence, turmoil, war, or enactment, promulgation, amendment, replacement, interpretation of laws by power authority or administrative authority of any jurisdiction (irrespective of whether it is within or outside of the PRC).

10.2 The Party claiming being effected by a force majeure event shall promptly notify the other Parties in writing and shall furnish the other Party within thirty (30) days thereafter appropriate proof of the occurrence of the force majeure and the expected duration of the adverse effects resulting from such force majeure. The Party claiming a force majeure event renders the performance of all or part of this Agreement impossible or impracticable shall also use all practicable and reasonable efforts to eliminate or mitigate the impacts of the force majeure event on performance of its obligations hereunder.

10.3 Upon occurrence of a force majeure event, the Parties shall immediately consult with each other in order to find an equitable solution and shall use all reasonable efforts to minimize the consequences of such force majeure event. If the occurrence or effect of the force majeure event causes material hindrance to the assignment contemplated hereunder with the duration lasting for more than six(6) months, and the Parties fail to agree on any equitable solution, then any Party may terminate this Agreement unilaterally.

Article 11 Governing Law and Dispute Resolution

41

Confidential

11.1 The entry, validity, interpretation, performance, and dispute resolution in connection with this Agreement shall be governed by the PRC laws. Where the ancillary agreements hereto stipulate otherwise with respect to the governing law and application, such stipulations shall prevail.

11.2 Any dispute between the Parties hereto in connection with this Agreement shall first be settled by friendly consultations between the Parties. If such dispute cannot be settled through friendly consultations within thirty days after the occurrence of the dispute, any Party may submit the dispute to the China International Economic and Trade Arbitration Commission for arbitration in Beijing in accordance with the arbitration rules then in effect. The arbitration shall be conducted in Chinese language. Where the ancillary agreements hereto stipulate otherwise with respect to the governing law and application, such stipulations shall prevail.

11.3 The arbitral award shall be final and binding upon the Parties hereto.

11.4 During the period of dispute resolution, other than the disputed matters, the Parties hereto shall continue to perform all other provisions in this Agreement.

Article 12 Notice and Delivery

- 12.1** All notices or written communications to be sent by any Party to other Parties as required under this Agreement shall be given by facsimile or by courier service to any other Parties promptly that shall also be notified via fax, e-mail or telephone. Such notices or written communications given hereunder, unless an earlier date otherwise evidenced, shall be deemed to be delivered on the third calendar day after being given to the courier service company, if delivered by courier service company, or the next Business Day after being given by facsimile, if delivered by facsimile.
- 12.2** All notices and written communications shall be delivered to the addresses set forth below, or any other addresses notified by any Party to the other Parties. In case a Party fails to notify in time any other Parties of any change to such address, the documents delivered to the original addresses shall be deemed having been delivered to such Party.

If to the Seller and Guarantor:

Attention: Yuen Kam
Address: 48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong
Tel: +852 3605 8180
Fax: +852 3605 8180

If to the Purchaser:

Attention: Lijian Pan
Address: No. 1 Zhongshan South Road, Nanjing
Postal code: 210005
Tel: 025-84717494
Fax: 025-84717494

Confidential

Article 13 Miscellaneous

13.1 Guarantee

Without prejudicing the validity of other provisions hereto, the representations, warranties, covenants, obligations made by the Seller hereunder shall be deemed to be repeated and assumed by the Guarantor, and the Guarantor shall be liable jointly and severally to the obligations of the Seller under this Agreement.

13.2 Entire Agreement

This Agreement constitutes the entire agreement among the Parties with respect to the matters under the Proposed Transaction as of the date of this Agreement. In case of any conflict between this Agreement and the relevant advice, representations, warranties, agreements, or covenants which were made by Parties prior to this Agreement, the Parties agree this Agreement shall prevail.

13.3 Assignment, Amendment and Supplement

Without prior written consent of the other Parties, any Party may not assign this Agreement or any rights or obligations hereunder. Any amendment and supplement of this Agreement shall be made and mutually agreed in written by and sent to the Parties.

13.4 Further Assurance

For the purposes of granting all rights, power, and relief that are vested under this Agreement to the relevant parties, upon reasonable request by one Party from time to time, the other Parties shall take all such further acts and steps, or shall cause such further acts and steps to be taken, and shall execute all such other documents or procure to execute all such other documents.

13.5 Waiver

No delay or omission on the part of any Party to this Agreement in exercising any right, power or privilege provided by law or provided hereunder shall be deemed a waiver thereof. The single or partial exercise of any right, power or privilege provided by law or provided hereunder shall not preclude any other exercise of any other right, power or privilege.

13.6 Severability

If any provision of this Agreement is held invalid, illegal or incapable of being enforced, the Parties agree such provision shall be enforced to the greatest extent possible so as to effect the intent of the Parties and the validity, legality, and enforceability of all other provisions of this Agreement shall not be affected in any manner. The Parties hereto shall negotiate in good faith to modify this

Confidential

Agreement so as to effect the original intent of the Parties hereto as closely as possible and replace such language that is unenforceable with language that shall be enforceable.

13.7 Application

Unless otherwise provided herein, this Agreement shall be inure solely to the benefit of and binding upon the Parties hereto and their respective successors and permitted assigns.

13.8 Language

This Agreement shall be written in Chinese language and the Chinese version shall prevail.

13.9 Counterpart

This Agreement shall be executed in eight (8) counterparts, which are equally authentic. Each Party shall hold one (1) counterpart, and the remaining counterparts to be maintained by the Purchaser for purposes of obtaining approvals and completing registration in connection with the Proposed Transaction. Each counterpart shall have the same legal effect.

[Signature page follows]

44

Confidential

(Signature Page to Agreement to Purchase Assets by Share Issuance and Cash Payment in relation to Nanjing Xinjiekou Department Store Co., Ltd.)

Purchaser: Nanjing Xinjiekou Department Store Co., Ltd. (Seal)

Authorized Representative: (Signature) /S/ YANG Huaizhen

Date: [], 2016

45

Confidential

(Signature Page to Agreement to Purchase Assets by Share Issuance and Cash Payment in relation to Nanjing Xinjiekou Department Store Co., Ltd.)

Seller: Golden Meditech Stem Cells (BVI) Company Limited (Seal)

Authorized Representative: (Signature) /S/ Yuen KAM

Date: [], 2016

Guarantor: Golden Meditech Holdings Limited (Seal) /S/ Yuen KAM

Authorized Representative: (Signature)

Date: [], 2016

46

Confidential

Agreement to Purchase Assets by Share Issuance and Cash Payment

Exhibit 1 Basic Information and Capitalization Structure of the Target Company

(1) As at the date of this Agreement, the basic particulars of the operating entity to which the Target Assets relate hereunder are as follows:

Company Name:	China Cord Blood Corporation
Registered Address:	Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111, Cayman Islands
Date of Establishment:	June 30, 2009
Authorized Share Capital:	US\$25,100

(2) As at the date of this Agreement, the details of the Target Company shares owned or to be owned by the Seller are as follows:

Class	Underlying Number of Shares
Ordinary Shares	38,352,612

CGL-GM CBs	8,809,020
ECHIL CBs	22,903,454
Magnum CBs	8,809,020
Subtotal	78,874,106
Total share capital after all the CBs are converted into ordinary shares	120,604,742
Percentage	65.4%

Confidential

Agreement to Purchase Assets by Share Issuance and Cash Payment

Exhibit 2 Representations and Warranties of the Purchaser to the Seller and the Guarantor

The Purchaser hereby makes the following additional representations and warranties to the Seller and the Guarantor, and for purpose of this Exhibit 2, any and all references to the Target Company shall include all the subsidiaries subject to the merger, and the following representations and warranties shall be deemed repeated on the Asset Closing Date as if made at such time. As of the date hereof and the Asset Closing Date, except for those disclosed by the Purchaser publicly, by way of an information disclosure letter as of the date of this Agreement or in this Agreement or any other transaction documents executed by the Seller to which it is a party, or incurred for purpose of implementation or consummation of the Proposed Transaction and notified to the Seller, or fulfilled for purpose of this Agreement and notified to the Seller, or that have been disclosed by the Purchaser on the website of SSE or in the information disclosure channel designated by the CSRC:

- (1) The documents filed by and the statements made or the information disclosed by the Purchaser to the competent securities regulator (or its branches) for purpose of this Agreement are true, accurate and complete without any false representation, misleading statement or significant omission. To the best knowledge of the Purchaser, there is no administrative investigation, criminal investigation, prosecution, criminal case registration, administrative penalty, criminal punishment, administrative or judicial mandatory measures or supervision measures against or in connection with the Proposed Issuance, or any director, supervisor or executive officer of the Purchaser.
- (2) To the reasonable knowledge of the Purchaser, the professional reports, opinions and memorandum prepared by the professional services engaged by the Purchaser for purpose of the Proposed Issuance or in connection with any other matters of the Proposed Issuance are true, accurate and complete in all respects without any false representation, misleading statement or significant omission.
- (3) The Consideration Shares to be issued and delivered to the Seller by the Purchaser are free and clear of any right defects, encumbrances, any other rights, pledge and freezing and are not subject to any right of first refusal, privilege, option or any contract or deeds to which the Purchaser is a party.
- (4) Valid existence. The Purchaser is duly established or incorporated in the jurisdiction where it is established or incorporated. There is no circumstance under which it may be cancelled or deregistered. The Purchaser has all the necessary power, authority or qualification to own, lease and operate its property and assets and carry out the business it currently conducts, and its articles of association, business license and any other permits, licenses and qualifications are in full force and effect from the date of this Agreement through the Asset Closing Date.

Confidential

- (5) Affiliates. Except for the related party transactions that have been publicly disclosed, there is no other significant related-party transaction or arrangement between the Purchaser and any of the other Affiliates that are required to be disclosed under the Applicable Law, which includes without limitation, those in connection with possession of funds, financing, procurement, licensing, creditor's rights and obligations.
- (6) Finance and Accounting
 - (a) The financial statements of the Purchaser shall be prepared based on the transactions or events actually incurred and are in compliance with the PRC GAAP, which have fairly reflected the financial conditions, performance results and cash flows of the Purchaser in all material respects.
 - (b) The Purchaser has established an independent financial accounting system which enables it to make financial decision independently, and has set up standard financial accounting policies and financial management policies. The Purchaser has no joint bank account with its controlling shareholder, de facto controlling person and any other enterprises under its control.
- (7) Absence of undisclosed liabilities which should have been disclosed. The Purchaser does not have any other significant liabilities that should have been disclosed pursuant to any Applicable Law, nor does it have any existing or contingent condition which is reasonably expected to result in such other material liabilities.
- (8) No material changes. Other than those disclosed by the Purchaser, no material change has occurred that may have a material adverse effect on the Purchaser.
- (9) Compliance of Business Operation. The Purchaser has not violated or did not materially violate any Applicable Law. The Purchaser has been conducting its business in accordance with all the Applicable Law. During the last three years, the Purchaser has not committed any material violation of any mandatory provisions or prohibitions under any Applicable Law in its business operation. The Purchaser has all the licenses, permits, consent and authorizations required for operating its assets and conducting its business. Such licenses, permits, consent and authorization do not materially contravene with the mandatory provisions or prohibitions of the Applicable Law and are in due force and effect. None of such

licenses, permits, consents or authorizations will be terminated or adversely affected as a result of the Proposed Transaction, and the Purchaser has not received any notification, either in writing or orally, from any Governmental Authority regarding the cancelling or revoking any license, permits, consent or authorization obtained by the Target Company.

- (10) Administrative Penalties, Administrative Mandatory Measures and Administrative Supervision Measures. No Governmental Authorities have imposed any administrative penalties, administrative mandatory measures or administrative supervision measures that have any material adverse effect on the assets or business of the Target Company. There are no administrative penalties, administrative

Confidential

mandatory measures or administrative supervision measures imposed by any Governmental Authorities that (i) has or has had materials adverse effect on the Purchaser or its assets, (ii) may affect the validity, effectiveness or enforceability of this Agreement, or (iii) affect the consummation of the Proposed Transaction.

- (11) Environment, health and safety compliance. The Purchaser has obtained and maintains all necessary environmental, health and safety licenses and permits issued by the Governmental Authorities required for its current use, possession or operation of its business. The Purchaser has conducted its business operation in compliance with the foregoing environmental, health and safety permits, licenses and approvals in all material respects. There will be no material administrative penalty or litigation arising out of environmental, health or safety issues within the last three years.
- (12) Purchaser Intellectual Property Rights
- (a) The Purchaser has used the Intellectual Property owned, leased or otherwise obtained by it, such as the names, domain names, trademarks, copy rights, patent rights, invention, technical data, process, know-how, drawings, design (the "**Purchaser Intellectual Property**") in compliance with the requirements of PRC law.
- (b) There is no pending or potential material action, dispute, claim or demand affecting the Purchaser Intellectual Property of the Purchaser. The Purchaser has not received any written notice from any person challenging the rights of the Purchaser to use the Purchaser Intellectual Property owned, leased or otherwise obtained by the Purchaser, and such right of use is not subject to any governmental orders that may affect the free use by the Purchaser of each of the Purchaser Intellectual Property.
- (c) To the best knowledge of the Purchaser, no officer, employee, or consultant of the Purchaser is subject to any obligations under any agreement, contract (including any permits, covenants and undertakings of any nature) or deed or any judgment, decree or order of any court, which may affect its ability to use their best efforts to promote the interest of the Purchaser, result in any conflict with the business currently or proposed to be operated by the Purchaser, or prevent it from transferring to the Purchaser all the Intellectual Property designed, developed or created by them in connection with their service to the Purchaser. The Purchaser does not and will not need to use any invention created by its officers or employees (or any persons it currently intends to employ) prior to their employment with the Purchaser or beyond the scope of service as stipulated between such officers or employees with Purchaser.
- (13) Labor Matters
- (a) The Purchaser has fully complied with the labor laws of the place of its incorporation and any employment contract to which it is a party. There is no material dispute or controversy pending or threatened between the Purchaser

Confidential

and any of its employees or the labor union. No strike, slowdown, work stoppage or plant closure has occurred in the Purchaser.

- (14) Taxes
- (a) Except for those that have been publicly disclosed, the Purchaser has complied with the mandatory provisions or prohibitions under the PRC tax laws in all material respects.
- (15) Improper Payment
- (a) The Purchaser does not pay or cause any other person to pay or give anything of significant value to or enter into any transaction with any Governmental Authority, governmental officials or officers of any enterprises, for purpose of influencing such persons in official positions to obtain or retain business or transfer any business to the Purchaser or any other person.
- (b) Throughout the negotiation and execution of this Agreement, to the knowledge of the Purchaser, neither the Purchaser nor its Affiliates, including the directors, officers, business personnel, representatives and intermediaries (the "**Project Representatives**") has provided any commercial bribery to the Seller and the Guarantor's project representatives by any way or by any reason in the form of cash, anything of value, consumption or otherwise. For purpose of this Section (15), any benefit such as work meal, accommodation, transportation or any gift with insignificant value publicly provided by the Purchaser to the project representatives of the Seller or the Guarantor based on business reception etiquette and for purpose of completion of the share transfer contemplated under this Agreement, shall not be deemed commercial bribery.
- (16) Litigation and Claims. There is no litigation, arbitration, mediation or administrative or criminal proceeding to which the Purchaser is the claimant, defendant, appellant, appellee or respondent that is ongoing or reasonably expected to be incurred and may have material adverse effect on the

Purchaser. The Purchaser is not aware of any litigation, arbitration, mediation, administrative or criminal proceedings that may be initiated against the Purchaser or its director, supervisor or executive officer which may have material adverse effect on the Purchaser. There is no event that may result in any challenge or objection brought by any third party against this Agreement or the Proposed Transaction, invalidity of this Agreement or the Proposed Transaction or any material adverse effect on or change of control of the Purchaser, or any other event that may affect the consummation of the Proposed Transaction by the Seller and the Guarantor. There is no litigation, arbitration or administrative investigation proceeding against the Purchaser alleging that it has violated any securities laws and regulations, anti-corruption, anti-bribery, antitrust laws or any other Applicable Law that may have material adverse effect on the Purchaser.

- (17) No Proceedings or Litigations. To the best knowledge of the Purchaser, there is no investigation, penalty, mandatory measure or supervision measure taken by any

Confidential

Governmental Authority or non-Governmental Authority against the Purchaser for enjoining or materially changing the Proposed Transaction.

- (18) The documents, forms filed and information disclosed by the Purchaser to the CSRC or its branches or local regulators, SSE and the Share Registry each year did not include any false representations, misleading statements or significant omissions in all material respects;
- (19) The procedure of the Proposed Issuance is in full compliance with the PRC Securities Law, Company Law and the relevant CSRC administrative rules and regulations and the MOFCOM rules.
- (20) Full Disclosure. Any representations, warranties or materials provided by the Purchaser to the Seller and the Guarantor under this Agreement in connection with the Proposed Transaction are true, accurate and complete in all material respects without any false representation, misleading statement or significant omission in all material respects. If the Proposed Transaction is subject to investigation by any judicial authority or the CSRC due to any alleged false representation, misleading statement or material omission existing in the information so provided or disclosed, before any conclusion for such investigation is made, the Purchaser shall suspend any transfer of the shares directly or indirectly held by it in the Seller and the Guarantor.
- (21) There is no and to the reasonable knowledge of the Purchaser, there is no circumstance which may disqualify the Purchaser from being listed on the SSE.
- (22) As the Purchaser is a company listed on SSE as of the date of this Agreement, therefore, the risks and information disclosed by the Purchaser in the information disclosure materials to the SSE shall be deemed an integral part of the information disclosure letter provided by the Purchaser to the Seller and the Guarantor.

Confidential

Agreement to Purchase Assets by Share Issuance and Cash Payment

Annex 1 Target Assets Reverse Pledge Agreement

Confidential

English Translation of Chinese Original

Share Sale and Purchase Agreement

In relation to
China Cord Blood Corporation
 By and among
Nanjing Xinjiekou Department Store Co., Ltd.
 and
Golden Meditech Stem Cells (BVI) Company Limited
Golden Meditech Holdings Limited
 January 2016

Confidential

Table of Contents

ARTICLE 1	DEFINITIONS	2
ARTICLE 2	TRANSACTION ARRANGEMENTS	6
ARTICLE 3	CLOSING CONDITIONS	9
ARTICLE 4	REPRESENTATIONS AND WARRANTIES	12
ARTICLE 5	FURTHER COVENANTS	14
ARTICLE 6	CONFIDENTIALITY	14
ARTICLE 7	EFFECTIVENESS AND TERMINATION	15
ARTICLE 8	LIABILITY FOR BREACH AND INDEMNIFICATION	19
ARTICLE 9	CLOSING SECURITY AND REMEDIES	21
ARTICLE 10	FORCE MAJEURE	23
ARTICLE 11	GOVERNING LAW AND DISPUTE RESOLUTION	23
ARTICLE 12	NOTICE AND DELIVERY	24
ARTICLE 13	MISCELLANEOUS	24

Confidential

Share Sale and Purchase Agreement

This Share Sale and Purchase Agreement (this “**Agreement**”) is made on the sixth day of January 2016 by and among:

- (1) **Nanjing Xinjiekou Department Store Co., Ltd.**, a joint stock company established and validly existing under the laws of the PRC (the “**Purchaser**” or “**XJK**”);
- (2) **Golden Meditech Stem Cells (BVI) Company Limited**, a limited liability company established and validly existing under the laws of the British Virgin Islands (the “**Seller**”); and

- (3) **Golden Meditech Holdings Limited**, a limited liability company established and validly existing under the laws of the Cayman Islands, and the sole shareholder of the Seller (the “**Guarantor**”).

The parties hereto each individually a “**Party**” or such “**Party**”, and collectively the “**Parties**”; and with respect to each other a “**Party**” or the other “**Party**”.

Whereas,

- (A) The Purchaser is a joint stock company duly established and legally existing, with its RMB-denominated ordinary shares being publicly listed on the Shanghai Stock Exchange under the stock code of 600682, and as of the date of this Agreement, the Purchaser has a registered capital of RMB828,016,327, consisting of 828,016,327 RMB-denominated ordinary shares issued and outstanding;
- (B) China Cord Blood Corporation (the “**Target Company**”) is a life sciences enterprise dedicated to the storage of umbilical cord blood stem cells incorporated in the Cayman Islands and listed on the New York Stock Exchange of the United States of America. As of the date of this Agreement, the issued and outstanding share capital of the Target Company consists of 80,083,248 ordinary shares. Upon full conversion of all the Golden Meditech CBs (as defined below) into the Target Company ordinary shares, the Target Company will by then have 120,604,742 ordinary shares issued and outstanding;
- (C) The Seller intends to take the Target Company private and delist it from the NYSE (as defined below) through a Long Form Merger;
- (D) The Purchaser, the Seller and the Guarantor entered into an Agreement to Purchase Assets by Share Issuance and Cash Payment on January 6, 2016 (the “**Purchase Agreement**”), pursuant to which the Purchaser shall purchase from the Seller the Golden Meditech Shares (as defined in the Purchase Agreement) by issuance of certain shares and payment of certain cash amount to the Seller,

Confidential

subject to relevant terms and conditions thereunder. For the avoidance of doubt, the Seller will receive the Golden Meditech Rollover Shares upon Consummation of the Going-private;

- (E) As of the date of this Agreement, the minority shareholders of the Target Company shall collectively hold 34.6% of the aggregate number of shares in the Target Company (taking into account any ordinary shares converted from the convertible bonds) as calculated on a fully-diluted basis, which shall consist of 41,730,636 ordinary shares in the Target Company. Upon Consummation of the Going-private, the Target Company Minority Interest will be cancelled, in consideration of which, the Target Company surviving the Going-private will issue to the Seller 41,730,636 shares, which shall constitute the Target Assets hereunder;
- (F) The Seller or the Guarantor will pay in cash the consideration for the Going-private by using the proceeds received from its financing, and the Seller shall obtain the Target Assets (as defined below) upon Consummation of the Going-private; and
- (G) The Purchaser intends to purchase from the Seller by paying the price in cash, and the Seller intends to sell to the Purchaser, the Target Assets to be obtained by the Seller upon Consummation of the Going-private.

NOW, THEREFORE, the Parties hereby enter into this Agreement for mutual observance after friendly consultations by adhering to the principle of equality, mutual benefit, integrity and good faith.

Article 1 Definitions

1.1 Unless otherwise specified herein, the following terms shall have the meanings as set forth below:

“**Proposed Transaction**” means the proposed transaction through which the Purchaser shall acquire from the Seller by paying the price in cash the Target Assets (as defined below) to be held by the Seller.

“**Target Assets**” means 41,730,636 shares to be issued to the Seller by the Target Company surviving the Going-private upon Consummation of the Going-private.

“**Long Form Merger**” means a process in which the Seller will establish the Merger Sub under the laws of the Cayman Islands and the Merger Sub will be merged with and into the Target Company by a reverse merger. As a result of such merger, the Merger Sub will be merged with and into the Target Company, and the Target Company will survive as a wholly-owned subsidiary of the Seller.

“**COM**” shall have the meaning ascribed to it in the Purchase Agreement.

Confidential

“**HKSFC**” means the Securities and Futures Commission of Hong Kong.

“**HKE**” means the Stock Exchange of Hong Kong Limited.

“**Business Day**” means a day on which banks are generally open for regular banking business in the PRC and the Hong Kong Special Administrative Region, other than Saturdays, Sundays or statutory holidays.

“**Affiliate**” means, with respect to a particular natural person, any of the spouse, children, parents, grandparents, grandparents in law, grandchildren, grandchildren in law, siblings, and the spouses thereof, the siblings of the spouse and other close relatives of such natural person; and with respect to a particular entity, any other entity that controls, or is controlled by or is under common control with such entity, whether directly or indirectly.

“**Transitional Period**” means the period from the date of this Agreement to the Asset Closing Date (as defined below).

“**Merger Agreement**” means the Merger Agreement to be entered into by and among the Seller, certain Affiliates of the Seller, and the Target Company after the date hereof where such parties have reached agreement on the Going-private by then, as amended from time to time after execution thereof.

“**NYSE**” means the New York Stock Exchange.

“**Encumbrance**” means any security interest, pledge, mortgages lien, charge, encumbrance, adverse claim, preferential arrangement, option, right of first refusal, attachment, freezing, entrusted management, or restriction of any kind.

“**Person**” or “**Persons**” shall include any natural person, legal person, enterprise, association of natural persons or enterprises, or group of any of the foregoing.

“**day**” means a natural day, unless otherwise specified herein to be a Business Day.

“**Applicable Law**” means, with respect to a particular Person, any binding published, valid and applicable law, treaty, regulation, inter-governmental agreement, decision, order, local regulation, regulation on the exercise of autonomy and regulation on the exercise of separate autonomy, rule and local government rule, listing rule of any stock exchange, any rule formulated by any competent regulatory authority, and other code in any other form with a legally binding force, whether of the PRC or any other jurisdiction, which in each case is applicable to such Person or binding upon such Person or any of his/her assets.

“**Taxes**” means any and all mandatory taxes, assessments, duties, fees, or levies of any form or any kind (together with any and all penalties, fines, surcharges or interest imposed with respect thereto) imposed by any central, local or municipal

Confidential

Governmental Authority or organization or institution of the PRC or Hong Kong or any other jurisdiction, and shall include income taxes, business taxes, resource taxes, value-added taxes, stamp duties, tariffs and any other charges.

“**Going-private**” means the process through which the Seller shall take the Target Company private and have the Target Company delisted from NYSE by means of the Long Form Merger, pursuant to which, the Target Company shall survive, the Golden Meditech Shares owned by the Seller shall be cancelled in exchange for the Golden Meditech Rollover Shares (as defined in the Purchase Agreement), and the Seller shall pay the Target Company Minority Shareholders (as defined below) cash consideration in consideration of the cancellation of the Target Company Minority Interest and at the same time receive certain equity interest to be newly issued by the Target Company of an amount equal to the Target Company Minority Interest, upon consummation of which, the Seller will own 100% of the equity interest in the Target Company.

“**Consummation of the Going-private**” means that the Going-private has been approved by the shareholders of the Target Company at the shareholders’ meeting, the plan of merger (i.e., the Plan of Merger under the Cayman Islands) has been registered with the Registrar of the Company of the Cayman Islands and become effective, the delisting application submitted to the U.S. Securities and Exchange Commission by the Target Company has become effective, and the Seller has obtained the entire ownership of the Target Assets.

“**Damages**” means any losses, expenses (including reasonable investigation expenses and reasonable attorney fees), damages or harm, or claims against any Person, including without limitation, any liabilities for indemnification determined by any judgment, decision or settlement.

“**RMB**” means, for the purpose of this Agreement, Renminbi Yuan, the lawful currency of the PRC, unless otherwise indicated.

“**Governmental Authority**” means any legislative, administrative, judicial, regulatory or governmental authority, agency, commission, or securities regulatory authority, including any stock exchange, whether in China or any other jurisdiction.

“**China**” or “**PRC**” means the People’s Republic of China, which for the purpose of this Agreement, shall exclude the Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan.

“**Asset Closing Date**” means the date on which the sale and purchase of the Target Assets takes place, or in other words, the date on which the Target Assets are transferred to XJK and the registration of such transfer is completed in accordance with the procedures required by Applicable Laws.

“**Target Company Minority Shareholders**” means as of the date of this Agreement, all the shareholders of the Target Company other than the Seller,

who shall collectively own 34.6% of the aggregate number of shares in the Target Company (taking into account any ordinary shares converted from the convertible bonds) as calculated on a fully-diluted basis.

“**Target Company Minority Interest**” shall have the meaning ascribed to it in the Purchase Agreement.

“**Purchase Price**” means the price to be paid by the Purchaser to the Seller in consideration of its acquisition of the Target Assets, which shall be equivalent to US\$267,076,070 calculated on the basis of the exchange rate of US\$1 against RMB6.466.

1.2 Interpretation

Unless otherwise specified herein, this Agreement shall be interpreted as follows:

- (1) Any reference to any law or regulation in this Agreement shall include a reference to any and all of the laws and regulations as amended or reenacted, that are applicable, published, and publicly available, or revised (whether prior to or after the date hereof) in accordance with any other law or regulation of the PRC.
- (2) Any reference to any chapter, article, section, item, exhibit or annex shall be a reference to the corresponding chapter, article, section, item, exhibit or annex in or to this Agreement.
- (3) The headings used in this Agreement are for convenience only, and shall not affect the interpretation of this Agreement.
- (4) Any annex referred to herein or attached hereto shall constitute an integral part of this Agreement, and shall have the equal legal effect as this Agreement.
- (5) The word “written” or “writing” means any communication transmitted by letter, email or fax.
- (6) The word “including” used herein shall be interpreted to be “including without limitation”.
- (7) Any Party hereto shall include any of its successors and permitted assigns.
- (8) Where the date on which any action, matter or issue shall be taken, done or handled under this Agreement is not a Business Day, such action, matter or issue shall be taken, done or handled on the Business Day immediately following such date.

Confidential

Article 2 Transaction Arrangements

2.1 Target Assets

2.1.1 As of the date of this Agreement, the basic particulars of the operating entity to which the Target Assets hereunder relate are as follows:

Company Name:	China Cord Blood Corporation
Registered Address:	Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111, Cayman Islands
Date of Establishment:	June 30, 2009
Authorized Share Capital:	US\$25,100

2.1.2 As of the date of this Agreement, the Target Company Minority Shareholders that the Seller intends to buy out as part of the Going-private shall collectively hold 34.6% of the Target Company shares, which shall consist of 41,730,636 ordinary shares in the Target Company. In connection with the Going-private, the Target Company shall survive, and the Seller shall pay in cash the Target Company Minority Shareholders a price in consideration of the cancellation of the Target Company Minority Interest. The Target Company surviving the Going-private shall issue to the Seller 41,730,636 shares, i.e., the Target Assets.

2.1.3 The Seller agrees to sell to the Purchaser the Target Assets following the Seller’s receipt of the same, in accordance with the terms and conditions in this Agreement. For the avoidance of doubt, this Section shall not be interpreted as to obligate the Seller and/or the Guarantor to consummate the Going-private in any event.

2.1.4 The Purchaser agrees to purchase from the Seller the Target Assets in accordance with the terms and conditions in this Agreement. With a view to ensuring the effectuation of the purpose of each Party for entering into the Proposed Transaction, the Purchaser further undertakes irrevocably that, subject to satisfaction of each and both of the following conditions, the Purchaser shall be obligated to perform the obligation to purchase the Target Assets hereunder, which obligation shall be irrevocable in any event, and the Purchaser shall waive irrevocably in advance any of the contractual right, right of defense or right of action that may be available to it pursuant to which it may be released from the performance of or not perform the obligation to purchase the Target Assets hereunder:

Confidential

- (a) This Agreement has taken effect in accordance with Section 7.2 hereof; and

- (b) Each and all of the closing conditions set forth in Article 3 herein below have been fully satisfied or waived in accordance with Section 3.6 herein below.

Subject to satisfaction of each and both of the conditions described above, unless the Purchaser is given and does exercise pursuant to this Agreement the right to unilaterally dissolve this Agreement, the Seller shall have the right to reject the Purchaser's request to dissolve or terminate this Agreement and shall have the right to demand the Purchaser's further performance of this Agreement and bring a claim for enforcement of this Agreement against the Purchaser. The Purchaser shall waive irrevocably in advance any of the right of action or right of defense that may be available to it under those or any of the above-mentioned circumstances, including without limitation, the right to dissolve this Agreement by assuming the liability for breach and/or indemnification and/or paying a termination fee and/or any other consideration, and may not reject any of the Seller's demand for the Purchaser's further performance of this Agreement, and shall further and properly perform the obligation to acquire the Target Assets. In the event that as a result of the Purchaser's breach of its undertaking or obligation as described above, the Seller applies to an arbitral institution in accordance with this Section for the making of an arbitral award ordering the Purchaser to further perform the obligation to purchase the Target Assets from the Seller, the Purchaser shall irrevocably undertake to waive any of the right of action and/or right of defense that may be available to it under those or any of the above-mentioned circumstances, including without limitation, the right to dissolve this Agreement by assuming the liability for breach and/or indemnification and/or paying a termination fee and/or any other consideration, as well as any and all of the right of action, right of defense and/or any other right/power that may be available to the Purchaser and may prevent and/or prejudice the Seller's bringing of a claim against the Purchaser for performance of or enforcing against the Purchaser the obligation to purchase the Target Assets, so as to ensure the effectuation of the Seller's demand for the Purchaser's further performance of the obligation to purchase the Target Assets and the Seller's purpose for entering into the Proposed Transaction. The Purchaser's obligation to purchase the Target Assets as mentioned above shall include at least, the obligation to close by acceptance of the Target Assets, the obligation to conduct the said closing and the obligation to pay the Purchase Price.

2.2 Basis for Purchase Price Determination and Purchase Price

- 2.2.1 The Parties agree that the Cash Consideration hereunder shall be converted to US dollar equivalent at the exchange rate of US\$1 against RMB6.466 and then paid to the Seller in US dollar. The Cash

7

Confidential

Consideration payable by the Purchaser to the Seller shall be equal to US\$267,076,070.

- 2.2.2 Where upon the Consummation of the Going-private, the aggregate amount paid by the Seller in order to obtain the shares constituting the Target Assets exceeds the Purchase Price, any such excessive amounts shall be borne by the Seller and the Guarantor. Where the Purchaser or the Target Company is obligated to bear such excessive amounts as required by applicable Laws, the Seller and the Guarantor shall reimburse the Purchaser or the Target Company accordingly within five Business Days following the payment of such excessive amounts by the Purchaser or the Target Company. For the avoidance of doubt, notwithstanding this Section, any obligation for additional payment resulting from the exercise by the dissenting shareholders of the Target Company of their appraisal rights in the course of the Going-private, shall be borne by the Seller and the Guarantor in accordance with Section 8.4 herein below.

2.3 Closing

- 2.3.1 Subject to the taking effect of this Agreement in accordance with Section 7.2 and the continuous satisfaction or waiver of each of the Purchaser's Closing Conditions and the Seller's Closing Conditions, the Asset Closing Date shall fall on a date within 20 Business Days as of the fulfillment or waiver in accordance with Article 3 of each and all of the closing conditions set forth under Article 3 (including the Seller's Closing Conditions and the Purchaser's Closing Conditions), or on any other date as otherwise mutually agreed among the Parties.
- 2.3.2 On the Asset Closing Date, the Seller shall register the Target Assets under the name of the Purchaser in accordance with the procedures required by Applicable Laws, and deliver to the Purchaser the following documents:
- The Target Company shall deliver to the Purchaser a copy of its register of members signed for acknowledgement by one director of the Target Company evidencing that the Purchaser has been effectively registered on its shareholder register as owner of the Target Assets, and a copy of a share certificate signed for acknowledgement by one director of the Target Company evidencing that the Purchaser owns the Target Assets; and
 - The Seller shall or shall cause the Target Company to, deliver to the Purchaser a copy of the Memorandum and Articles of Association of the Target Company adopted immediately after Consummation of the Going-private (the "**Post-Going-Private M&A**") and the shareholder resolution of the Target Company approving the

8

Confidential

Post-Going-Private M&A.

- Directors of the Target Company nominated by the Seller shall have delivered to the Purchaser letters of resignation to resign from their position as directors of the Target Company, effective immediately as of the Purchaser's full performance of its obligation to pay the Purchase Price; and the shareholder meeting of the Target Company shall have approved that the director nominated by the Purchaser shall be elected as directors of the Target Company and constitute all the member of the board of directors of the Target

Company, the appointment of which directors so elected shall take effect immediately as of the Purchaser's full performance of its obligation to pay the Purchase Price.

For the avoidance of doubt, Section 2.3.2 shall not limit in any way any other agreement among the Parties.

2.3.3 The Purchaser shall become a legal shareholder of the Target Company as of the Asset Closing Date.

2.3.4 The Purchaser shall pay the Seller the Purchase Price within 40 Business Days following the Asset Closing Date.

Article 3 Closing Conditions

3.1 Closing Conditions

The closing under this Agreement shall be subject to (a) the satisfaction or waiver of each of the Purchaser's closing conditions and the Seller's closing conditions on or prior to December 31, 2016 or any other date otherwise agreed in writing among the Parties (the "**Closing Condition Fulfillment Deadline**"), and (b) the fulfillment of each of the conditions to effectiveness of this Agreement set forth in Section 7.2 hereof.

3.2 Purchaser's Closing Conditions

3.2.1 Each of the Seller and the Guarantor shall have disclosed fully and completely to the Purchaser the information relating to the assets, liabilities, interests, security interest provided to third parties, and status of the equity interest of the Target Company which may have a material effect on the Proposed Transaction;

3.2.2 Except as disclosed publicly or disclosed to the Purchaser by using an information disclosure letter which refers specifically to Section 3.2.2 and waived by the Purchaser, within the Transitional Period, the Target Company shall have conducted its business normally, no material adverse change shall have occurred to the legal person status,

Confidential

capitalization structure, financial status or substantial assets of the Target Company, and the Target Company shall not have committed any material violation of law or regulation, other than any material adverse change and/or material violation of law or regulation arising from any litigation resulting from and/or any restructuring or recapitalization related to the Going-private;

3.2.3 Except as disclosed to or waived by the Purchaser, within the Transitional Period, the Target Company shall not have disposed of its substantial assets or created any security interest or any other encumbrance on its substantial assets, or incurred or assumed any material indebtedness, unless as confirmed by all the Parties as necessary for its ordinary course of business and does not subject the Target Company to any material indebtedness;

3.2.4 On the Asset Closing Date, all the representations and warranties made by each of the Seller and the Guarantor hereunder are true, accurate, and complete, free from false records, misleading representations or material omissions; and

3.2.5 Each of the Seller and the Guarantor shall have performed and complied with in material aspects all the undertakings that are required hereunder to be performed or complied with on or prior to the Asset Closing Date.

3.3 Seller's Closing Conditions

3.3.1 Except as disclosed publicly or disclosed to the Seller by using an information disclosure letter which refers specifically to Section 3.3.1 and waived by the Seller, within the Transitional Period, the Purchaser shall have conducted its business normally, no material adverse change shall have occurred to the legal person status, capitalization structure, financial status or substantial assets of the Purchaser, and the Purchaser shall not have committed any material violation of law or regulation;

3.3.2 On the Asset Closing Date, all the representations and warranties made by the Purchaser hereunder are true, accurate, and complete, free from false records, misleading representations or material omissions;

3.3.3 The Purchaser shall have performed and complied with in material aspects all the undertakings that are required hereunder to be performed or complied with on or prior to the Asset Closing Date;

3.3.4 The Target Assets Reverse Pledge Agreement in the form of Annex 1 hereto, together with all the appendices thereto, shall have been executed and delivered to the Seller;

3.3.5 The Purchaser shall maintain its status as a listed company on SSE, and

Confidential

there shall not exist any circumstances which by common business or legal sense are reasonably expected to result in the Purchaser's loss of the status as a listed company on SSE.

3.4 Responsibility for Fulfillment of Closing Conditions

3.4.1 Each of the Seller and the Guarantor shall use its best efforts to maintain or fulfill the conditions set forth in Section 3.2.

3.4.2 The Purchaser shall use its best efforts to maintain or fulfill the conditions set forth in Section 3.3.

3.5 Other Conditions Imposed by Governmental Authorities

Where in the course of seeking approvals from applicable Governmental Authorities as set forth under Section 7.2, any competent Governmental Authority demands any change to any term of this Agreement or any addition of any term or condition to this Agreement or imposes any additional condition on any Party which has a material adverse effect on the interest of such Party, the Parties shall as soon as practicable and in principle no later than ten (10) Business Days as of the occurrence of such event, have discussions and enter into renegotiations in good faith on the relevant terms and conditions with a view to achieving the commercial objectives originally contemplated by the Parties to the extent permitted by Applicable Laws; provided however that, where the Parties fail to reach agreement on any amendment to this Agreement or to any term or condition of this Agreement within 20 Business Days as of the date on which such competent Governmental Authority makes such demand or any other period agreed among the Parties, any Party shall within 10 Business Days as of expiration of the aforementioned period, have the right to unilaterally terminate this Agreement by written notice.

3.6 Waiver of Closing Conditions

3.6.1 On or prior to the Asset Closing Date and no later than December 31, 2016, by giving written notice to the Seller, the Purchaser may waive conditionally or unconditionally, any or all of the conditions set forth in Section 3.2. In the event that the Purchaser gives a written notice that all or any of the conditions set forth in Section 3.2 have or has been fulfilled or waived, such written notice or waiver shall not operate as the Purchaser's nonreliance upon the representations and warranties made by the Seller or release the Seller from any obligation required to be performed by the Seller on or prior to the Asset Closing Date and no later than December 31, 2016, instead, it shall represent only that the Purchaser will proceed with the closing of the transactions under this Agreement in reliance on such representations, warranties and status of the performance of such obligation, and that the Purchaser will reserve its right to hold the Seller liable for the relevant default in accordance with this Agreement.

Confidential

3.6.2 On or prior to the Asset Closing Date and no later than December 31, 2016, by giving written notice to the Purchaser, the Seller and the Guarantor may waive conditionally or unconditionally, any or all of the conditions set forth in Section 3.3. In the event that the Seller and the Guarantor give a written notice that all or any of the conditions set forth in Section 3.3 have or has been fulfilled or waived, such written notice or waiver shall not operate as the nonreliance by the Seller or the Guarantor upon the representations and warranties made by the Purchaser or release the Purchaser from any obligation required to be performed by the Purchaser on or prior to the Asset Closing Date and no later than December 31, 2016, instead, it shall represent only that the Seller and the Guarantor will proceed with the closing under this Agreement in reliance on such representations, warranties and status of the performance of such obligation, and that each of the Seller and the Guarantor will reserve its right to hold the Purchaser liable for the relevant default in accordance with this Agreement.

3.7 Delay in Fulfillment of the Closing Conditions

3.7.1 In the event that any of the Purchaser's closing conditions fails to be fully fulfilled and satisfied and the Purchaser has indicated expressly that it will not waive any of such Purchaser's closing conditions that fails to be satisfied, the Purchaser shall have the right to terminate this Agreement, in which case, Section 7.5.2 shall apply.

3.7.2 In the event that any of the Seller's closing conditions fails to be fully fulfilled and satisfied and the Seller has indicated expressly that it will not waive any of such Seller's closing conditions that fails to be satisfied, the Seller shall have the right to terminate this Agreement, in which case, Section 7.5.1 shall apply.

Article 4 Representations and Warranties

4.1 Common Representations and Warranties

Each Party hereby represents to the other Parties that:

4.1.1 It is a company or enterprise duly organized, validly existing and in good standing under the laws of the jurisdiction of its establishment and has full civil rights and civil capacity to independently carry out its obligations to any other parties;

4.1.2 It has all the necessary power, authority and approval under Applicable Law to enter into this Agreement and to perform each of its obligations under this agreement. For the avoidance of doubt, each of those stated in Section 7.2 (as applicable) shall be excluded;

Confidential

4.1.3 It has taken all appropriate and necessary corporate actions to authorize the execution and delivery of this Agreement and any other documents hereunder to which it is a party, and has authorized to perform and comply with the terms and conditions set forth in this Agreement and such other documents. For the avoidance of doubt, each of those stated in Section 7.2 (as applicable) shall be excluded;

- 4.1.4 The person acting on behalf of it to enter into this Agreement and any other documents hereunder to which it is a party has been granted irrevocable, legal and full authorization to enter into on its behalf and bound by this Agreement and such other documents; and it shall not defend itself against any other Parties by reason of lack of power of attorney, exceeding the scope of power of attorney or any other defects in the authorization;
- 4.1.5 Its execution of this Agreement and any other documents hereunder to which it is a party does not and will not violate (a) any of its organizational documents, (b) any contracts, agreements, permits or any other instruments to which it is a party or by which it is bound, or (c) any orders, effective judgments, arbitral awards, judicial rulings, administrative decisions, policies, regulations, orders or rules applicable to it. For the avoidance of doubt, each of those stated in Section 7.2 (as applicable) shall be excluded; and
- 4.1.6 There are no actions, arbitrations or any other legal or administrative proceedings or governmental investigations pending against it, which would have a substantial effect on its execution of or ability to perform this Agreement, and to its knowledge, there are no such actions, arbitrations or any other legal or administrative proceedings or governmental investigations threatened by any Governmental Authority or other third parties against it for its execution or performance of this Agreement.

4.2 Representation, Warranties and Covenants of the Seller and the Guarantor

The representations, warranties and covenants made by the Seller and the Guarantor in Section 4.2 of the Purchase Agreement shall be applicable to this Agreement and constitute an integral part of this Agreement.

4.3 Representations and Warranties of the Purchaser

The representations, warranties and covenants made by the Purchaser in Section 4.3 of the Purchase Agreement shall be applicable to this Agreement and constitute an integral part of this Agreement.

4.4 Reliance on the Representations and Warranties

13

Confidential

One Party acknowledges that the other parties have considered the representations and warranties made by such Party in entering into this Agreement, which representations and warranties are factors considered by the other Parties determined to execute this Agreement.

4.5 Further Statement

Each representation and warranty made in this Agreement shall be deemed a separate representation and warranty, unless otherwise agreed in this Agreement, and each forgoing representation and warranty shall not be subject to any restriction or limitation due to reference to or be quoted by any other clauses of representations or warranties or any other clauses of this Agreement.

4.6 Effectiveness

The representations and warranties under Article 4 of this Agreement shall continue to be effective from the execution of this Agreement throughout the Asset Closing Date. Each Party undertakes that it shall promptly notify the other Parties in writing if it becomes aware of anything occurring during the period from the date of this Agreement throughout the Asset Closing Date that would make any representation or warranty become untrue, inaccurate or misleading in any material respect.

Article 5 Further Covenants

- 5.1 The Seller and its Affiliates will make all reasonable efforts to consummate the Going-private and cause the Seller to obtain the ownership in the Target Assets.
- 5.2 Sections 5.1, 5.2, 5.3, 5.4, 5.8, 5.9, and 5.10 of the Purchase Agreement shall be applicable to this Agreement and constitute an integral part of this Agreement.
- 5.3 Subject to any Applicable Law, the Seller and the Guarantor shall notify other Party of any progress in relation to the Going-private.

Article 6 Confidentiality

6.1 Obligation of Confidentiality

Other than circumstances set forth in Section 6.2 hereof, any Party hereto shall not, and shall cause any of its Affiliates, directors, officers, employees, shareholders, agents or the directors, officers, employees, agents, financial advisor or accountant of the Target Company not to, disclose information set forth below to any third parties, without the prior written consent of other Parties: (a) any discussions and assessments among the Parties in relation to the assignment contemplated hereunder, and any terms and conditions thereof; (b) the existence of this Agreement and any of its terms and conditions; and (c) any

14

Confidential

private, secretive, or confidential data and information obtained by any Party from other Parties in connection with the execution of this Agreement or performance of the assignment contemplated hereunder (collectively “**Confidential Information**”), and shall keep the Confidential Information in strict confidence, provided that the obligation of confidentiality shall not apply to any information that, at the time of disclosure, (i) is or has been available publicly, other than for the reason of disclosure directly or indirectly by the receiving party; or (ii) has been made available to the receiving party and not bound by the obligation of confidentiality, or Confidential Information obtained independently by the receiving party without assistance, utilization, or use of Confidential Information.

6.2 Exceptions

Each Party agree, it may disclose or divulge the Confidential Information only to the extent that:

- 6.2.1 for the purpose of the performance of the assignment contemplated hereunder, it may disclose to the officers, directors, legal counsel, financial advisor, accountant on a need to know basis in connection with the performance of duties and only to the extent of such basis. The disclosing party shall procure that any person receiving Confidential Information shall be fully aware of the confidential nature of Confidential Information and the obligation of confidentiality assumed by such disclosing party, and shall procure that any person receiving Confidential Information shall abide by the same obligation of confidentiality; or
- 6.2.2 it is permitted to make disclosures to the person otherwise agreed in writing by other Parties hereto; or
- 6.2.3 it is required by Applicable Laws to make disclosures or announcements to any stock exchange or Governmental Authority, in which case it shall give other Parties reasonable written notice in advance and make accurate disclosure with the content being determined by the Parties jointly to the extent as required by Applicable Laws.

6.3 Duties

Each Party shall be liable for any breach of terms set forth in Section 6.1 by any of its Affiliates, directors, officers, employees, shareholders, agents, and its legal counsel, financial advisor and/or accountant.

Article 7 Effectiveness and Termination

7.1 Formation

15

Confidential

This Agreement shall be formed after being executed by the Parties.

7.2 Effectiveness

This Agreement shall take effect on the date when all conditions set forth below are satisfied:

- 7.2.1 The matters under the Proposed Transaction have been approved by the board of directors and the shareholder meeting of the Purchaser;
- 7.2.2 The matters under the Proposed Transaction have been approved by the board of directors of the Seller;
- 7.2.3 This Agreement and the matters under the Proposed Transaction have been approved by the board of directors and the shareholder meeting of the Guarantor;
- 7.2.4 The Guarantor has fulfilled applicable requirements of HKex and other regulatory authorities, and has obtained the approval or verification (if applicable) of such regulatory authorities in relation to the Proposed Transaction;
- 7.2.5 The Seller and the Guarantor have obtained any and all consents and/or waivers of the sponsors that will provide financing to the Going-private in relation to the execution/performance by the Seller and the Guarantor of this Agreement and the Proposed Transaction;
- 7.2.6 The Purchase Agreement has become effective;
- 7.2.7 The Going-private has been consummated and the Seller has acquired the Target Assets pursuant to Applicable Laws; and
- 7.2.8 The Purchaser has obtained approval or verification (if applicable) of relevant regulatory authorities in relation to the Proposed Transaction.

7.3 Termination

This Agreement may be terminated:

- 7.3.1 by mutual written consent of the Parties;
- 7.3.2 if this Agreement fails to take effect on or prior to the first anniversary of the date hereof;
- 7.3.3 upon the occurrence of any circumstance under which the Purchase Agreement shall be terminated;

Confidential

- 7.3.4 by any Party pursuant to Section 3.7 hereof;
- 7.3.5 if any permanent injunction, regulation, rules or order rendered by the competent Governmental Authority that makes restrictions on, bans or terminates the assignment contemplated hereunder has become final and non-appealable, then any Party is entitled to terminate this Agreement by giving a written notice; where a Party terminates this Agreement by giving a notice, the termination date shall be the date as set forth in such notice, or the day when the notice is given, in case no date contained therein.
- 7.3.6 upon the occurrence of any circumstance as set forth in Section 10.3 (Force Majeure) hereof;
- 7.3.7 if the Purchaser fails to pay the entire Purchase Price in full within the prescribed period set forth in this Agreement, and such payment of the entire Purchase Price is overdue for more than thirty (30) days, the Seller has the right to dissolve this Agreement unilaterally in writing;
- 7.3.8 In the event any Party commits material breach of the terms of this Agreement which affects the specific performance of this Agreement, and such Party fails to remedy such breaches within thirty (30) days after receipt of the written notice given by the non-breaching party that requests an immediate remedy, the non-breaching party shall have the right to terminate this Agreement unilaterally by written notice; or
- 7.3.9 by any Party after serving other Parties the written notice of termination in accordance with the contractual rights (if any) expressly provided by the relevant terms of this Agreement (including supplementary agreement hereof).

7.4 Effect of Termination

- 7.4.1 All rights and obligations of each Party under this Agreement shall become void upon termination of this Agreement, provided that:
- (a) any terms that shall survive the termination of this Agreement in accordance with provisions of this Agreement, or determined based on the nature of the terms or in the context of this Agreement, and any terms that are required for the interpretation or implementation of this Agreement, shall survive the termination of this Agreement; and
 - (b) termination of this Agreement shall not affect any rights and obligations of any Party incurred prior to such termination and, without prejudicing the generality of such provisions, termination of

Confidential

this Agreement shall not cancel or affect any rights of a Party to seek Damages in respect of any violations by other Party of this Agreement, unless otherwise specified in this Agreement.

- 7.4.2 None of the Parties shall be held liable for default in case this Agreement is terminated in accordance with Sections 7.3.1, 7.3.2, 7.3.3, 7.3.5 and 7.3.6 above, other than the liabilities for termination as provided in the Purchase Agreement;
- 7.4.3 Each of the Parties shall assume liabilities of breach arising from termination of this Agreement pursuant to Section 7.5 in case this Agreement is terminated in accordance with Section 7.3.4;
- 7.4.4 If this Agreement is terminated by Section 7.3.7 and Section 7.3.8, the breaching party shall be liable for breach and indemnify other Parties of any losses that are actually incurred. For the avoidance of doubt, none of the Parties shall be liable for any breach in case this Agreement is terminated due to the matters under Section 8.5 and Section 8.6; and
- 7.4.5 The terms in relation to confidentiality, liability of breach, governing law and dispute resolution shall survive the termination of this Agreement.

7.5 Termination Fee

- 7.5.1 The Purchaser shall pay the Seller a termination fee equal to US\$30 million within 20 Business Days upon receipt of the written notice of the Seller, in the event that the Seller shall dissolve this Agreement unilaterally in accordance with this Agreement, if:
- (a) Any circumstances set forth in Section 3.7.2;
 - (b) Subject to other covenants contained herein, upon full satisfaction (or waiver in accordance of this Agreement) of the closing conditions, the Purchaser refuses to close or accept the closing conditions, and continue to refuses to close or accept the closing conditions within 30 days following the notice of the Seller, then the Seller shall (have the right but not be obligated to) dissolve this Agreement unilaterally; or
 - (c) Subject to other covenants contained herein, upon 40 Business Days following the Asset Closing Date, if the Purchaser fails to perform or improperly performs the obligation of payment of the Purchase Price and continues to fail to perform the obligation of payment of the Purchase Price within 30 days after the Seller gives a written notice to the Purchaser, then the Seller shall dissolve this Agreement unilaterally.

Confidential

For the avoidance of doubt, the Purchaser shall not be required to pay any termination fee arising from the matter as set forth in Section 8.6.

- 7.5.2 The Seller shall pay the Purchaser a termination fee equal to US\$30 million within 20 Business Days following receipt of the written notice from the Purchaser, in the event that the Purchaser shall terminate this Agreement unilaterally under any circumstance set forth in Section 3.7.1.

For the avoidance of doubt, the Seller shall not be required to pay any termination fee arising from the matters as set forth in Section 8.5.

Article 8 Liability for Breach and Indemnification

- 8.1** Any breach by a Party hereto of its representations, warranties, covenants, or any false representations, non-performance of any rights and obligations hereunder shall constitute a breach, and upon request of the non-breaching party, the breaching party shall continue to perform its obligations, take remedy measures, or make any indemnification that shall be comprehensive, timely, adequate, and effective.
- 8.2** In case that any non-performance, delay in performance, or unduly performance of any obligations hereunder by any Party results in any failure to achieve the purposes of this Agreement, the non-breaching Party shall have the right to dissolve this Agreement, and the breaching Party shall indemnify any other Parties of the losses on a full indemnity basis, provided that, in no event the maximum amount of damages to be made by the breaching Party to other Parties shall exceed the Purchase Price. Such maximum amount of Damages shall not in any way conflict with, and shall be subject to, the terms in relation to the termination fee set forth in Section 7.5. Where any Party is liable for payment of both Damages and the termination fee, such party shall make payment of both Damages and the termination fee, and shall not seek defenses or refuse to perform such obligation by the excuse of the maximum amount of Damages.
- 8.3** None of the Parties shall be liable for any breach in case the Proposed Transaction does not take effect or consummate with no fault of the Parties hereto.
- 8.4** Without prejudicing any other rights and remedies to which the Purchaser is entitled hereunder, the Seller and the Guarantor shall, jointly and severally, indemnify the Purchaser from and against any liabilities and losses (including without limitation, any damages, penalties, fines, and any costs of investigation, legal costs, professional fees, accountant fees, and other costs that are

Confidential

reasonably incurred in relation to any action, or asset or value impairment of the Target Company), arising out of, or in connection with matters set forth below; the Seller shall, jointly and severally, indemnify the Purchaser from and against any liabilities and losses (including without limitation, any damages, penalties, fines, and any costs of investigation, legal costs, professional fees, accountant fees, and other costs that are reasonably incurred in relation to any action, or asset or value impairment of the Target Company), arising out of, or in connection with any matters set forth below, which include, without limitation: (i) any action or arbitration against the Target Company, the Purchaser and its Affiliates arising from Going-private; (ii) the appraisal rights under the Merger Agreement to be exercised by the shareholders of the Target Company pursuant to Companies Law of Cayman Islands Cap 22 (Law 3 of 1961, as revised) — Section 238, and any costs to be borne by the Target Company (including without limitation, costs in lawsuit, costs to shareholders who exercise the appraisal rights); and (iii) all indemnification paid by the Target Company or its surviving entity under the Merger Agreement for Going-private, and all costs arising from Going-private (including without limitation, costs to legal counsel, financial advisor, payment agent, etc.)

- 8.5** For the avoidance of doubt, subject to the good faith and great efforts of the Seller and the Guarantor to promote satisfaction of transactional conditions, any case set forth below shall not constitute a breach and the Seller or Guarantor is not obliged to guarantee:
- (a) No approval is obtained at the shareholder meeting of the Guarantor and/or from the HKEx and/or other regulatory authorities (if applicable) in relation to the Going-private or the Proposed Transaction;
 - (b) No approval is obtained from the power authority of the Target Company (including, without limitation, the special committee) and/or NYSE and/or SEC and/or U.S. courts and/or Cayman Islands regulatory authorities in relation to the Going-private or the Proposed Transaction.
 - (c) The Going-private fails to be consummated and the Seller fails to obtain the Target Assets.
- 8.6** For the avoidance of doubt, subject to the good faith and great efforts of the Purchaser to promote satisfaction of transactional conditions, any case set forth below shall not constitute a breach and the Purchaser is not obliged to guarantee:
- (a) No approval or verification is obtained at the shareholder meeting of the Purchaser and/or from the SSE in relation to the Proposed Transaction.

Article 9 Closing Security and Remedies

9.1 Closing Security and Remedies Available to the Purchaser

- 9.1.1 In the event that the Seller fails to duly perform its obligation to conduct the closing of the sale and purchase of the Target Assets on the Asset Closing Date, the Purchaser shall be entitled to bring a claim against the Seller for specific performance of the obligation to conduct such closing, and to receive liquidated damages for delayed closing in accordance with Section 9.1.2. In order to exercise such remedy, the Purchaser shall notify the Seller in writing. Whether the Purchaser terminates this Agreement or not, it shall have the right to claim and receive liquidated damages for delayed payment in accordance with this Agreement
- 9.1.2 For each day the Seller delays the closing of the sale and purchase of any Target Assets past the Asset Closing Date, the Seller shall pay the Purchaser daily liquidated damages which shall be equal to the portion of the value of such Target Assets as of such day (calculated by assuming that the shares constituting the Target Assets shall each have a value of US\$6.4) multiplied by 0.05% (the “**Seller Daily Liquidated Damages Rate**”). The aggregate liquidated damages for delayed closing payable by the Seller shall be equal to the Seller daily liquidated damages multiplied by the number of calendar days elapsed from the date on which the delay in the closing commences and to the date on which the liquidated damages are determined. The Seller Daily Liquidated Damages Rate shall be doubled on the basis of compounding whenever a delay amounts to 30 consecutive days or an integral multiple of such delay arrives.

9.2 Closing Security and Remedies Available to the Seller

- 9.2.1 In the event that the Purchaser fails to perform its obligation to pay the Purchase Price in accordance with this Agreement, the Seller shall have the right to demand the Purchaser to perform its obligation to pay the Purchase Price, and also the right to receive liquidated damages for delayed payment in accordance with Section 9.2.4. In order to exercise such remedy, the Seller shall notify the Purchaser in writing. Whether the Seller terminates this Agreement or not, the Seller shall have the right to claim and receive the liquidated damages for delayed payment in accordance with this Agreement.
- 9.2.2 Where the Purchaser fails to perform properly its obligation to pay the Purchase Price for more than 30 consecutive days, the Seller shall have the right (but no obligation) to exercise any one or more of the following remedies and the security right, all at its own discretion: a) to terminate this Agreement; b) to enforce the pledge created on the relevant Target Company shares set forth in Section 9.3; c) to receive liquidated damages so as to hold the Seller and/or the Target Company harmless from any loss in accordance with the other terms of this

Agreement; and d) to claim the payment of liquidated damages for delayed payment set forth under Section 9.2.4.

- 9.2.3 Any exercise of any remedy or security right by the Seller set forth under Section 9.2 shall not in any way operate as or be interpreted as a waiver of any other remedy or security right.
- 9.2.4 For each day the Purchaser delays the payment of any portion of the Purchase Price, the Purchaser shall pay the Seller the daily liquidated damages which shall be equal to the portion of the Purchase Price delayed as of such day multiplied by 0.05% (the “**Purchaser Daily Liquidated Damages Rate**”). The aggregate liquidated damages payable by the Purchaser shall be equal to the Purchaser daily liquidated damages multiplied by the number of calendar days elapsed from the date on which the delay in the payment commences and to the date on which the liquidated damages are determined. The Purchaser Daily Liquidated Damages Rate shall be doubled on the basis of compounding whenever a delay amounts to 30 consecutive days or an integral multiple of such delay arrives.

9.3 Reverse Pledge of the Target Assets

- 9.3.1 Prior to the Closing Condition Fulfillment Deadline, the Purchaser and the Seller shall, in accordance with the laws of Cayman Islands, enter into a Share Pledge Agreement in the form of Annex 1 hereto, together with all the appendices thereto (including without limitation, a share transfer instrument) (the “**Target Assets Reverse Pledge Agreement**”). The Target Assets Reverse Pledge Agreement shall take effect upon satisfaction of certain conditions, including, the actual performance and consummation by the Parties of the closing of the sale and purchase of the Target Assets, and shall provide that, assuming that the Parties have consummated the closing of the sale and purchase of the Target Assets in accordance with this Agreement, until the Purchaser has actually performed fully its obligation to pay the Purchase Price and any other amount payable by it under this Agreement and relevant transaction documents, including without limitation, liquidated damages, Damages, termination fee, and any other amount, the Purchaser shall pledge to the Seller the Target Assets obtained by it hereunder to secure the Purchaser’s performance of its obligation to pay all or any portion of the Purchase Price and any other amount payable by it under this Agreement and relevant transaction documents. Promptly within 10 Business Days as of the payment in full by the Purchaser of the Purchase Price and any other amount payable by it in accordance with the foregoing provisions, the Seller shall have such pledge so created over the Target Assets released and return to the Purchaser any and all of the documents and share certificates that should be returned.
- 9.3.2 In addition, the Purchaser undertakes that it shall bear the reasonable expenses and fees incurred by the Seller in the exercise or enforcement

Confidential

of the security interest, including without limitation, the expenses and fees to be incurred in the pursuit of litigations, obtaining of writs, enforcement, evaluation (to the extent necessary), and engagement of intermediary agencies.

Article 10 Force Majeure

- 10.1** If any Party hereto fails to perform all or part of its obligations hereunder affected by a force majeure event, performance of such obligations may be suspended for a period when such force majeure event lasts. An force majeure event means any event which is beyond the reasonable control of the affected Party, unforeseeable, or even if foreseeable is unavoidable or insurmountable, and occurs after the date of this Agreement, and such events render the performance of all or part of this Agreement impossible or impracticable. Such events include, without limitation, failure to perform all of part of its obligations hereunder affected by flood, fire, drought, typhoon, earthquake, or other natural disaster, traffic accident, strikes, turbulence, turmoil, and war, and performance of such obligations shall be suspended during the period in which such force majeure events persist.
- 10.2** The Party claiming being effected by a force majeure event shall promptly notify the other Parties in writing and shall furnish the other Party within thirty (30) days thereafter appropriate proof of the occurrence of the force majeure and the expected duration of the adverse effects resulting from such force majeure. The Party claiming a force majeure event renders the performance of all or part of this Agreement impossible or impracticable shall also use all practicable and reasonable efforts to eliminate or mitigate the impacts of the force majeure event on performance of its obligations hereunder.
- 10.3** Upon occurrence of a force majeure event, the Parties shall immediately consult with each other in order to find an equitable solution and shall use all reasonable efforts to minimize the consequences of such force majeure event. If the occurrence or effect of the force majeure event causes material hindrance to the assignment contemplated hereunder with the duration lasting for more than six months, and the Parties fail to agree on any equitable solution, then any Party may terminate this Agreement unilaterally.

Article 11 Governing Law and Dispute Resolution

- 11.1** The entry, validity, interpretation, performance, and dispute resolution in connection with this Agreement shall be governed by PRC laws. Where the ancillary agreements hereto stipulate otherwise with respect to the governing law and application, such stipulations shall prevail.
- 11.2** Any dispute between the Parties hereto in connection with this Agreement shall first be settled by friendly consultations between the Parties. If such dispute cannot be settled through friendly consultations within thirty (30) days after the occurrence of the dispute, any Party may submit the dispute to the China

Confidential

International Economic and Trade Arbitration Commission for arbitration in Beijing in accordance with the arbitration rules then in effect. The arbitration shall be conducted in Chinese language. Where the ancillary agreements hereto stipulate otherwise with respect to the governing law and application, such stipulations shall prevail.

- 11.3** The arbitral award shall be final and binding upon the Parties hereto.
- 11.4** During the period of dispute resolution, other than the disputed matters, the Parties hereto shall continue to perform all other provisions in this Agreement.

Article 12 Notice and Delivery

- 12.1** All notices or written communications to be sent by any Party to other Parties as required under this Agreement shall be given by facsimile or by courier service to any other Parties promptly that shall also be notified via fax, e-mail or telephone. Such notices or written communications given hereunder, unless an earlier date otherwise evidenced, shall be deemed to be delivered on the third calendar day after being given to the courier service company, if delivered by courier service company, or the next Business Day after being given by facsimile, if delivered by facsimile.
- 12.2** All notices and written communications shall be delivered to the addresses set forth below, or any other addresses notified by any Party to the other Parties. In case a Party fails to notify in time any other Parties of any change to such address, the documents delivered to the original addresses shall be deemed having been delivered to such Party.

If to the Seller and Guarantor:

Attention: Yuen Kam
Address: 48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong
Tel: +852 3605 8180
Fax: +852 3605 8181

If to the Purchaser:

Attention: Lijian Pan
Address: No. 1 Zhongshan South Road, Nanjing
Postal code: 210005
Tel: 025-84717494
Fax: 025-84717494

13.1 Guarantee

Without prejudicing the validity of other provisions hereto, the representations,

24

Confidential

warranties, covenants, obligations made by the Seller hereunder shall be deemed to be repeated and assumed by the Guarantor, and the Guarantor shall be liable jointly and severally to the obligations of the Seller under this Agreement.

13.2 Entire Agreement

This Agreement constitutes the entire agreement among the Parties with respect to the matters under the Proposed Transaction as of the date of this Agreement. In case of any conflict between this Agreement and the relevant advice, representations, warranties, agreements, or covenants which were made by Parties prior to this Agreement, the Parties agree this Agreement shall prevail.

13.3 Assignment, Amendment and Supplement

Without prior written consent of the other Parties, any Party may not assign this Agreement or any rights or obligations hereunder. Any amendment and supplement of this Agreement shall be made and mutually agreed in written by and sent to the Parties.

13.4 Further Assurance

For the purposes of granting all rights, power, and relief that are vested under this Agreement to the relevant parties, upon reasonable request by one Party from time to time, the other Parties shall take all such further acts and steps, or shall cause such further acts and steps to be taken, and shall execute all such other documents or procure to execute all such other documents.

13.5 Waiver

No delay or omission on the part of any Party to this Agreement in exercising any right, power or privilege provided by law or provided hereunder shall be deemed a waiver thereof. The single or partial exercise of any right, power or privilege provided by law or provided hereunder shall not preclude any other exercise of any other right, power or privilege.

13.6 Severability

If any provision of this Agreement is held invalid, illegal or incapable of being enforced, the Parties agree such provision shall be enforced to the greatest extent possible so as to effect the intent of the Parties and the validity, legality, and enforceability of all other provisions of this Agreement shall not be affected in any manner. The Parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties hereto as closely as possible and replace such language that is unenforceable with language that shall be enforceable.

25

Confidential

13.7 Application

Unless otherwise provided herein, this Agreement shall be inure solely to the benefit of and binding upon the Parties hereto and their respective successors and permitted assigns.

13.8 Language

This Agreement shall be written in Chinese language and the Chinese version shall prevail.

13.9 Counterpart

This Agreement shall be executed in eight (8) counterparts, which are equally legally authentic. Each Party shall hold one (1) counterpart, and the remaining counterpart to be maintained by the Purchaser for purposes of obtaining approvals and completing registration in connection with the Proposed Transaction. Each counterpart shall have the same legal effect.

[Signature page follows]

26

Confidential

Purchaser: Nanjing Xinjiekou Department Store Co., Ltd. (Seal)

Legal Representative or Authorized Representative: (Signature)

/S/ YANG Huaizhen

Date: [], 2016

27

Confidential

(Signature Page to Share Sale and Purchase Agreement in relation to China Cord Blood Corporation)

Seller: Golden Meditech Stem Cells (BVI) Company Limited (Seal)

Authorized Representative: (Signature)

/S/ Yuen KAM

Date: [], 2016

Guarantor: Golden Meditech Holdings Limited (Seal)

Authorized Representative: (Signature)

/S/ Yuen KAM

Date: [], 2016

28

Confidential

Share Sale and Purchase Agreement

Annex 1 Target Assets Reverse Pledge Agreement

1

Profit Compensation Agreement

By and between

Nanjing Xinjiekou Department Store Co., Ltd.

and

Golden Meditech Stem Cells (BVI) Company Limited

January 2016

Profit Compensation Agreement

This **Profit Compensation Agreement** (this “**Agreement**”) is made on this sixth day of January 2016 by and between:

Party A: Nanjing Xinjiekou Department Store Co., Ltd.

Address: 1 South Zhongshan Road, Qinhuai District, Nanjing, Jiangsu Province

Legal Representative: Huaizhen Yang

Party B: Golden Meditech Stem Cells (BVI) Company Limited

Address: PO BOX 957, Offshore Incorporation Center, Road Town, Tortola, British Virgin Islands

Authorized Representative: Yuen Kam

Whereas,

- (1) Party A is a joint stock company duly established and legally existing, with its RMB-denominated ordinary shares being publicly listed on the Shanghai Stock Exchange (“**SSE**”) under the stock code of 600682, and as of the date of this Agreement, Party A has a registered capital of RMB828,016,327 and a share capital consisting of 828,016,327 shares;
- (2) Party B is a limited liability company established and validly existing under the laws of the British Virgin Islands;
- (3) China Cord Blood Corporation (the “**Target Company**”) is a limited liability company incorporated in the Cayman Islands and listed on the New York Stock Exchange of the United States of America, being dedicated to the storage of umbilical cord blood stem cells; and
- (4) Party A, Party B and Golden Meditech Holdings Limited entered into an Agreement to Purchase Assets by Share Issuance and Cash Payment on January 6, 2016, pursuant to which Party B has agreed to make a business performance commitment in respect of the profitability of the Target Company and to compensate for the amount by which the actual profit achieved by the Target Company is lower than the committed profit.

For the purpose of protecting the interests of the small and medium-sized shareholders of Party A and after friendly consultation, Party A and Party B hereby reach an agreement as follows for mutual observance in respect of the business performance commitment and compensation involved in the Proposed Transaction:

Article 1 Definitions

For purposes of this Agreement, unless otherwise specified herein or otherwise expressly required by the context, the following terms shall have the meanings set forth below:

“Party A” or “XJK”	means Nanjing Xinjiekou Department Store Co., Ltd.
“Party B”	means Golden Meditech Stem Cells (BVI) Company Limited.
“Target Company”	means China Cord Blood Corporation.
“Proposed Transaction”	means the transaction under which Party A shall issue shares and pay cash consideration to Party B in order to purchase from Party B the Target Company shares held by Party B in accordance with the Agreement to

“Target Assets”	has the same meaning ascribed to “Target Assets” in Purchase Agreement.
“Agreement to Purchase Assets by Share Issuance and Cash Payment”	means the Agreement to Purchase Assets by Share Issuance and Cash Payment entered into by and among Party A, Party B and Golden Meditech Holdings Limited on January 6, 2016, together with any supplements and amendments executed in writing that have taken effect after being legally approved.
“Private Placement”	means the issuance by XJK of shares to Party B as payment of part of the consideration for the Target Assets in accordance with the terms and conditions set forth in the Agreement to Purchase Assets by Share Issuance and Cash Payment.
“Consideration Shares”	means part of the purchase price for the Target Assets to be paid by XJK to Party B in the form of RMB-denominated ordinary shares, which shall be equivalent to RMB2,500 million.
“Commitment Period”	means the period during which the business performance commitment and compensation undertaking shall be applicable, i.e., the three fiscal years 2016, 2017 and 2018 (each of these fiscal years referring to the period starting from January 1 of the relevant year and ending on December 31 of the same year).

“Net Profit”	means the net profit of the Target Company excluding the Non-Recurring Loss/Gain, the loss/gain from changes in the fair value of the convertible bonds, the net gain/loss generated by the equity incentive plan with respect to the restricted shares, together with the professional service fees incurred in the performance of the relevant contract, and all the costs and expenses etc. incurred by the Target Company in the implementation of the going-private transaction, in each case as reflected on the consolidated financial statements of the Target Company. Where within the Commitment Period, subject to prior written consent of Party B, Party A provides any loan to the Target Company, the Net Profit shall exclude any interest expenses in relation to such loan.
“Non-Recurring Loss/Gain”	means the loss/gain determined in accordance with the definition of “Non-Recurring Loss/Gain” and rules regarding items of Non-Recurring Loss/Gain set forth in the <i>Interpretative Announcement of China Securities Regulatory Commission on Information Disclosure by Companies who have Publicly Issued Securities No. 1—Non-Recurring Loss/Gain (2008)</i> .
“CSRC”	means the China Securities Regulatory Commission.
“SSE”	means the Shanghai Stock Exchange.
“Business Day”	means a day on which banks are generally open for regular banking business in the PRC and the Hong Kong Special Administrative Region, other than Saturdays, Sundays or statutory holidays.
“China” or “PRC”	means the People’s Republic of China, which for the purpose of this Agreement, shall exclude the Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan.
“RMB”	means, for the purpose of this Agreement, Renminbi Yuan, the lawful currency of the PRC, unless otherwise indicated.

Article 2 Net Profit Undertaking

- 2.1 The parties mutually agree that the amount based on which the business performance commitment and compensation hereunder are to be determined shall be the Net Profit of the Target Company for any applicable fiscal year during the Commitment Period, as calculated at the end (December 31) of such fiscal year. The fiscal year involved in the calculation of such Net Profit shall be determined in accordance with Section 2.2.
- 2.2 The parties mutually agree that as requested by Party A, Party B undertakes that the Net Profit to be achieved by the Target Company in each of fiscal years 2016, 2017, and 2018 will be as set forth in the following table (the “**Committed Net Profit**”):

Measurement Unit: RMB10,000

	Fiscal year 2016	Fiscal year 2017	Fiscal year 2018
Committed Net Profit	30,000	36,000	43,200

- 2.3 The parties to the Proposed Transaction agree that the Net Profit actually achieved by the Target Company during the Commitment Period shall be calculated based on the following principles:
- 2.3.1 The financial statements of the Target Company shall be prepared in compliance with the *PRC Accounting Standards for Business Enterprises* and other applicable laws and regulations.
- 2.3.2 For the purpose of calculation of the Net Profit, all of the Non-Recurring Loss/Gain, the loss/gain from changes in the fair value of the convertible bonds, the net gain/loss generated by the equity incentive plan with respect to the restricted shares, together with the professional

service fees incurred in the performance of the relevant contract, and all the costs and expenses etc. incurred by the Target Company in the implementation of the going-private transaction shall be excluded.

2.3.3 Where within the Commitment Period, subject to prior written consent of Party B, Party A provides any loan to the Target Company, the Net Profit shall exclude any interest expenses in relation to such loan.

2.4 Exchange Rate and Conversion

Unless otherwise agreed between the parties hereto or otherwise specified herein, any conversion between RMB and US dollar or any other foreign currency involved in the determination of the "Net Profit" hereunder shall be conducted at the exchange rate equal to the central parity rate of Renminbi Yuan against the corresponding foreign currency prevailing on the inter-bank foreign exchange market as published by China Foreign Exchange Trade System on December 31 of the applicable fiscal year under the authorization granted by the People's Bank of China.

4

Article 3 Determination of the Business Performance Commitment

- 3.1 XJK shall engage an accounting firm acceptable to both parties and satisfying the requirements of the competent regulatory authorities to conduct the annual audit on the Target Company for each of the fiscal years during the Commitment Period, and to issue a special audit report on the difference between the Net Profit actually achieved by the Target Company for the relevant period (the "Achieved Net Profit") and the Committed Net Profit for the relevant period. Such difference shall be disclosed separately on the annual report of XJK for the applicable fiscal year during the Commitment Period.
- 3.2 The Achieved Net Profit mentioned above shall be determined subject to Section 2.3.
- 3.3 Where the accumulated Achieved Net Profit of the Target Company at the end of any fiscal year during the Commitment Period under Section 2.2 is lower than the accumulated Committed Net Profit, Party B shall compensate Party A for the shortfall in accordance with Article 4. Where the Achieved Net Profit is equal to or higher than the Committed Net Profit, Party B shall not be required to compensate Party A.
- 3.4 For the avoidance of doubt, in the event that Party A fails to comply with any of its obligations under this Agreement, or Party A takes any action or does any thing whether actively or passively that may have a direct effect on the Net Profit of the Target Company without prior written consent of Party B, any effect on the Net Profit of the Target Company as a result of such failure or action or thing shall be excluded for the purpose of calculation of the Net Profit. The amount of any effect on the Net Profit of the Target Company arising therefrom shall be jointly confirmed by both parties.

Article 4 Implementation of Business Performance Commitment

- 4.1 During the Commitment Period, where the Target Company's accumulated Achieved Net Profit as of the end of the relevant period (meaning the relevant fiscal year, the same hereinafter) is lower than the accumulated Committed Net Profit as of the end of the relevant period, Party B shall pay a compensatory amount to XJK. The aggregate amount of the compensatory amount for the relevant year plus the accumulated compensatory amount for previous years (if any) shall be capped at the amount of Consideration Shares under the Proposed Transaction and calculated as follows:

5

Compensatory amount payable for the relevant year = (accumulated Committed Net Profit as of the end of the relevant year — accumulated Achieved Net Profit as of the end of the relevant year) / aggregate of Committed Net Profit for each fiscal year during the compensation period * Target Assets purchase price (i.e., RMB 5,764 million) – accumulated compensatory amount in relation to business performance undertaking that has been paid.

The aggregate amount of the compensatory amount for the relevant year plus the accumulated compensatory amount for previous years (if any) shall be capped at the amount of Consideration Shares.

- 4.2 Where Party B is required to pay any compensatory amount to XJK for the relevant period in accordance with this Article, Party B shall have the right to choose the compensation in form of shares and/or cash, and the aggregate amount of compensation in form of shares and/or cash paid by Party B for the relevant period to XJK plus the accumulated compensatory amount for previous years (in whatsoever form, if any), in any event, shall not exceed the Consideration Shares acquired by Party B in connection with the Proposed Transaction. The compensatory arrangements shall be made as follows:
- 4.2.1 Number of compensatory shares payable for the relevant year = compensatory amount payable for the relevant year / price per share of the shares to be issued under the Proposed Transaction.
- 4.2.2 Where XJK converts capital reserves into share capital or distributes stock dividends during the Commitment Period, the number of compensatory shares shall be adjusted accordingly:
- Number of compensatory shares for the relevant year (after adjustment) = number of compensatory shares for the relevant year (before adjustment) * (1 + ratio of bonus issue of capital reserves conversion or stock dividends).
- 4.2.3 The cash dividend distributed by XJK during the Commitment Period shall be refunded accordingly. The formula for calculation of such cash dividend to be so refunded shall be:
- Refunded amount = cash dividend per share paid prior to the compensatory payment (subject to the after-tax amount) * number of compensatory shares payable for the relevant year.

6

- 4.2.4 Where Party B makes compensation in form of shares, the compensatory shares shall be repurchased by XJK at the aggregate price of RMB1.00 for cancellation. Where such share repurchase and cancellation are not approved at the shareholder meeting or not recognized by the relevant creditors or otherwise, XJK shall give Party B a written notice. Party B undertakes, within 2 months upon receipt of such notice, to gift such shares to other shareholders of XJK in proportion to the respective percentage of such shares held by other shareholders of XJK to all shares held by all other shareholders of XJK on record as of the date of record for such compensation.
- 4.2.5 The accumulated compensatory amount paid to XJK by Party B shall not exceed the amount of Consideration Shares as part of the Target Assets purchase price. Where the compensatory amount payable on an accumulated basis is lower than or equal to zero, the compensatory amount payable shall be deemed zero, and any compensatory amount that has been paid will not be refunded.
- 4.3 Where upon expiration of the Commitment Period, the accumulated Achieved Net Profit is lower than the accumulated Committed Net Profit, XJK shall, within three months as of expiration of the Commitment Period, engage an accounting firm or appraisal firm acceptable to both parties and satisfying the requirements of the competent regulatory authorities, to issue an impairment test report in relation to the Target Assets. The parties mutually agree, the period-end amount of impairment of the Target Assets calculated based on the spirit and principles set forth in Section 2.3 shall not include (i) non-recurring loss; (ii) the loss/gain from changes in the fair value of the convertible bonds; (iii) loss generated by the equity incentive plan with respect to the restricted shares, (iv) the professional service fees incurred in the performance of the relevant contract, and (v) all the costs and expenses etc. incurred by the Target Company in the implementation of the going-private transaction. Where within the Commitment Period, subject to prior written consent of Party B, Party A provides any loan to the Target Company, the Net Profit, when calculating the period-end amount of impairment of the Target Assets, shall exclude any interest expenses in relation to such loan.

Where the period-end amount of impairment of the Target Assets is higher than the accumulated business performance commitment compensatory amount that has been paid, Party B shall make additional compensation to XJK.

7

Party B shall have the right to choose to make compensation either in form of shares or cash, i.e., the formula for the calculation of compensatory amount payable arising from impairment test in relation to the Target Assets shall be:

Compensatory amount payable as a result of the impairment test = period-end amount of impairment of the Target Assets - compensatory amount that has been paid as the Achieved Net Profit is less than the Committed Net Profit during the Commitment Period (i.e., the aggregate amount of the compensatory amount in cash that has been paid plus the amount equal to the compensatory shares multiplied by price per share of the shares to be issued under the Proposed Transaction); where Party B chooses to make compensation in form of shares, then the formula shall be:

Number of compensatory shares under impairment test = compensatory amount payable as a result of the impairment test / price per share of the shares to be issued under the Proposed Transaction;

Provided that, the aggregate amount of the compensatory amount for impairment of the Target Assets and the accumulated compensatory amount for shortfall in profit shall not exceed the amount of Consideration Shares (A shares) as part of the Target Assets purchase price, i.e., RMB2,500 million.

When calculating such period-end impairment amount, the effect on the net assets caused by such factors as any increase or decrease by XJK of the capital of the Target Company, subject to obtaining the prior written consent of Party B, and any profit distribution to XJK by the Target Company, during the Commitment Period, shall be eliminated. For example, where the capital in the Target Company is decreased during the Commitment Period, the impairment in nominal value of net assets arising from any decrease in paid-up capital and other amount (for example, capital reserve) shall not be counted in the impairment amount, instead, it shall be deemed no capital decrease or impairment in nominal value shall occur; where the Target Company distributes profit to Party A during the Commitment Period, the impairment in nominal value of net assets arising from such profit distribution shall not be counted in the impairment amount, instead, it shall be deemed no profit distribution or impairment in nominal value shall occur.

Where the result is below zero, then the result shall be deemed zero. For the avoidance of doubt, in case the accumulated Achieved Net Profit reaches or exceeds the accumulated Committed Net Profit upon expiration of the Commitment Period, no impairment test is required and Party B is not required to make any compensation to any person in connection with the period-end impairment, if any, of the Target Assets.

8

-
- 4.4 If Party B is liable for shares compensation pursuant to the terms of this Agreement, XJK shall, within 10 trading days following disclosure of the special audit report in relation to profit difference or the impairment test report for the relevant year, calculate and determine the number of compensatory shares to be given by Party B in accordance with the terms of this Agreement and formulas set forth herein, and provide Party B with a written notice. Party B shall give the instructions to the securities registration and clearing company within 10 trading days as of receipt of the notice of XJK, that the compensatory shares given for the relevant year shall be transferred to and locked up in a special account to be established by the board of directors of the listed company. Party B shall expressly indicate that only the listed company shall have the right to make any instructions to unlock the shares so locked. Where there are shares left in the special account after the deduction of such compensatory shares, unlocking shall not be conducted unless and until after the board of directors of the listed company issues a confirmatory document to Party B. Where Party B calculates the number of compensatory shares pursuant to the terms of this Agreement and entrusted such shares so calculated to the board of directors of the listed company, the listed company shall issue such confirmatory document within five trading days. Where Party B is not liable for compensation, XJK shall issue to Party B the confirmatory document within 10 trading days following disclosure of the special audit report in relation to profit difference or the impairment test report (if any) for the relevant year.
- 4.5 Where the repurchase and cancellation of such lockup shares is not approved by the shareholder meeting of XJK or fails to receive any required regulatory approval, XJK shall give a written notice to Party B within ten (10) days following the announcement of shareholder meeting or

determination that such required regulatory approval will not be obtained. Party B shall, within sixty (60) days following receipt of such notice and subject to applicable securities regulatory rules and regulations, gift such shares in accordance with Section 4.2 hereof to all other shareholders of XJK on record as of the date of record for the relevant shareholder meeting or the date of record determined by XJK board of directors, in proportion to the respective percentage of shares held by other shareholders of XJK to all shares held by all other shareholders of XJK.

Article 5 Exemption Conditions

5.1 During the Commitment Period, if the Target Company plans to change the scope of the principal business, it shall notify Party A in the appropriate written form permitted by applicable laws at the appropriate time following the beginning of each year (the "Annually Notified Matters"). Party A shall, by taking advantage of its shareholder's rights and through the members of the board of directors of the Target Company nominated by it (and Party A shall be obligated to ensure that such directors nominated by it shall), adequately ensure that, subject to the Annually Notified Matters, the key management team members of the Target Company shall have the power to decide (and adjust from time to time) the scope of business, development plans, business strategies, investment plans and business models in compliance with laws and regulations and based on the internal and external business environment faced by the Target Company from time to time ("Business Decision-Making Power"), and Party A will not substantially interfere in any manner with the exercise and achievement of such Business Decision-making Power. Party A confirms that during the Commitment Period, where the key management team members of the Target Company duly perform their functions, it will not, by taking advantage of its shareholder's rights and through the directors nominated by it (and Party A shall be obligated to ensure that such directors nominated by it will not), make any of the following decisions or commit any of the following action. If Party A makes any of the following decisions or commits any of the following action without prior written consent of Party B and the consent of the majority of the then incumbent key management team members listed under Section 5.1.1, then Party B may not assume liabilities for any business performance commitment that has not been incurred under this Agreement or any liabilities for the business performance commitment for the fiscal year affected by the following decisions or actions.

9

-
- 5.1.1 To change the key management of the Target Company, including but without limitation, to change the number of the members or its composition. The scope of positions constituting the key management will be determined by Party A and Party B after negotiation. Any change with the consent of the majority of the other then incumbent key management team members of the Target Company as at the time of change and with the prior written consent of Party B shall be excluded. Notwithstanding the foregoing, the following events shall not be deemed violation of the foregoing agreement: (i) resignation of such management team member; or (ii) any termination of the employment of any such management team member in accordance with laws and his/her employment agreement and with the prior written consent of Party B, due to his/her material violation of any mandatory provisions or prohibitions of laws or regulations or material violation of the rules and procedures of the Target Company;
- 5.1.2 To substantially change the principal business or the scope of business, the development plans, the business strategies, the investment plans and the business model made (or adjusted) from time to time by the key management team members of the Target Company within the scope of the Annually Notified Matters, and/or unreasonably hinder or interfere with the ordinary operation, management or decision-making of the Target Company, other than any change with the consent of the majority of the other then incumbent key management team members listed in Section 5.1.1 and with the prior written consent of Party B; or
- 5.1.3 During the Commitment Period, to substantially change the internal ownership structure or controlling relationship of the Target Company in any manner, to change the consolidation of the financial statements, other than any change with the consent of the majority of the other then incumbent key management team members listed in Section 5.1.1 and with the prior written consent of Party B.

10

5.2 Notwithstanding the foregoing, if, at or prior to the date of this Agreement, the Target Company fails to conduct normal operation, or suffers any material adverse change affecting its business operation, or materially violates laws or regulations, in each case, due to reasons not attributable to Party A, resulting in the accumulated Achieved Net Profit during the Commitment Period less than the accumulated Committed Net Profit, any decisions made by Party A on the matters described under Sections 5.1.1 and 5.1.2 shall not release Party B from the liabilities in connection with the business performance commitment under this Agreement that have not been incurred. For the avoidance of doubt, any exemptions described under Sections 5.1.1 and 5.1.2 shall not relieve Party B from any liabilities.

Article 6 Liability for Breach of Contract

6.1 Other than due to any force majeure event, any failure by one party to perform any material obligations under this Agreement, including, without limitation, any material breach by one party of its obligations or commitments under this Agreement and any material errors or serious misrepresentations of the representations or warranties made by one party in this Agreement, shall be deemed a breach of this Agreement. The breaching party shall be liable for breach of this Agreement to the non-breaching parties pursuant to this Agreement and applicable laws, and indemnify the non-breaching parties against all losses arising out of its breach of this Agreement, including any reasonable costs and expenses incurred for avoidance of the losses.

Article 7 Force Majeure

7.1 Any force majeure event means any objective event which is unforeseeable, unavoidable and insurmountable, including, without limitation, war, earthquake, flood, fire, strikes or enactment, repeal, replacement or amendment of laws by the State or the government. If a party is unable to perform any of its obligations due to a force majeure event, the performance period for the obligations under this Agreement that is unable to be performed due to the force majeure event shall be prolonged accordingly to be equal to the period delayed as a result of the force majeure event. The party claiming inability to perform its obligation due to the force majeure event shall take appropriate measures to eliminate or mitigate the influence of the force majeure event and endeavor to resume performance of its obligations affected by the force majeure event within the shortest possible period of time. In case of any force majeure event, no party is liable for any damages, increased costs or expenses or losses sustained by the other party resulting from the failed or delayed performance of the obligations due to the force majeure event.

11

- 7.2 The party affected by a force majeure event shall notify the other parties of the force majeure event and furnish any available evidence within ten (10) business days following the occurrence of the force majeure event. If the failure to perform this Agreement due to the force majeure event continues for sixty (60) days, any party to this Agreement shall have the right to terminate this Agreement by notifying the other party in writing.
- 7.3 During the period of force majeure event, except for those unable to be performed due to the force majeure event, the parties shall continue to perform this Agreement in any other respects.

Article 8 Governing Law and Dispute Resolution

- 8.1 This Agreement shall be governed and interpreted in accordance with the PRC law.
- 8.2 Any dispute in connection with the performance of this Agreement shall first be settled through friendly consultations between the parties. If such dispute failed to be settled through friendly consultations within sixty (60) days following the occurrence of the dispute, any party shall have the right to submit the dispute to the China International Economic and Trade Arbitration Commission for arbitration in Beijing in accordance with the arbitration rules then in effect. The arbitration shall be conducted in Chinese language.
- 8.3 Other than the disputed matters, the parties hereto shall continue to perform all other provisions in this Agreement.

Article 9 Conclusion and Effectiveness

- 9.1 This Agreement shall be concluded upon duly execution of each party to this Agreement.
- 9.2 This Agreement shall become effective immediately upon satisfaction of all the following conditions:
- 9.2.1 The Agreement to Purchase Assets by Share Issuance and Cash Payment and its supplemental agreement (if any) have taken effect;
- 9.2.2 The closing of the purchase and sale of the Target Asset has been completed; and

12

9.2.3 Party A has fully performed its obligations to issue A shares through Private Placement and pay cash considerations to Party B in accordance with the Agreement to Purchase Assets by Share Issuance and Cash Payment and its supplemental agreement (if any).

Article 10 Miscellaneous

- 10.1 Any amendment to this Agreement shall be in writing upon mutual agreement between the parties.
- 10.2 Without prior written consent of other party, no Party may transfer this Agreement or any rights or obligations hereunder. In accordance with the above provisions, this Agreement shall be binding on and enforceable against any successor and transferee of each party.
- 10.3 If any terms or conditions of this Agreement have been held invalid or unenforceable in any jurisdiction under any condition by any court or other authorities with jurisdiction, the validity or enforceability of any other terms or conditions under this Agreement, or the validity or enforceability of such disputed terms or conditions under any other condition or in any other jurisdiction shall not be affected.
- 10.4 Any waiving by either party of certain rights in this Agreement shall not be deemed waiver of any other rights of it in this Agreement, nor permanent waiver of such rights, unless in accordance with PRC law, such rights cannot be resumed to be performed once waived. Any failure or delayed performance by either party of any rights under this Agreement shall not be deemed waiver of the same or affect the continuing exercise of the same. Any single or partial exercise of the rights under this Agreement shall not exclude the exercise of the remaining part of the rights or any other rights.
- 10.5 This Agreement shall be executed in Chinese, and shall have equal legal and binding effect on each party.
- 10.6 Matters not included in this Agreement shall be negotiated by the parties and settled by entering into a separate supplemental agreement and the supplemental agreement shall have the same legal effect as this Agreement.
- 10.7 This Agreement may be executed in six (6) counterparts, each of which shall have the same legal effect. Each party shall hold one (1) copy and the remaining shall be held by XJK for purpose of filing for approval and registration in connection with the Proposed Transaction.

13

(Signature Page to the Profit Compensation Agreement)

Party A:

Authorized Representative: (signature): /S/ YANG Huaizhen

Nanjing Xinjiekou Department Store Co., Ltd. (seal)

(Signature Page to Profit Compensation Agreement)

Party B:

Authorized Representative: (signature): /S/ Yuen KAM

Golden Meditech Stem Cells (BVI) Company Limited (seal)

Dated this []

B E T W E E N :

[]

(as Chargor)

AND

GOLDEN MEDITECH STEM CELLS (BVI) LIMITED

(as Chargee)

AND

CHINA CORD BLOOD CORPORATION

**SHARE CHARGE over
shares representing
[65.4%] of the issued
share capital of China
Cord Blood
Corporation**

TABLE OF CONTENTS

1.	INTERPRETATION	1
2.	COMPANY'S REPRESENTATIONS AND WARRANTIES	4
3.	CHARGOR'S COVENANTS	5
4.	COMPANY'S COVENANTS	6
5.	SECURITY	8
6.	DEALINGS WITH CHARGED PROPERTY	9
7.	PRESERVATION OF SECURITY	10
8.	ENFORCEMENT OF SECURITY	13
9.	FURTHER ASSURANCES	16
10.	INDEMNITIES	17
11.	POWER OF ATTORNEY	17
12.	EXPENSES	18
13.	NOTICES	19
14.	ASSIGNMENTS	20
15.	MISCELLANEOUS	20
16.	LAW AND JURISDICTION	21
17.	CONTRACTS (RIGHTS OF THIRD PARTIES) LAW, 2014	22

BETWEEN:

- (A) China Cord Blood Corporation, a company incorporated under the laws of the Cayman Islands and having its registered office at Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman KY1-1111, the Cayman Islands (the “Company”);
- (B) [], a company incorporated under the laws of [] and having its registered office at [] (the “Chargor”); and
- (C) Golden Meditech Stem Cells (BVI) Limited, a company incorporated under the laws of the British Virgin Islands and having its registered office at [Offshore Incorporations Limited, PO Box 957, Offshore Incorporations Centre, Road Town, Tortola, British Virgin Islands] (the “Chargee”).

WHEREAS:

- (A) By the Sale Agreement made between the Chargor, as buyer, and the Chargee as seller, the Chargee has agreed to sell to the Chargor the Charged Shares on the terms and conditions therein set out.
- (B) As security for the Secured Obligations, the Chargor has agreed to charge, inter alia, its interest in all of the Charged Shares registered in the name of the Chargor in the Company.
- (C) The Company has an authorised share capital of US\$[amount] consisting of [number] shares having a par value of US\$[0.0001] and, as of the Acquisition Date, [] of which will be in issue, fully paid, owned by the Chargor, and registered in the name of the Chargor.
- (D) It is a condition precedent to the Chargee selling the Charged Shares to the Chargor that the Chargor shall execute this Charge in favour of the Chargee and the same is executed by the Chargor in consideration of the Chargee agreeing to sell the Charged Shares to the Chargee and for other good and valuable consideration (the sufficiency of which the Company and the Chargor hereby acknowledge).

NOW THIS CHARGE WITNESSES as follows:

1. INTERPRETATION

1.1 In this Charge, unless the context otherwise requires, the following words and expressions shall have the following meanings:

1

“Acquisition Date”	means the date of completion of the purchase of the Charged Shares by the Chargor under the Sale Agreement;
“Business Day”	has the same meaning as in the Sale Agreement;
“Charge”	means this share charge;
“Charged Property”	means all of the Charged Shares and all dividends or other distributions, interest and other moneys paid or payable after the date hereof in connection therewith and all interests in and all rights accruing at any time to or in respect of all or any of the Charged Shares and all and any other property that may at any time be received or receivable by or otherwise distributed to the Chargor in respect of or in substitution for, or in addition to, or in exchange for, or on account of, any of the foregoing, including, without limitation, any shares or other securities resulting from the sub-division, consolidation, change, conversion or reclassification of any of the Charged Shares, or the reorganization, merger, or amalgamation of the Company with any other body corporate, or the occurrence of any event which results in the substitution or exchange of the Charged Shares;
“Charged Shares”	means [] shares of the Company, registered in the name of the Chargor as legal and beneficial owner thereof on the Acquisition Date;
“Contemporaneous SPA”	means a conditional sale agreement relating to the sale by the Chargee and the purchase by the Chargor of shares representing [34.6%] of the issued share capital of the Company, made between (i) the Chargee, as seller, (ii) the Chargor, as buyer, and (iii) Golden Meditech Holdings Limited, as guarantor dated [6] January 2016, as amended, restated or supplemented in any manner whatsoever from time to time;

2

“Event of Default”	means (i) any breach by the Chargor of any of the provisions of this Charge, or (ii) the occurrence of any event which gives rise to the Chargee’s rights and remedies under clause 9.2(2)(b) of the Sale Agreement;
“Parties”	means the parties to this Charge collectively; “Party” means any one of them;
“Sale Agreement”	means a conditional sale agreement relating to the sale by the Chargee and the purchase by the Chargor of the Charged Shares made between (i) the Chargee, as seller, (ii) the Chargor, as buyer, and (iii) Golden Meditech Holdings Limited, as guarantor dated [6] January 2016, as amended, restated or supplemented in any manner whatsoever from time to;
“Secured Obligations”	means (i) all of the present and future payment obligations of the Chargor under the Sale Agreement, and (ii) all of the present and future payment and other obligations of the Chargor under this Charge;

“Security Interest”	means any charge, mortgage, pledge, lien, security interest or other encumbrance; and
“Security Period”	means the period commencing on the Acquisition Date and terminating upon discharge of the security created by this Charge by payment in full or other satisfaction in their entirety of the Secured Obligations.

1.2 In this Charge unless the context otherwise requires:

- (a) references to statutory provisions shall be construed as references to those provisions as amended or re-enacted or as their application is modified by other provisions from time to time and shall include references to any provisions of which they are re-enactments (whether with or without modification);
- (b) references to clauses and schedules are references to clauses hereof and schedules hereto; references to sub-clauses or paragraphs are, unless

3

otherwise stated, references to sub-clauses of the clauses hereof or paragraphs of the schedule in which the reference appears;

- (c) references to the singular shall include the plural and vice versa and references to the masculine shall include the feminine and/or neuter and vice versa;
- (d) references to persons shall include companies, partnerships, associations and bodies of persons, whether incorporated or unincorporated;
- (e) references to assets include property, rights and assets of every description; and
- (f) references to any document are to be construed as references to such document as amended, restated or supplemented in any manner whatsoever from time to time.

2. CHARGOR’S REPRESENTATIONS AND WARRANTIES

The Chargor hereby represents and warrants to the Chargee that:

- 2.1 The shares of the Company are as described in Recital (C) hereof and such shares are registered as described in the said recital;
- 2.2 The Company is an exempted company duly incorporated, validly existing and in good standing under the laws of the Cayman Islands;
- 2.3 The Company is not a land holding corporation for the purposes of the Land Holding Company Share Transfer Tax Law of the Cayman Islands;
- 2.4 Other than pursuant to the provisions of, or as contemplated by, or as required to give effect to the provisions of, the Sale Agreement or the Contemporaneous SPA, the Company is under no obligation, nor is it liable to become under any obligation, to issue any further shares;
- 2.5 Without limiting the generality of the foregoing clause, the Company has not created any option to acquire shares in the Company nor any securities exchangeable for or convertible into shares of the Company;
- 2.6 Each of the Chargor and the Company has full power and authority (i) to execute and deliver this Charge and (ii) to comply with the provisions of, and perform all its obligations under, this Charge;
- 2.7 This Charge constitutes the Chargor and the Company’s legal, valid and binding obligations enforceable against the Chargor and the Company in accordance

4

with its terms except as such enforcement may be limited by any relevant bankruptcy, insolvency, administration or similar laws affecting creditors’ rights generally;

- 2.8 The entry into and performance by the Chargor and the Company of this Charge does not violate (i) any law or regulation of any governmental or official authority, or (ii) any agreement, contract or other undertaking to which the Chargor or the Company is a party or which is binding upon the Chargor or the Company or any of its respective assets;
- 2.9 All consents, licences, approvals and authorisations required in connection with the entry into, performance, validity and enforceability of this Charge have been obtained and are in full force and effect; and
- 2.10 The Chargor or the Company has each taken all corporate and other action required to approve its execution, delivery and performance of this Charge.

3. CHARGOR’S COVENANTS

The Chargor hereby covenants with the Chargee:

- 3.1 That the Chargor will, on demand of the Chargee and at the expense of the Chargor, execute and deliver to the Chargee or to such person or persons as the Chargee may nominate, such additional charge or charges of the Charged Property (or any part thereof) for the purpose of further securing the

payment and discharge of all Secured Obligations, each such additional charge to be in such form as the Chargee may reasonably require;

3.2 That the Chargor shall, on request of the Chargee, provide to the Chargee immediately on receipt by the Chargor a copy of all notices, written consents, reports, accounts, circulars and other communications issued by the Company or by any third party in respect of the Charged Shares;

3.3 That the Chargor will not without the prior written consent of the Chargee:

- (a) permit any person other than the Chargor, the Chargee or any transferee nominated by the Chargee on enforcement of this Charge to be the registered holder of any of the Charged Shares;
- (b) permit any variation of the rights attaching to the Charged Shares;
- (c) take or permit any action which might result in an increase or reduction in the authorised issued share capital of the Company;

5

- (d) effect or permit the Company to be continued to another jurisdiction outside of the Cayman Islands;
- (e) effect or permit the appointment of any new or further directors or officers of the Company;
- (f) effect or permit any scheme of arrangement, merger, consolidation, or other reorganisation applicable to the Company; or
- (g) permit any amendment to the memorandum or articles of association of the Company.

3.4 That the Chargor shall (i) procure that there is entered a statement on the register of members of the Company on the Acquisition Date as follows: “the [] shares held in the name of [Chargor] as represented by share certificate [] have been charged by it to Golden Meditech Stem Cells (BVI) Limited (the “Chargee”) pursuant to a Share Charge dated [date] made among [Chargor] as Chargor, the Chargee and the Company.”; and (ii) make any and all such filings and/or registrations as requested by the Chargee from time to time to the extent required to ensure the full compliance with any and all applicable laws.

4. COMPANY’S COVENANTS

4.1 The (i) Company hereby covenants with the Chargee, and (ii) the Chargor hereby covenants with the Chargee that it will use its best efforts to procure the Company;

- (a) to pay all amounts, interest, expenses, claims, liabilities, losses, costs, duties, fees, charges or other moneys as are stated in the Sale Agreement and this Charge to be payable by the Company or to be recoverable from the Company by the Chargee (or in respect of which the Company agrees in this Charge to indemnify the Chargee) at the times and in the manner specified in the Sale Agreement and this Charge;
- (b) to pay interest on any such amounts, interests, expenses, claims, liabilities, losses, costs, duties, fees, charges or other moneys referred to in

6

Sub-Clause 4.1(a) from the date on which the relevant amount, interest, expense, liability, loss, cost, duty, fee, charge or other money is paid or discharged by the Chargee until the date of reimbursement thereof to the Chargee (both before and after any relevant judgment) at the rate described in the Sale Agreement, such interest to be payable on demand;

- (c) to provide to the Chargee promptly on issue or, as the case may be, receipt by the Company of, a copy of all notices, written consents, reports, accounts, circulars and other communications issued by the Company or by any third party which may affect the Chargee’s Charge or Security Interest in respect of the Charged Shares;
- (d) to register all transfers of Charged Shares submitted to the Company for registration by the Chargee (or any transferee nominated by the Chargee) pursuant to the exercise of its rights under this Charge forthwith upon the submission to the Company of such transfers;
- (e) not to permit any person other than the Chargor, the Chargee or any transferee nominated by the Chargee on enforcement of this Charge to be the registered holder of any of the Charged Shares, without the prior written consent of the Chargee;
- (f) not to take or permit any action which might result in a variation of the rights attaching to the Charged Shares, without the prior written consent of the Chargee;
- (g) not to take or permit any action which might result in the Company being continued to another jurisdiction outside of the Cayman Islands, or permit or enter into any scheme of arrangement, merger, or other reorganisation applicable to the Company, without the prior written consent of the Chargee;
- (h) not to take any action which would impair or adversely affect the Chargee’s Security interest in the Charged Property and/or the effectiveness of this Charge;
- (i) to obtain and maintain in full force, validity and effect all material governmental and other approvals, authorities, licences and consents required in connection with this Charge, and to do or cause to be done all other acts and things necessary or desirable for the performance of the Company’s obligations pursuant to this Charge;

- (j) following the execution of this Charge, enter a statement on the register of members of the Company in the same terms as set out in Clause 3.4 above; and
- (k) not to take any action which would result in the Security created or expressed to be created pursuant to this Charge being or becoming unlawful or not being or ceasing to be legal, valid, binding or enforceable or otherwise ceasing to be effective.

5. SECURITY

- 5.1 In consideration of the Chargee agreeing to sell the Charged Shares to the Chargor and as a continuing security for the Secured Obligations, the Chargor as legal and beneficial owner hereby assigns and agrees to assign to the Chargee all benefits, present and future, actual and contingent, accruing in respect of the Charged Property including (without limitation) any distributions, dividends or other moneys or assets accruing in respect of the Charged Shares or any part thereof) and all the Chargor's right, title and interest to and in the Charged Property including (without limitation) all voting and other consensual powers pertaining to the Charged Shares and hereby charges and agrees to charge in favour of the Chargee all of its interest in the Charged Property by way of a first fixed and floating charge.
- 5.2 The Chargor hereby agrees to deliver, or cause to be delivered, to the Chargee:
- (a) duly executed undated share transfers in respect of the Charged Shares in favour of the Chargee or its nominees in the form set out in Schedule 1;
 - (b) all share certificates representing the Charged Shares;
 - (c) an executed irrevocable proxy made in respect of the Charged Shares in favour of the Chargee in respect of all general meetings of the Company in the form set out in Schedule 2; and
 - (d) executed but undated letters of resignation and release together with letters of authority to date the same from each of the directors, alternate directors and officers of the Company in the form set out in Schedule 3.
- 5.3 The Chargor will deliver, or cause to be delivered, to the Chargee immediately upon the issue of any further Charged Shares, the items listed in Clause 5.2(a), 5.2(b) and 5.2(c) in respect of all such further Charged Shares.
- 5.4 The Chargor will deliver, or cause to be delivered, to the Chargee immediately upon the appointment of any further director, alternate director or officer of the

Company an undated, signed letter of resignation from such further director, alternate director or officer in a form acceptable to the Chargee.

- 5.5 The Chargor hereby covenants that during the Security Period it will remain the legal and beneficial owner of the Charged Property (subject only to the Security Interests hereby created) and that it will not:
- (a) create or suffer the creation of any Security Interests (other than those created by this Charge) on or in respect of the whole or any part of the Charged Property or any of its interest therein; or
 - (b) sell, assign, transfer or otherwise dispose of any of its interest in the Charged Property;
 - (c) vote in respect of the Charged Shares or receive any dividends or other distributions paid by the Company in respect of the Charged Shares,
- in any such case without the prior consent in writing of the Chargee.
- 5.6 The Chargor and the Company shall remain liable to perform all the obligations assumed by each of them in relation to the Charged Property and the Chargee shall be under no obligation of any kind whatsoever in respect thereof or be under any liability whatsoever in the event of any failure by the Chargor or the Company to perform its obligations in respect thereof.
- 5.7 Upon the Chargee being satisfied that the Secured Obligations have been unconditionally and irrevocably paid and discharged in full, the Chargee will, subject to being indemnified to its reasonable satisfaction for the costs and expenses incurred by the Chargee in connection therewith, release the security constituted by this Charge within 10 Business Days from the date the Secured Obligations are unconditionally and irrevocably paid and discharged in full.

6. DEALINGS WITH CHARGED PROPERTY

- 6.1 Unless and until an Event of Default has occurred:
- (a) the Chargor shall be entitled to exercise all voting and/or consensual powers pertaining to the Charged Property or any part thereof for all purposes not inconsistent with the terms of this Charge and/or the Sale Agreement;
 - (b) the Chargor shall be entitled to receive and retain any dividends, interest or other moneys or assets accruing on or in respect of the Charged Property or any part thereof; and

(c) the Chargor shall be entitled to receive all notices pertaining to the Charged Shares.

6.2 The Chargor shall pay all calls, instalments or other payments, and shall discharge all other obligations, which may become due in respect of any of the Charged Property and in an Event of Default, the Chargee may if it thinks fit make such payments or discharge such obligations on behalf of the Chargor. Any sums so paid by the Chargee in respect thereof shall be repayable on demand and pending such repayment shall constitute part of the Secured Obligations.

6.3 The Chargee shall not have any duty to ensure that any dividends, distributions interest or other moneys and assets receivable in respect of the Charged Property are duly and punctually paid, received or collected as and when the same become due and payable or to ensure that the correct amounts (if any) are paid or received on or in respect of the Charged Property or to ensure the taking up of any (or any offer of any) stocks, shares, rights, moneys or other property paid, distributed, accruing or offered at any time by way of redemption bonus, rights, preference, or otherwise on or in respect of, any of the Charged Property.

6.4 The Chargor hereby authorises the Chargee to arrange at any time and from time to time (whether before or after the occurrence of an Event of Default) for the Charged Property or any part thereof to be registered in the name of the Chargee (or its nominee) thereupon to be held as so registered subject to the terms of this Charge.

7. PRESERVATION OF SECURITY

7.1 It is hereby agreed and declared that:

- (a) the Security Interest created by this Charge shall be held by the Chargee as a continuing security for the payment and discharge of the Secured Obligations and the security so created shall not be satisfied by any intermediate payment or satisfaction of any part of the Secured Obligations;
- (b) the Security Interest so created shall be in addition to and shall not in any way be prejudiced or affected by any of the other [Security Documents];
- (c) the Chargee shall not be bound to enforce any other security before enforcing the security created by this Charge;
- (d) no delay or omission on the part of the Chargee in exercising any right, power or remedy under this Charge shall impair such right, power or remedy or be construed as a waiver thereof nor shall any single or partial

10

exercise of any such right, power or remedy preclude any further exercise thereof or the exercise of any other right, power or remedy. The rights, powers and remedies herein provided are cumulative and not exclusive of any rights, powers and remedies provided by law and may be exercised from time to time and as often as the Chargee may deem expedient; and

- (e) any waiver by the Chargee of any terms of this Charge shall only be effective if given in writing and then only for the purpose and upon the terms for which it is given.

7.2 Any settlement or discharge under this Charge between the Chargee and the Chargor shall be conditional upon no security or payment to the Chargee by the Company or the Chargor or any other person being avoided or set-aside or ordered to be refunded or reduced by virtue of any provision or enactment relating to bankruptcy, insolvency, administration or liquidation for the time being in force and, if such condition is not satisfied, the Chargee shall be entitled to recover from the Chargor on demand the value of such security or the amount of any such payment as if such settlement or discharge had not occurred.

7.3 The rights of the Chargee under this Charge and the security hereby constituted shall not be affected by any act, omission, matter or thing which, but for this provision, might operate to impair, affect or discharge such rights and security, in whole or in part, including without limitation, and whether or not known to or discoverable by the Company, the Chargor, the Chargee or any other person:

- (a) any time or waiver granted to or compromise with the Company or any other person;
- (b) the taking, variation, compromise, renewal or release of or refusal or neglect to perfect or enforce any rights, remedies or securities against the Company or any other person;
- (c) any legal limitation, disability, incapacity or other circumstances relating to the Company or any other person;
- (d) any amendment or supplement to the Sale Agreement, the other Security Documents or any other document or security;
- (e) the dissolution, liquidation, merger, consolidation, reconstruction or reorganisation of the Company or any other person; or
- (f) the unenforceability, invalidity or frustration of any obligations of the Company or any other person under the Sale Agreement, the other Security Documents or any other document or security.

11

7.4 Until the Secured Obligations have been unconditionally and irrevocably satisfied and discharged in full to the satisfaction of the Chargee, the Chargor shall not by virtue of any payment made hereunder on account of the Secured Obligations or by virtue of any enforcement by the Chargee of its rights under, or the security constituted by, this Charge or by virtue of any relationship between or transaction involving the Chargor and the Company (whether such relationship or transaction shall constitute the Chargor a creditor of the Company, a guarantor of the obligations of the Company or a party subrogated to the rights of others against the Company or otherwise howsoever and whether or not such relationship or transaction shall be related to, or in connection with, the subject matter of this Charge):

- (a) exercise any rights of subrogation in relation to any rights, security or moneys held or received or receivable by the Chargee or any person;
- (b) exercise any right of contribution from any co-surety liable in respect of such moneys and liabilities under any other guarantee, security or agreement;
- (c) exercise any right of set-off or counterclaim against the Company or any such co-surety;
- (d) receive, claim or have the benefit of any payment, distribution, security or indemnity from the Company or any such co-surety; or
- (e) unless so directed by the Chargee (when the Chargor will prove in accordance with such directions), claim as a creditor of the Company or any such co-surety in competition with the Chargee.

7.5 The Chargor shall hold in trust for the Chargee and forthwith pay or transfer (as appropriate) to the Chargee any such payment (including an amount equal to any such set-off), distribution or benefit of such security, indemnity or claim in fact received by it.

7.6 Until the Secured Obligations have been unconditionally and irrevocably satisfied and discharged in full to the satisfaction of the Chargee, the Chargee may at any time keep in a separate account or accounts (without liability to pay interest thereon) in the name of the Chargee for as long as it may think fit, any moneys received, recovered or realised under this Charge or under any other guarantee, security or agreement relating in whole or in part to the Secured Obligations without being under any immediate obligation to apply the same or any part thereof in or towards the discharge of such amount.

12

8. ENFORCEMENT OF SECURITY

8.1 Upon the expiry of 30 calendar days following the giving by the Chargee to the Chargor of written notice of the enforcement of this Charge following the occurrence of an Event of Default, the security hereby constituted shall become immediately enforceable and the Chargee may, at any time following the expiry of such 30 calendar day period, without further notice to, or consultation with, or the consent of, the Chargor:

- (a) solely and exclusively exercise all voting and/or consensual powers pertaining to the Charged Property or any part thereof and may exercise such powers in such manner as the Chargee may think fit; and/or
- (b) remove the then existing directors and officers (with or without cause) by dating and presenting the undated, signed letters of resignation delivered pursuant to this Charge; and/or
- (c) receive and retain all dividends, interest, distributions or other moneys or assets accruing on or in respect of the Charged Property or any part thereof, such dividends, interest, distributions or other moneys or assets to be held by the Chargee, until applied in the manner described in Sub-Clause 8.4, as additional security charged under and subject to the terms of this Charge and any such dividends, interest, distributions or other moneys or assets received by the Chargor after such time shall be held in trust by the Chargor for the Chargee and paid or transferred to the Chargee on demand; and/or
- (d) appoint by instrument any person to be a receiver of the Charged Property (the "Receiver") and remove any Receiver so appointed and appoint another or others in his stead; and/or
- (e) sell, transfer, grant options over or otherwise dispose of the Charged Property or any part thereof at such place and in such manner and at such price or prices as the Chargee may deem fit, and thereupon the Chargee shall have the right to deliver, assign and transfer in accordance therewith the Charged Property so sold, transferred, granted options over or otherwise disposed of; and/or
- (f) complete any undated blank share transfer forms of all or any part of the Charged Property by dating the same and/or inserting its name or the name of its nominee as transferee.

8.2 The Chargee shall not be obliged to make any enquiry as to the nature or sufficiency of any payment received by it under this Charge or to make any claim

13

or to take any action to collect any moneys assigned by this Charge or to enforce any rights or benefits assigned to the Chargee by this Charge or to which the Chargee may at any time be entitled hereunder.

8.3 Upon any sale of the Charged Property or any part thereof by the Chargee the purchaser shall not be bound to see or enquire whether the Chargee's power of sale has become exercisable in the manner provided in this Charge and the sale shall be deemed to be within the power of the Chargee, and the receipt of the Chargee for the purchase money shall effectively discharge the purchaser who shall not be concerned with the manner of application of the proceeds of sale or be in any way answerable therefor.

- 8.4** All moneys received by the Chargee pursuant to this Charge shall be held in the first place to pay or make good all such expenses, liabilities, losses, costs, duties, fees, charges or other moneys whatsoever as may have been paid or incurred by the Chargee in exercising any of the powers specified or otherwise referred to in this Charge and the balance shall be applied in the following manner:
- (a) **FIRSTLY:** in or towards satisfaction of any amounts in respect of the balance of the Secured Obligations as are then accrued due and payable or are then due and payable by virtue of payment demanded, in such order or application as the Chargee shall think fit;
 - (b) **SECONDLY:** in retention of an amount equal to any part or parts of the Secured Obligations as are or are not then due and payable but which (in the sole and absolute opinion of the Chargee) will or may become due and payable in the future and, upon the same becoming due and payable, in or towards satisfaction thereof in accordance with the foregoing provisions of this Sub-Clause 8.4; and
 - (c) **THIRDLY:** the surplus (if any) shall be repaid promptly to the Chargor or whosoever else may be entitled thereto.
- 8.5** Neither the Chargee nor its agents, managers, officers, employees, delegates or advisers shall be liable for any claim, demand, liability, loss, damage, cost or expense incurred or arising in connection with the exercise or purported exercise of any rights, powers and discretions hereunder [in the absence of fraud or dishonesty; however, in no event shall the Chargee be liable for consequential damages.
- 8.6** The Chargee shall not by reason of the taking of possession of the whole or any part of the Charged Property hereof be liable to account as mortgagee-in-possession or for anything except actual receipts or be liable for any loss upon

14

realisation or for any default or omission for which a mortgagee-in-possession might be liable.

- 8.7** In addition to all other rights or powers vested in the Chargee hereunder or by statute or otherwise, the Receiver may take such action in relation to the enforcement of this Charge to:
- (a) take possession of, redeem, collect and get in all or any part of the Charged Property;
 - (b) raise or borrow money and grant security therefor over all or any part of the Charged Property;
 - (c) appoint an attorney or accountant or other professionally qualified person to assist him in the performance of his functions;
 - (d) do all acts and to execute in the name and on behalf of the Chargor any document or deed in respect of all or any part of the Charged Property;
 - (e) in the name of the Chargor or in his own name, bring, prosecute, enforce, defend and abandon applications, claims, disputes, actions, suits and proceedings in connection with all or any part of the Charged Property and to submit to arbitration, negotiate, compromise and settle any such applications, claims, disputes, actions, suits or proceedings;
 - (f) sell, call in, collect and convert to money the Charged Property or any of it at such place and in such manner and at such price or prices as he shall think fit;
 - (g) exercise any powers, discretion, voting or other rights or entitlements in relation to the Charged Property and generally to carry out any other action which he may in his sole discretion deem appropriate in relation to the enforcement of this Charge;
 - (h) make any arrangement or compromise which he shall think expedient; and
 - (i) do all such other acts and things as may be considered to be incidental or conducive to any of the matters or powers aforesaid and which the Receiver lawfully may or can do as agent for the Chargor.
- 8.8** Every Receiver shall, so far as it concerns responsibility for his acts, be deemed to be an agent of the Chargor, which shall be solely responsible for his acts and defaults and for the payment of his remuneration and no Receiver shall at any time act as agent for the Chargee.

15

- 8.9** Every Receiver shall be entitled to remuneration for his services at a rate to be fixed by agreement between him and the Chargee (or, failing such agreement, to be fixed by the Chargee) appropriate to the work and responsibilities involved, upon the basis of current industry practice.

9. FURTHER ASSURANCES

- 9.1** The Chargor shall execute and do all such assurances, acts and things as the Chargee in its absolute discretion may require for:

- (a) perfecting, protecting or ensuring the priority of the Security Interest hereby created (or intended to be created);
- (b) preserving or protecting any of the rights of the Chargee under this Charge;
- (c) ensuring that the security constituted by this Charge and the covenants and obligations of the Chargor under this Charge shall inure to the benefit of any assignee of the Chargee;
- (d) facilitating the appropriation or realisation of the Charged Property or any part thereof; or

(e) exercising any power, authority or discretion vested in the Chargee under this Charge,

in any such case forthwith upon demand by the Chargee and at the expense of the Chargor.

- 9.2 Without limitation to the generality of Sub-Clause 9.1, the Chargor covenants with the Chargee that it will on demand of the Chargee [use its best endeavours to] procure any amendment to the memorandum and articles of association of the Company necessary or, in the opinion of the Chargee desirable, in order to give effect to the terms of this Charge or any documents or transactions provided for herein.
- 9.3 The Chargor shall provide such assurances and do all acts and things the Receiver may in his absolute discretion require for the purpose of exercising the powers (or giving effect to the exercise of the powers) conferred on the Receiver hereunder and the Chargor hereby irrevocably appoints the Receiver to be the lawful attorney in fact of the Chargor to do any act or thing and to exercise all the powers of the Chargor for the purpose of exercising the powers (or giving effect to the exercise of the powers) conferred on the Receiver hereunder.

16

10. INDEMNITIES

10.1 The Chargor will indemnify and hold harmless the Chargee, the Receiver and each agent or attorney appointed under or pursuant to this Charge from (each an “**Indemnitee**”) and against any and all expenses, claims, liabilities, losses, taxes, costs, duties, fees and charges properly and reasonably suffered, incurred or made by the Chargee, the Receiver or such agent or attorney:

- (a) in the exercise or purported exercise of any rights, powers or discretions vested in them pursuant to this Charge;
- (b) in the preservation or enforcement of the Chargee’s rights under this Charge or the priority thereof; or
- (c) on the release of any part of the Charged Property from the security created by this Charge,

and the Chargee, the Receiver or such agent or attorney may retain and pay all sums in respect of the same out of money received under the powers conferred by this Charge. All amounts recoverable by the Chargee, the Receiver or such agent or attorney or any of them shall be recoverable on a full indemnity basis.

10.2 If, under any applicable law or regulation, and whether pursuant to a judgment being made or registered against the Chargor or the bankruptcy or liquidation of the Chargor or for any other reason any payment under or in connection with this Charge is made or falls to be satisfied in a currency (the “**Payment Currency**”) other than the currency in which such payment is due under or in connection with this Charge (the “**Contractual Currency**”), then to the extent that the amount of such payment actually received by the Chargee when converted into the Contractual Currency at the rate of exchange, falls short of the amount due under or in connection with this Charge, the Chargor, as a separate and independent obligation, shall indemnify and hold harmless the Chargee against the amount of such shortfall. For the purposes of this Clause, “rate of exchange” means the rate at which the Chargee is able on or about the date of such payment to purchase the Contractual Currency with the Payment Currency and shall take into account any premium and other costs of exchange with respect thereto.

11. POWER OF ATTORNEY

11.1 The Chargor, by way of security and in order more fully to secure the performance of its obligations hereunder hereby irrevocably appoints the Chargee and the persons deriving title under it jointly and also severally to be its attorney:

17

- (a) to execute and complete in favour of the Chargee or its nominees or of any purchaser any documents which the Chargee may from time to time require for perfecting its title to or for vesting any of the assets and property hereby charged or assigned in the Chargee or its nominees or in any purchaser and to give effectual discharges for payments;
- (b) to take and institute on non-payment (if the Chargee in its sole discretion so decides) all steps and proceedings in the name of the Chargor or of the Chargee for the recovery of such moneys, property and assets hereby charged and to agree accounts;
- (c) to act as the Chargor’s corporate representative (and/or to appoint any officer or nominee of the Chargee for such purpose) to represent the Chargor at any general meeting of the members of the Company and to sign any resolution in writing of the members of the Company or to requisition or convene general meetings of the Company or to waive or consent to short notice of such in that capacity;
- (d) to make allowances and give time or other indulgence to any surety or other person liable;
- (e) otherwise generally to act for it and in its name and on its behalf; and
- (f) to sign, execute, seal and deliver and otherwise perfect and do any such legal assignments and other assurances, charges, authorities and documents over the moneys, property and assets hereby charged, and all such deeds, instruments, acts and things (including, without limitation, those referred to in Clause 9) which may be required for the full exercise of all or any of the powers conferred or which may be deemed proper on or in connection with any of the purposes aforesaid.

11.2 The power hereby conferred shall be a general power of attorney and the Chargor hereby ratifies and confirms and agrees to ratify and confirm any instrument, act or thing which any such attorney may execute or do. In relation to the power referred to herein, the exercise by the Chargee of such power shall be conclusive evidence of its right to exercise the same.

12. EXPENSES

12.1 The Chargor shall pay to the Chargee on demand all costs, fees and expenses (including, but not limited to, legal fees and expenses) and taxes thereon incurred by the Chargee or for which the Chargee may become liable in connection with:

(a) the negotiation, preparation and execution of this Charge;

18

(b) the preserving or enforcing of, or attempting to preserve or enforce, any of its rights under this Charge or the priority hereof;

(c) any variation of, or amendment or supplement to, any of the terms of this Charge; and/or

(d) any consent or waiver required from the Chargee in relation to this Charge,

and in any case referred to in Paragraphs (c) and (d) regardless of whether the same is actually implemented, completed or granted, as the case may be.

12.2 The Chargor shall pay promptly any stamp, documentary and other like duties and taxes to which this Charge may be subject or give rise and shall indemnify the Chargee on demand against any and all liabilities with respect to or resulting from any delay or omission on the part of the Chargor to pay any such duties or taxes.

13. NOTICES

13.1 Any notice required to be given hereunder shall be in writing in the English language and shall be served by sending the same by prepaid recorded post, facsimile or by delivering the same by hand to the address of the Party or Parties in question as set out below (or such other address as such Party or Parties shall notify the other Parties of in accordance with this Clause). Any notice sent by post as provided in this Clause shall be deemed to have been served five Business Days after despatch and any notice sent by facsimile as provided in this Clause shall be deemed to have been served at the time of despatch and in proving the service of the same it will be sufficient to prove in the case of a letter that such letter was properly stamped, addressed and placed in the post; and in the case of a facsimile that such facsimile was duly despatched to a current facsimile number of the addressee.

Chargor

Name:

Address:

Fax:

Chargee:

19

Name:

Address:

Fax:

Company:

Name:

Address:

Fax:

14. ASSIGNMENTS

14.1 This Charge and all non-contractual obligations arising out of or in connection with it shall be binding upon and shall inure to the benefit of the Chargor and the Chargee and each of their respective successors and (subject as hereinafter provided) assigns and references in this Charge to any of them shall be construed accordingly.

14.2 The Chargor may not assign or transfer all or any part of its rights and/or obligations under this Charge.

14.3 The Chargee may assign or transfer all or any part of its rights or obligations under this Charge to any assignee or transferee without the consent of the Chargor, such consent not to be unreasonably withheld, provided that no such consent shall be required if an Event of Default affecting the Chargor has occurred and is continuing. The Chargee shall notify the Chargor promptly following any such assignment or transfer.

15. MISCELLANEOUS

15.1 The Chargee, at any time and from time to time, may delegate by power of attorney or in any other manner to any person or persons all or any of the powers, authorities and discretions which are for the time being exercisable by the Chargee under this Charge in relation to the Charged Property or any part thereof. Any such delegation may be made upon such terms and be subject to such regulations as the Chargee may think fit. The Chargee shall not be in any way liable or responsible to the Chargor for any loss or damage arising from any

act, default, omission or misconduct on the part of any such delegate provided the Chargee has acted reasonably in selecting such delegate.

15.2 This Charge, including its Schedules and together with any documents referred to herein, contains the whole agreement between the Parties in respect of the subject matter of this Charge and supersedes and replaces any prior written or oral agreements, representations or understandings between them relating to such subject matter. The Parties confirm that they have not entered into this Charge on the basis of any representation that is not expressly incorporated into this Charge. Without limiting the generality of the foregoing, no Party shall have any remedy in respect of any untrue statement made to him upon which he may have relied in entering into this Charge, and a Party's only remedy is for breach of contract.

However, nothing in this Charge purports to exclude liability for any fraudulent statement or act.

15.3 No variations of this Charge shall be effective unless made in writing and signed by each of the Parties.

15.4 The headings in this Charge are inserted for convenience only and shall not affect the construction of this Charge.

15.5 This Charge may be executed in counterparts each of which when executed and delivered shall constitute an original but all such counterparts together shall constitute one and the same instrument.

15.6 If any of the Clauses, Sub-Clauses, Paragraphs, conditions, covenants or restrictions of this Charge or any deed or document emanating from it shall be found to be void but would be valid if some part thereof were deleted or modified, then such Clause, Sub-Clause, Paragraph, condition, covenant or restriction shall apply with such deletion or modification as may be necessary to make it valid and effective.

16. LAW AND JURISDICTION

16.1 This Charge shall be governed by and construed in accordance with the laws of the Cayman Islands and the Parties hereby irrevocably submit to the non-exclusive jurisdiction of the courts of the Cayman Islands, provided that nothing in this Clause shall affect the right of the Chargee to serve process in any manner permitted by law or limit the right of the Chargee to take proceedings with respect to this Charge against the Chargor in any jurisdiction nor shall the taking of proceedings with respect to this Charge in any jurisdiction preclude the Chargee from taking proceedings with respect to this Charge in any other jurisdiction, whether concurrently or not.

17. RIGHTS UNDER THE CONTRACTS (RIGHTS OF THIRD PARTIES) LAW, 2014

17.1 The parties hereby agree that each Indemnitee who is not a party to this Agreement (a "Third Party") has the express right to enforce the contractual terms of this agreement pursuant to the terms of The Contracts (Rights of Third Parties) Law, 2014. However, no Third Party may bring any action to enforce its rights under this agreement without the prior written consent of the Chargee, which may be withheld at the sole discretion of Party A.

17.2 The consent of each Third Party is not required for any rescission or variation of this agreement agreed to by the Parties hereto.

IN WITNESS whereof the Parties have caused this Charge to be duly executed as a Deed the day and year first before written.

The **Common Seal** of)
[Company]) [Affix seal]
was affixed hereto)
in the presence of:)

Name: _____
Signature of Legal Representative
(or Authorized Representative)

The **Common Seal** of)
China Cord Blood Corporation) was affixed hereto
in the presence of:)

Name: _____

The **Common Seal of**)
Golden Meditech Stem)
Cells (BVI) Limited) [Affix seal]
was affixed hereto)
in the presence of:)

Name: _____
[Name of person attesting]

SCHEDULE 1
SHARE TRANSFER FORM

SCHEDULE 2
IRREVOCABLE PROXY
IRREVOCABLE PROXY

I/We, [] of [] (the "Shareholder") being the holder of [number] shares of China Cord Blood Corporation, a Cayman Islands exempted company (the "Company"), hereby appoint(s) each and every officer of the Chargee (as defined in the Share Charge dated [] made between the Shareholder, the Company and Golden Meditech Stem Cells (BVI) Limited (the "Share Charge")) from time to time (the "Proxy Holders") the true and lawful attorney and proxy of the Shareholder for and in the Shareholder's name, place and stead to attend all meetings of the shareholders of the Company and to vote at a meeting any and all shares in the Company at the time standing in the Shareholder's name and to exercise all consensual rights in respect of such shares (including without limitation giving or withholding written consents of shareholders and calling special general meetings of shareholders) upon and during the continuance of an Event of Default (as defined in the Share Charge).

The Shareholder hereby affirms that this proxy is given pursuant to Clause 4 of the Share Charge. **THIS PROXY IS COUPLED WITH AN INTEREST AND IS IRREVOCABLE.**

The Shareholder hereby ratifies and confirms and undertakes to ratify and confirm all that the Chargee or any Proxy Holder may lawfully do or cause to be done by virtue hereof.

If at any time this proxy shall or for any reason be ineffective or unenforceable or fail to provide the Chargee with the rights or the control over the Shareholder's shares of the Company purported to be provided herein, the Shareholder shall execute a replacement instrument which provides the Chargee with substantially the same control over the Company as contemplated herein. This irrevocable proxy shall be governed by the laws of the Cayman Islands and the Shareholder irrevocably submits to the jurisdiction of the courts of the Cayman Islands in relation to the matters contained herein.

IN WITNESS whereof this Deed is duly executed and delivered the day and year first before written.

SIGNED as a DEED by)
By [Name of Authorised Signatory],)
authorised signatory for) _____
[Name])
in the presence of:)

Name: _____
[Name of witness]

Address:

Occupation:

28

SCHEDULE 3

LETTER OF RESIGNATION AND RELEASE

To: [Name and address of Company]

And to: Codan Trust Company (Cayman) Limited

Cricket Square, Hutchins Drive

PO Box 2681 GT

George Town, Grand Cayman

Cayman Islands

I, [Name of Director], hereby tender my resignation as a Director [and [other office]] of China Cord Blood Corporation with effect from the date [of this letter/that this letter is received by the Company at its registered office].

I confirm that I have no claims or rights of action against the Company whether for damages or for compensation for loss of office.

[NAME]

Director

Date: _____

29

AUTHORITY TO DATE LETTER OF RESIGNATION AND RELEASE

TO: [NAME AND ADDRESS OF CHARGE]

I, [NAME OF DIRECTOR], hereby irrevocably authorise any officer or agent of Golden Meditech Stem Cells (BVI) Limited at any time to date and submit the attached letter of resignation on my behalf.

Executed and delivered as a deed this [date]

[NAME]

Director

Witness signature: _____

Witness name: _____

30

Dated this []

B E T W E E N :

[]

(as Chargor)

AND

GOLDEN MEDITECH STEM CELLS (BVI) LIMITED

(as Chargee)

AND

CHINA CORD BLOOD CORPORATION

**SHARE CHARGE over
shares representing
[34.6%] of the issued
share capital of China
Cord Blood
Corporation**

TABLE OF CONTENTS

1.	INTERPRETATION	1
2.	COMPANY'S REPRESENTATIONS AND WARRANTIES	4
3.	CHARGOR'S COVENANTS	5
4.	COMPANY'S COVENANTS	6
5.	SECURITY	8
6.	DEALINGS WITH CHARGED PROPERTY	9
7.	PRESERVATION OF SECURITY	10
8.	ENFORCEMENT OF SECURITY	13
9.	FURTHER ASSURANCES	16
10.	INDEMNITIES	17
11.	POWER OF ATTORNEY	17
12.	EXPENSES	18
13.	NOTICES	19
14.	ASSIGNMENTS	20
15.	MISCELLANEOUS	20
16.	LAW AND JURISDICTION	21
17.	CONTRACTS (RIGHTS OF THIRD PARTIES) LAW, 2014	22

BETWEEN:

- (A) China Cord Blood Corporation, a company incorporated under the laws of the Cayman Islands and having its registered office at Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman KY1-1111, the Cayman Islands (the “Company”);
- (B) [], a company incorporated under the laws of [] and having its registered office at [] (the “Chargor”); and
- (C) Golden Meditech Stem Cells (BVI) Limited, a company incorporated under the laws of the British Virgin Islands and having its registered office at [Offshore Incorporations Limited, PO Box 957, Offshore Incorporations Centre, Road Town, Tortola, British Virgin Islands] (the “Chargee”).

WHEREAS:

- (A) By the Sale Agreement made between the Chargor, as buyer, and the Chargee as seller, the Chargee has agreed to sell to the Chargor the Charged Shares on the terms and conditions therein set out.
- (B) As security for the Secured Obligations, the Chargor has agreed to charge, inter alia, its interest in all of the Charged Shares registered in the name of the Chargor in the Company.
- (C) The Company has an authorised share capital of US\$[amount] consisting of [number] shares having a par value of US\$[0.0001] and, as of the Acquisition Date, [] of which will be in issue, fully paid, owned by the Chargor, and registered in the name of the Chargor.
- (D) It is a condition precedent to the Chargee selling the Charged Shares to the Chargor that the Chargor shall execute this Charge in favour of the Chargee and the same is executed by the Chargor in consideration of the Chargee agreeing to sell the Charged Shares to the Chargee and for other good and valuable consideration (the sufficiency of which the Company and the Chargor hereby acknowledge).

NOW THIS CHARGE WITNESSES as follows:

1. INTERPRETATION

1.1 In this Charge, unless the context otherwise requires, the following words and expressions shall have the following meanings:

1

“Acquisition Date”	means the date of completion of the purchase of the Charged Shares by the Chargor under the Sale Agreement;
“Business Day”	has the same meaning as in the Sale Agreement;
“Charge”	means this share charge;
“Charged Property”	means all of the Charged Shares and all dividends or other distributions, interest and other moneys paid or payable after the date hereof in connection therewith and all interests in and all rights accruing at any time to or in respect of all or any of the Charged Shares and all and any other property that may at any time be received or receivable by or otherwise distributed to the Chargor in respect of or in substitution for, or in addition to, or in exchange for, or on account of, any of the foregoing, including, without limitation, any shares or other securities resulting from the sub-division, consolidation, change, conversion or reclassification of any of the Charged Shares, or the reorganization, merger, or amalgamation of the Company with any other body corporate, or the occurrence of any event which results in the substitution or exchange of the Charged Shares;
“Charged Shares”	means [] shares of the Company, registered in the name of the Chargor as legal and beneficial owner thereof on the Acquisition Date;
“Contemporaneous SPA”	means a conditional sale agreement relating to the sale by the Chargee and the purchase by the Chargor of shares representing [65.4%] of the issued share capital of the Company, made between (i) the Chargee, as seller, (ii) the Chargor, as buyer, and (iii) Golden Meditech Holdings Limited, as guarantor dated [6] January 2016, as amended, restated or supplemented in any manner whatsoever from time to time;

2

“Event of Default”	means (i) any breach by the Chargor of any of the provisions of this Charge, or (ii) the occurrence of any event which gives rise to the Chargee’s rights and remedies under clause 9.2(2)(b) of the Sale Agreement;
“Parties”	means the parties to this Charge collectively; “Party” means any one of them;
“Sale Agreement”	means a conditional sale agreement relating to the sale by the Chargee and the purchase by the Chargor of the Charged Shares made between (i) the Chargee, as seller, (ii) the Chargor, as buyer, and (iii) Golden Meditech Holdings Limited, as guarantor dated [6] January 2016, as amended, restated or supplemented in any manner whatsoever from time to;

“Secured Obligations”	means (i) all of the present and future payment obligations of the Chargor under the Sale Agreement, and (ii) all of the present and future payment and other obligations of the Chargor under this Charge;
“Security Interest”	means any charge, mortgage, pledge, lien, security interest or other encumbrance; and
“Security Period”	means the period commencing on the Acquisition Date and terminating upon discharge of the security created by this Charge by payment in full or other satisfaction in their entirety of the Secured Obligations.

1.2 In this Charge unless the context otherwise requires:

- (a) references to statutory provisions shall be construed as references to those provisions as amended or re-enacted or as their application is modified by other provisions from time to time and shall include references to any provisions of which they are re-enactments (whether with or without modification);
- (b) references to clauses and schedules are references to clauses hereof and schedules hereto; references to sub-clauses or paragraphs are, unless

3

otherwise stated, references to sub-clauses of the clauses hereof or paragraphs of the schedule in which the reference appears;

- (c) references to the singular shall include the plural and vice versa and references to the masculine shall include the feminine and/or neuter and vice versa;
- (d) references to persons shall include companies, partnerships, associations and bodies of persons, whether incorporated or unincorporated;
- (e) references to assets include property, rights and assets of every description; and
- (f) references to any document are to be construed as references to such document as amended, restated or supplemented in any manner whatsoever from time to time.

2. CHARGOR’S REPRESENTATIONS AND WARRANTIES

The Chargor hereby represents and warrants to the Chargee that:

- 2.1 The shares of the Company are as described in Recital (C) hereof and such shares are registered as described in the said recital;
- 2.2 The Company is an exempted company duly incorporated, validly existing and in good standing under the laws of the Cayman Islands;
- 2.3 The Company is not a land holding corporation for the purposes of the Land Holding Company Share Transfer Tax Law of the Cayman Islands;
- 2.4 Other than pursuant to the provisions of, or as contemplated by, or as required to give effect to the provisions of Sale Agreement or the Contemporaneous SPA, the Company is under no obligation, nor is it liable to become under any obligation, to issue any further shares;
- 2.5 Without limiting the generality of the foregoing clause, the Company has not created any option to acquire shares in the Company nor any securities exchangeable for or convertible into shares of the Company;
- 2.6 Each of the Chargor and the Company has full power and authority (i) to execute and deliver this Charge and (ii) to comply with the provisions of, and perform all its obligations under, this Charge;
- 2.7 This Charge constitutes the Chargor and the Company’s legal, valid and binding obligations enforceable against the Chargor and the Company in accordance

4

with its terms except as such enforcement may be limited by any relevant bankruptcy, insolvency, administration or similar laws affecting creditors’ rights generally;

- 2.8 The entry into and performance by the Chargor and the Company of this Charge does not violate (i) any law or regulation of any governmental or official authority, or (ii) any agreement, contract or other undertaking to which the Chargor or the Company is a party or which is binding upon the Chargor or the Company or any of its respective assets;
- 2.9 All consents, licences, approvals and authorisations required in connection with the entry into, performance, validity and enforceability of this Charge have been obtained and are in full force and effect; and
- 2.10 The Chargor or the Company has each taken all corporate and other action required to approve its execution, delivery and performance of this Charge.

3. CHARGOR’S COVENANTS

The Chargor hereby covenants with the Chargee:

- 3.1 That the Chargor will, on demand of the Chargee and at the expense of the Chargor, execute and deliver to the Chargee or to such person or persons as the Chargee may nominate, such additional charge or charges of the Charged Property (or any part thereof) for the purpose of further securing the payment and discharge of all Secured Obligations, each such additional charge to be in such form as the Chargee may reasonably require;
- 3.2 That the Chargor shall, on request of the Chargee, provide to the Chargee immediately on receipt by the Chargor a copy of all notices, written consents, reports, accounts, circulars and other communications issued by the Company or by any third party in respect of the Charged Shares;
- 3.3 That the Chargor will not without the prior written consent of the Chargee:
- (a) permit any person other than the Chargor, the Chargee or any transferee nominated by the Chargee on enforcement of this Charge to be the registered holder of any of the Charged Shares;
 - (b) permit any variation of the rights attaching to the Charged Shares;
 - (c) take or permit any action which might result in an increase or reduction in the authorised issued share capital of the Company;

5

- (d) effect or permit the Company to be continued to another jurisdiction outside of the Cayman Islands;
 - (e) effect or permit the appointment of any new or further directors or officers of the Company;
 - (f) effect or permit any scheme of arrangement, merger, consolidation, or other reorganisation applicable to the Company; or
 - (g) permit any amendment to the memorandum or articles of association of the Company.
- 3.4 That the Chargor shall (i) procure that there is entered a statement on the register of members of the Company on the Acquisition Date as follows: “the [] shares held in the name of [Chargor] as represented by share certificate [] have been charged by it to Golden Meditech Stem Cells (BVI) Limited (the “Chargee”) pursuant to a Share Charge dated [date] made among [Chargor] as Chargor, the Chargee and the Company.”; and (ii) make any and all such filings and/or registrations as requested by the Chargee from time to time to the extent required to ensure the full compliance with any and all applicable laws.

4. COMPANY’S COVENANTS

- 4.1 The (i) Company hereby covenants with the Chargee, and (ii) the Chargor hereby covenants with the Chargee that it will use its best efforts to procure the Company;
- (a) to pay all amounts, interest, expenses, claims, liabilities, losses, costs, duties, fees, charges or other moneys as are stated in the Sale Agreement and this Charge to be payable by the Company or to be recoverable from the Company by the Chargee (or in respect of which the Company agrees in this Charge to indemnify the Chargee) at the times and in the manner specified in the Sale Agreement and this Charge;
 - (b) to pay interest on any such amounts, interests, expenses, claims, liabilities, losses, costs, duties, fees, charges or other moneys referred to in Sub-Clause 4.1(a) from the date on which the relevant amount, interest,

6

expense, liability, loss, cost, duty, fee, charge or other money is paid or discharged by the Chargee until the date of reimbursement thereof to the Chargee (both before and after any relevant judgment) at the rate described in the Sale Agreement, such interest to be payable on demand;

- (c) to provide to the Chargee promptly on issue or, as the case may be, receipt by the Company of, a copy of all notices, written consents, reports, accounts, circulars and other communications issued by the Company or by any third party which may affect the Chargee’s Charge or Security Interest in respect of the Charged Shares;
- (d) to register all transfers of Charged Shares submitted to the Company for registration by the Chargee (or any transferee nominated by the Chargee) pursuant to the exercise of its rights under this Charge forthwith upon the submission to the Company of such transfers;
- (e) not to permit any person other than the Chargor, the Chargee or any transferee nominated by the Chargee on enforcement of this Charge to be the registered holder of any of the Charged Shares, without the prior written consent of the Chargee;
- (f) not to take or permit any action which might result in a variation of the rights attaching to the Charged Shares, without the prior written consent of the Chargee;
- (g) not to take or permit any action which might result in the Company being continued to another jurisdiction outside of the Cayman Islands, or permit or enter into any scheme of arrangement, merger, or other reorganisation applicable to the Company, without the prior written consent of the Chargee;
- (h) not to take any action which would impair or adversely affect the Chargee’s Security interest in the Charged Property and/or the effectiveness of this Charge;

- (i) to obtain and maintain in full force, validity and effect all material governmental and other approvals, authorities, licences and consents required in connection with this Charge, and to do or cause to be done all other acts and things necessary or desirable for the performance of the Company's obligations pursuant to this Charge;
- (j) following the execution of this Charge, enter a statement on the register of members of the Company in the same terms as set out in Clause 3.4 above; and

- (k) not to take any action which would result in the Security created or expressed to be created pursuant to this Charge being or becoming unlawful or not being or ceasing to be legal, valid, binding or enforceable or otherwise ceasing to be effective.

5. SECURITY

- 5.1 In consideration of the Chargee agreeing to sell the Charged Shares to the Chargor and as a continuing security for the Secured Obligations, the Chargor as legal and beneficial owner hereby assigns and agrees to assign to the Chargee all benefits, present and future, actual and contingent, accruing in respect of the Charged Property including (without limitation) any distributions, dividends or other moneys or assets accruing in respect of the Charged Shares or any part thereof) and all the Chargor's right, title and interest to and in the Charged Property including (without limitation) all voting and other consensual powers pertaining to the Charged Shares and hereby charges and agrees to charge in favour of the Chargee all of its interest in the Charged Property by way of a first fixed and floating charge.
- 5.2 The Chargor hereby agrees to deliver, or cause to be delivered, to the Chargee:
 - (a) duly executed undated share transfers in respect of the Charged Shares in favour of the Chargee or its nominees in the form set out in Schedule 1;
 - (b) all share certificates representing the Charged Shares;
 - (c) an executed irrevocable proxy made in respect of the Charged Shares in favour of the Chargee in respect of all general meetings of the Company in the form set out in Schedule 2; and
 - (d) executed but undated letters of resignation and release together with letters of authority to date the same from each of the directors, alternate directors and officers of the Company in the form set out in Schedule 3.
- 5.3 The Chargor will deliver, or cause to be delivered, to the Chargee immediately upon the issue of any further Charged Shares, the items listed in Clause 5.2(a), 5.2(b) and 5.2(c) in respect of all such further Charged Shares.
- 5.4 The Chargor will deliver, or cause to be delivered, to the Chargee immediately upon the appointment of any further director, alternate director or officer of the Company an undated, signed letter of resignation from such further director, alternate director or officer in a form acceptable to the Chargee.

- 5.5 The Chargor hereby covenants that during the Security Period it will remain the legal and beneficial owner of the Charged Property (subject only to the Security Interests hereby created) and that it will not:
 - (a) create or suffer the creation of any Security Interests (other than those created by this Charge) on or in respect of the whole or any part of the Charged Property or any of its interest therein; or
 - (b) sell, assign, transfer or otherwise dispose of any of its interest in the Charged Property;
 - (c) vote in respect of the Charged Shares or receive any dividends or other distributions paid by the Company in respect of the Charged Shares,in any such case without the prior consent in writing of the Chargee.
- 5.6 The Chargor and the Company shall remain liable to perform all the obligations assumed by each of them in relation to the Charged Property and the Chargee shall be under no obligation of any kind whatsoever in respect thereof or be under any liability whatsoever in the event of any failure by the Chargor or the Company to perform its obligations in respect thereof.
- 5.7 Upon the Chargee being satisfied that the Secured Obligations have been unconditionally and irrevocably paid and discharged in full, the Chargee will, subject to being indemnified to its reasonable satisfaction for the costs and expenses incurred by the Chargee in connection therewith, release the security constituted by this Charge within 10 Business Days from the date the Secured Obligations are unconditionally and irrevocably paid and discharged in full.

6. DEALINGS WITH CHARGED PROPERTY

- 6.1 Unless and until an Event of Default has occurred:
 - (a) the Chargor shall be entitled to exercise all voting and/or consensual powers pertaining to the Charged Property or any part thereof for all purposes not inconsistent with the terms of this Charge and/or the Sale Agreement;

- (b) the Chargor shall be entitled to receive and retain any dividends, interest or other moneys or assets accruing on or in respect of the Charged Property or any part thereof; and
- (c) the Chargor shall be entitled to receive all notices pertaining to the Charged Shares.

- 6.2 The Chargor shall pay all calls, instalments or other payments, and shall discharge all other obligations, which may become due in respect of any of the Charged Property and in an Event of Default, the Chargee may if it thinks fit make such payments or discharge such obligations on behalf of the Chargor. Any sums so paid by the Chargee in respect thereof shall be repayable on demand and pending such repayment shall constitute part of the Secured Obligations.
- 6.3 The Chargee shall not have any duty to ensure that any dividends, distributions interest or other moneys and assets receivable in respect of the Charged Property are duly and punctually paid, received or collected as and when the same become due and payable or to ensure that the correct amounts (if any) are paid or received on or in respect of the Charged Property or to ensure the taking up of any (or any offer of any) stocks, shares, rights, moneys or other property paid, distributed, accruing or offered at any time by way of redemption bonus, rights, preference, or otherwise on or in respect of, any of the Charged Property.
- 6.4 The Chargor hereby authorises the Chargee to arrange at any time and from time to time (whether before or after the occurrence of an Event of Default) for the Charged Property or any part thereof to be registered in the name of the Chargee (or its nominee) thereupon to be held as so registered subject to the terms of this Charge.

7. PRESERVATION OF SECURITY

- 7.1 It is hereby agreed and declared that:
 - (a) the Security Interest created by this Charge shall be held by the Chargee as a continuing security for the payment and discharge of the Secured Obligations and the security so created shall not be satisfied by any intermediate payment or satisfaction of any part of the Secured Obligations;
 - (b) the Security Interest so created shall be in addition to and shall not in any way be prejudiced or affected by any of the other [Security Documents];
 - (c) the Chargee shall not be bound to enforce any other security before enforcing the security created by this Charge;
 - (d) no delay or omission on the part of the Chargee in exercising any right, power or remedy under this Charge shall impair such right, power or remedy or be construed as a waiver thereof nor shall any single or partial exercise of any such right, power or remedy preclude any further exercise thereof or the exercise of any other right, power or remedy. The rights,

powers and remedies herein provided are cumulative and not exclusive of any rights, powers and remedies provided by law and may be exercised from time to time and as often as the Chargee may deem expedient; and

- (e) any waiver by the Chargee of any terms of this Charge shall only be effective if given in writing and then only for the purpose and upon the terms for which it is given.
- 7.2 Any settlement or discharge under this Charge between the Chargee and the Chargor shall be conditional upon no security or payment to the Chargee by the Company or the Chargor or any other person being avoided or set-aside or ordered to be refunded or reduced by virtue of any provision or enactment relating to bankruptcy, insolvency, administration or liquidation for the time being in force and, if such condition is not satisfied, the Chargee shall be entitled to recover from the Chargor on demand the value of such security or the amount of any such payment as if such settlement or discharge had not occurred.
- 7.3 The rights of the Chargee under this Charge and the security hereby constituted shall not be affected by any act, omission, matter or thing which, but for this provision, might operate to impair, affect or discharge such rights and security, in whole or in part, including without limitation, and whether or not known to or discoverable by the Company, the Chargor, the Chargee or any other person:
 - (a) any time or waiver granted to or compromise with the Company or any other person;
 - (b) the taking, variation, compromise, renewal or release of or refusal or neglect to perfect or enforce any rights, remedies or securities against the Company or any other person;
 - (c) any legal limitation, disability, incapacity or other circumstances relating to the Company or any other person;
 - (d) any amendment or supplement to the Sale Agreement, the other Security Documents or any other document or security;
 - (e) the dissolution, liquidation, merger, consolidation, reconstruction or reorganisation of the Company or any other person; or
 - (f) the unenforceability, invalidity or frustration of any obligations of the Company or any other person under the Sale Agreement, the other Security Documents or any other document or security.

- 7.4 Until the Secured Obligations have been unconditionally and irrevocably satisfied and discharged in full to the satisfaction of the Chargee, the Chargor shall not by virtue of any payment made hereunder on account of the Secured Obligations or by virtue of any enforcement by the Chargee of its rights under, or the security constituted by, this Charge or by virtue of any relationship between or transaction involving the Chargor and the Company (whether such relationship or transaction shall constitute the Chargor a creditor of the Company, a guarantor of the obligations of the Company or a party subrogated to the rights of others against the Company or otherwise howsoever and whether or not such relationship or transaction shall be related to, or in connection with, the subject matter of this Charge):
- (a) exercise any rights of subrogation in relation to any rights, security or moneys held or received or receivable by the Chargee or any person;
 - (b) exercise any right of contribution from any co-surety liable in respect of such moneys and liabilities under any other guarantee, security or agreement;
 - (c) exercise any right of set-off or counterclaim against the Company or any such co-surety;
 - (d) receive, claim or have the benefit of any payment, distribution, security or indemnity from the Company or any such co-surety; or
 - (e) unless so directed by the Chargee (when the Chargor will prove in accordance with such directions), claim as a creditor of the Company or any such co-surety in competition with the Chargee.
- 7.5 The Chargor shall hold in trust for the Chargee and forthwith pay or transfer (as appropriate) to the Chargee any such payment (including an amount equal to any such set-off), distribution or benefit of such security, indemnity or claim in fact received by it.
- 7.6 Until the Secured Obligations have been unconditionally and irrevocably satisfied and discharged in full to the satisfaction of the Chargee, the Chargee may at any time keep in a separate account or accounts (without liability to pay interest thereon) in the name of the Chargee for as long as it may think fit, any moneys received, recovered or realised under this Charge or under any other guarantee, security or agreement relating in whole or in part to the Secured Obligations without being under any immediate obligation to apply the same or any part thereof in or towards the discharge of such amount.

8. ENFORCEMENT OF SECURITY

- 8.1 Upon the expiry of 30 calendar days following the giving by the Chargee to the Chargor of written notice of the enforcement of this Charge following the occurrence of an Event of Default, the security hereby constituted shall become immediately enforceable and the Chargee may, at any time following the expiry of such 30 calendar day period, without further notice to, or consultation with, or the consent of, the Chargor:
- (a) solely and exclusively exercise all voting and/or consensual powers pertaining to the Charged Property or any part thereof and may exercise such powers in such manner as the Chargee may think fit; and/or
 - (b) remove the then existing directors and officers (with or without cause) by dating and presenting the undated, signed letters of resignation delivered pursuant to this Charge; and/or
 - (c) receive and retain all dividends, interest, distributions or other moneys or assets accruing on or in respect of the Charged Property or any part thereof, such dividends, interest, distributions or other moneys or assets to be held by the Chargee, until applied in the manner described in Sub-Clause 8.4, as additional security charged under and subject to the terms of this Charge and any such dividends, interest, distributions or other moneys or assets received by the Chargor after such time shall be held in trust by the Chargor for the Chargee and paid or transferred to the Chargee on demand; and/or
 - (d) appoint by instrument any person to be a receiver of the Charged Property (the "Receiver") and remove any Receiver so appointed and appoint another or others in his stead; and/or
 - (e) sell, transfer, grant options over or otherwise dispose of the Charged Property or any part thereof at such place and in such manner and at such price or prices as the Chargee may deem fit, and thereupon the Chargee shall have the right to deliver, assign and transfer in accordance therewith the Charged Property so sold, transferred, granted options over or otherwise disposed of; and/or
 - (f) complete any undated blank share transfer forms of all or any part of the Charged Property by dating the same and/or inserting its name or the name of its nominee as transferee.
- 8.2 The Chargee shall not be obliged to make any enquiry as to the nature or sufficiency of any payment received by it under this Charge or to make any claim

or to take any action to collect any moneys assigned by this Charge or to enforce any rights or benefits assigned to the Chargee by this Charge or to which the Chargee may at any time be entitled hereunder.

- 8.3 Upon any sale of the Charged Property or any part thereof by the Chargee the purchaser shall not be bound to see or enquire whether the Chargee's power of sale has become exercisable in the manner provided in this Charge and the sale shall be deemed to be within the power of the Chargee, and

the receipt of the Chargee for the purchase money shall effectively discharge the purchaser who shall not be concerned with the manner of application of the proceeds of sale or be in any way answerable therefor.

- 8.4** All moneys received by the Chargee pursuant to this Charge shall be held in the first place to pay or make good all such expenses, liabilities, losses, costs, duties, fees, charges or other moneys whatsoever as may have been paid or incurred by the Chargee in exercising any of the powers specified or otherwise referred to in this Charge and the balance shall be applied in the following manner:
- (a) **FIRSTLY:** in or towards satisfaction of any amounts in respect of the balance of the Secured Obligations as are then accrued due and payable or are then due and payable by virtue of payment demanded, in such order or application as the Chargee shall think fit;
 - (b) **SECONDLY:** in retention of an amount equal to any part or parts of the Secured Obligations as are or are not then due and payable but which (in the sole and absolute opinion of the Chargee) will or may become due and payable in the future and, upon the same becoming due and payable, in or towards satisfaction thereof in accordance with the foregoing provisions of this Sub-Clause 8.4; and
 - (c) **THIRDLY:** the surplus (if any) shall be repaid promptly to the Chargor or whosoever else may be entitled thereto.
- 8.5** Neither the Chargee nor its agents, managers, officers, employees, delegates or advisers shall be liable for any claim, demand, liability, loss, damage, cost or expense incurred or arising in connection with the exercise or purported exercise of any rights, powers and discretions hereunder [in the absence of fraud or dishonesty; however, in no event shall the Chargee be liable for consequential damages.
- 8.6** The Chargee shall not by reason of the taking of possession of the whole or any part of the Charged Property hereof be liable to account as mortgagee-in-possession or for anything except actual receipts or be liable for any loss upon

14

realisation or for any default or omission for which a mortgagee-in-possession might be liable.

- 8.7** In addition to all other rights or powers vested in the Chargee hereunder or by statute or otherwise, the Receiver may take such action in relation to the enforcement of this Charge to:
- (a) take possession of, redeem, collect and get in all or any part of the Charged Property;
 - (b) raise or borrow money and grant security therefor over all or any part of the Charged Property;
 - (c) appoint an attorney or accountant or other professionally qualified person to assist him in the performance of his functions;
 - (d) do all acts and to execute in the name and on behalf of the Chargor any document or deed in respect of all or any part of the Charged Property;
 - (e) in the name of the Chargor or in his own name, bring, prosecute, enforce, defend and abandon applications, claims, disputes, actions, suits and proceedings in connection with all or any part of the Charged Property and to submit to arbitration, negotiate, compromise and settle any such applications, claims, disputes, actions, suits or proceedings;
 - (f) sell, call in, collect and convert to money the Charged Property or any of it at such place and in such manner and at such price or prices as he shall think fit;
 - (g) exercise any powers, discretion, voting or other rights or entitlements in relation to the Charged Property and generally to carry out any other action which he may in his sole discretion deem appropriate in relation to the enforcement of this Charge;
 - (h) make any arrangement or compromise which he shall think expedient; and
 - (i) do all such other acts and things as may be considered to be incidental or conducive to any of the matters or powers aforesaid and which the Receiver lawfully may or can do as agent for the Chargor.
- 8.8** Every Receiver shall, so far as it concerns responsibility for his acts, be deemed to be an agent of the Chargor, which shall be solely responsible for his acts and defaults and for the payment of his remuneration and no Receiver shall at any time act as agent for the Chargee.

15

- 8.9** Every Receiver shall be entitled to remuneration for his services at a rate to be fixed by agreement between him and the Chargee (or, failing such agreement, to be fixed by the Chargee) appropriate to the work and responsibilities involved, upon the basis of current industry practice.

9. FURTHER ASSURANCES

- 9.1** The Chargor shall execute and do all such assurances, acts and things as the Chargee in its absolute discretion may require for:
- (a) perfecting, protecting or ensuring the priority of the Security Interest hereby created (or intended to be created);
 - (b) preserving or protecting any of the rights of the Chargee under this Charge;
 - (c) ensuring that the security constituted by this Charge and the covenants and obligations of the Chargor under this Charge shall inure to the benefit of any assignee of the Chargee;

(d) facilitating the appropriation or realisation of the Charged Property or any part thereof; or

(e) exercising any power, authority or discretion vested in the Chargee under this Charge,

in any such case forthwith upon demand by the Chargee and at the expense of the Chargor.

9.2 Without limitation to the generality of Sub-Clause 9.1, the Chargor covenants with the Chargee that it will on demand of the Chargee [use its best endeavours to] procure any amendment to the memorandum and articles of association of the Company necessary or, in the opinion of the Chargee desirable, in order to give effect to the terms of this Charge or any documents or transactions provided for herein.

9.3 The Chargor shall provide such assurances and do all acts and things the Receiver may in his absolute discretion require for the purpose of exercising the powers (or giving effect to the exercise of the powers) conferred on the Receiver hereunder and the Chargor hereby irrevocably appoints the Receiver to be the lawful attorney in fact of the Chargor to do any act or thing and to exercise all the powers of the Chargor for the purpose of exercising the powers (or giving effect to the exercise of the powers) conferred on the Receiver hereunder.

16

10. INDEMNITIES

10.1 The Chargor will indemnify and hold harmless the Chargee, the Receiver and each agent or attorney appointed under or pursuant to this Charge from (each an “**Indemnitee**”) and against any and all expenses, claims, liabilities, losses, taxes, costs, duties, fees and charges properly and reasonably suffered, incurred or made by the Chargee, the Receiver or such agent or attorney:

(a) in the exercise or purported exercise of any rights, powers or discretions vested in them pursuant to this Charge;

(b) in the preservation or enforcement of the Chargee’s rights under this Charge or the priority thereof; or

(c) on the release of any part of the Charged Property from the security created by this Charge,

and the Chargee, the Receiver or such agent or attorney may retain and pay all sums in respect of the same out of money received under the powers conferred by this Charge. All amounts recoverable by the Chargee, the Receiver or such agent or attorney or any of them shall be recoverable on a full indemnity basis.

10.2 If, under any applicable law or regulation, and whether pursuant to a judgment being made or registered against the Chargor or the bankruptcy or liquidation of the Chargor or for any other reason any payment under or in connection with this Charge is made or falls to be satisfied in a currency (the “**Payment Currency**”) other than the currency in which such payment is due under or in connection with this Charge (the “**Contractual Currency**”), then to the extent that the amount of such payment actually received by the Chargee when converted into the Contractual Currency at the rate of exchange, falls short of the amount due under or in connection with this Charge, the Chargor, as a separate and independent obligation, shall indemnify and hold harmless the Chargee against the amount of such shortfall. For the purposes of this Clause, “**rate of exchange**” means the rate at which the Chargee is able on or about the date of such payment to purchase the Contractual Currency with the Payment Currency and shall take into account any premium and other costs of exchange with respect thereto.

11. POWER OF ATTORNEY

11.1 The Chargor, by way of security and in order more fully to secure the performance of its obligations hereunder hereby irrevocably appoints the Chargee and the persons deriving title under it jointly and also severally to be its attorney:

17

(a) to execute and complete in favour of the Chargee or its nominees or of any purchaser any documents which the Chargee may from time to time require for perfecting its title to or for vesting any of the assets and property hereby charged or assigned in the Chargee or its nominees or in any purchaser and to give effectual discharges for payments;

(b) to take and institute on non-payment (if the Chargee in its sole discretion so decides) all steps and proceedings in the name of the Chargor or of the Chargee for the recovery of such moneys, property and assets hereby charged and to agree accounts;

(c) to act as the Chargor’s corporate representative (and/or to appoint any officer or nominee of the Chargee for such purpose) to represent the Chargor at any general meeting of the members of the Company and to sign any resolution in writing of the members of the Company or to requisition or convene general meetings of the Company or to waive or consent to short notice of such in that capacity;

(d) to make allowances and give time or other indulgence to any surety or other person liable;

(e) otherwise generally to act for it and in its name and on its behalf; and

(f) to sign, execute, seal and deliver and otherwise perfect and do any such legal assignments and other assurances, charges, authorities and documents over the moneys, property and assets hereby charged, and all such deeds, instruments, acts and things (including, without limitation, those referred to in Clause 9) which may be required for the full exercise of all or any of the powers conferred or which may be deemed proper on or in connection with any of the purposes aforesaid.

11.2 The power hereby conferred shall be a general power of attorney and the Chargor hereby ratifies and confirms and agrees to ratify and confirm any instrument, act or thing which any such attorney may execute or do. In relation to the power referred to herein, the exercise by the Chargee of such

power shall be conclusive evidence of its right to exercise the same.

12. EXPENSES

12.1 The Chargor shall pay to the Chargee on demand all costs, fees and expenses (including, but not limited to, legal fees and expenses) and taxes thereon incurred by the Chargee or for which the Chargee may become liable in connection with:

(a) the negotiation, preparation and execution of this Charge;

18

(b) the preserving or enforcing of, or attempting to preserve or enforce, any of its rights under this Charge or the priority hereof;

(c) any variation of, or amendment or supplement to, any of the terms of this Charge; and/or

(d) any consent or waiver required from the Chargee in relation to this Charge,

and in any case referred to in Paragraphs (c) and (d) regardless of whether the same is actually implemented, completed or granted, as the case may be.

12.2 The Chargor shall pay promptly any stamp, documentary and other like duties and taxes to which this Charge may be subject or give rise and shall indemnify the Chargee on demand against any and all liabilities with respect to or resulting from any delay or omission on the part of the Chargor to pay any such duties or taxes.

13. NOTICES

13.1 Any notice required to be given hereunder shall be in writing in the English language and shall be served by sending the same by prepaid recorded post, facsimile or by delivering the same by hand to the address of the Party or Parties in question as set out below (or such other address as such Party or Parties shall notify the other Parties of in accordance with this Clause). Any notice sent by post as provided in this Clause shall be deemed to have been served five Business Days after despatch and any notice sent by facsimile as provided in this Clause shall be deemed to have been served at the time of despatch and in proving the service of the same it will be sufficient to prove in the case of a letter that such letter was properly stamped, addressed and placed in the post; and in the case of a facsimile that such facsimile was duly despatched to a current facsimile number of the addressee.

Chargor

Name:

Address:

Fax:

Chargee:

19

Name:

Address:

Fax:

Company:

Name:

Address:

Fax:

14. ASSIGNMENTS

14.1 This Charge and all non-contractual obligations arising out of or in connection with it shall be binding upon and shall inure to the benefit of the Chargor and the Chargee and each of their respective successors and (subject as hereinafter provided) assigns and references in this Charge to any of them shall be construed accordingly.

14.2 The Chargor may not assign or transfer all or any part of its rights and/or obligations under this Charge.

14.3 The Chargee may assign or transfer all or any part of its rights or obligations under this Charge to any assignee or transferee without the consent of the Chargor, such consent not to be unreasonably withheld, provided that no such consent shall be required if an Event of Default affecting the

Chargor has occurred and is continuing. The Chargee shall notify the Chargor promptly following any such assignment or transfer.

15. MISCELLANEOUS

15.1 The Chargee, at any time and from time to time, may delegate by power of attorney or in any other manner to any person or persons all or any of the powers, authorities and discretions which are for the time being exercisable by the Chargee under this Charge in relation to the Charged Property or any part thereof. Any such delegation may be made upon such terms and be subject to such regulations as the Chargee may think fit. The Chargee shall not be in any way liable or responsible to the Chargor for any loss or damage arising from any

act, default, omission or misconduct on the part of any such delegate provided the Chargee has acted reasonably in selecting such delegate.

15.2 This Charge, including its Schedules and together with any documents referred to herein, contains the whole agreement between the Parties in respect of the subject matter of this Charge and supersedes and replaces any prior written or oral agreements, representations or understandings between them relating to such subject matter. The Parties confirm that they have not entered into this Charge on the basis of any representation that is not expressly incorporated into this Charge. Without limiting the generality of the foregoing, no Party shall have any remedy in respect of any untrue statement made to him upon which he may have relied in entering into this Charge, and a Party's only remedy is for breach of contract. However, nothing in this Charge purports to exclude liability for any fraudulent statement or act.

15.3 No variations of this Charge shall be effective unless made in writing and signed by each of the Parties.

15.4 The headings in this Charge are inserted for convenience only and shall not affect the construction of this Charge.

15.5 This Charge may be executed in counterparts each of which when executed and delivered shall constitute an original but all such counterparts together shall constitute one and the same instrument.

15.6 If any of the Clauses, Sub-Clauses, Paragraphs, conditions, covenants or restrictions of this Charge or any deed or document emanating from it shall be found to be void but would be valid if some part thereof were deleted or modified, then such Clause, Sub-Clause, Paragraph, condition, covenant or restriction shall apply with such deletion or modification as may be necessary to make it valid and effective.

16. LAW AND JURISDICTION

16.1 This Charge shall be governed by and construed in accordance with the laws of the Cayman Islands and the Parties hereby irrevocably submit to the non-exclusive jurisdiction of the courts of the Cayman Islands, provided that nothing in this Clause shall affect the right of the Chargee to serve process in any manner permitted by law or limit the right of the Chargee to take proceedings with respect to this Charge against the Chargor in any jurisdiction nor shall the taking of proceedings with respect to this Charge in any jurisdiction preclude the Chargee from taking proceedings with respect to this Charge in any other jurisdiction, whether concurrently or not.

17. RIGHTS UNDER THE CONTRACTS (RIGHTS OF THIRD PARTIES) LAW, 2014

17.1 The parties hereby agree that each Indemnitee who is not a party to this Agreement (a "**Third Party**") has the express right to enforce the contractual terms of this agreement pursuant to the terms of The Contracts (Rights of Third Parties) Law, 2014. However, no Third Party may bring any action to enforce its rights under this agreement without the prior written consent of the Chargee, which may be withheld at the sole discretion of Party A.

17.2 The consent of each Third Party is not required for any rescission or variation of this agreement agreed to by the Parties hereto.

IN WITNESS whereof the Parties have caused this Charge to be duly executed as a Deed the day and year first before written.

The **Common Seal** of)
[**Company**]) [Affix seal]
was affixed hereto)
in the presence of:

Name: _____
Signature of Legal Representative
(or Authorized Representative)

The **Common Seal** of)
China Cord Blood Corporation) was affixed hereto

)
in the presence of:

Name: _____
[Name of person attesting]

24

The **Common Seal** of)
Golden Meditech Stem)
Cells (BVI) Limited) [Affix seal]
was affixed hereto)
in the presence of:)

Name: _____
[Name of person attesting]

25

SCHEDULE 1
SHARE TRANSFER FORM

26

SCHEDULE 2
IRREVOCABLE PROXY
IRREVOCABLE PROXY

I/We, [] of [] (the "Shareholder") being the holder of [number] shares of China Cord Blood Corporation, a Cayman Islands exempted company (the "Company"), hereby appoint(s) each and every officer of the Chargee (as defined in the Share Charge dated [] made between the Shareholder, the Company and Golden Meditech Stem Cells (BVI) Limited (the "Share Charge")) from time to time (the "Proxy Holders") the true and lawful attorney and proxy of the Shareholder for and in the Shareholder's name, place and stead to attend all meetings of the shareholders of the Company and to vote at a meeting any and all shares in the Company at the time standing in the Shareholder's name and to exercise all consensual rights in respect of such shares (including without limitation giving or withholding written consents of shareholders and calling special general meetings of shareholders) upon and during the continuance of an Event of Default (as defined in the Share Charge).

The Shareholder hereby affirms that this proxy is given pursuant to Clause 4 of the Share Charge. **THIS PROXY IS COUPLED WITH AN INTEREST AND IS IRREVOCABLE.**

The Shareholder hereby ratifies and confirms and undertakes to ratify and confirm all that the Chargee or any Proxy Holder may lawfully do or cause to be done by virtue hereof.

If at any time this proxy shall or for any reason be ineffective or unenforceable or fail to provide the Chargee with the rights or the control over the Shareholder's shares of the Company purported to be provided herein, the Shareholder shall execute a replacement instrument which provides the Chargee with substantially the same control over the Company as contemplated herein. This irrevocable proxy shall be governed by the laws of the Cayman Islands and the Shareholder irrevocably submits to the jurisdiction of the courts of the Cayman Islands in relation to the matters contained herein.

IN WITNESS whereof this Deed is duly executed and delivered the day and year first before written.

27

SIGNED as a **DEED** by)
By [Name of Authorised Signatory],)
authorised signatory for)
[Name])
in the presence of:)

Name: _____

[Name of witness]

Address:

Occupation:

28

SCHEDULE 3

LETTER OF RESIGNATION AND RELEASE

To: [Name and address of Company]

And to: Codan Trust Company (Cayman) Limited

Cricket Square, Hutchins Drive

PO Box 2681 GT

George Town, Grand Cayman

Cayman Islands

I, [Name of Director], hereby tender my resignation as a Director [and [other office]] of China Cord Blood Corporation with effect from the date [of this letter/that this letter is received by the Company at its registered office].

I confirm that I have no claims or rights of action against the Company whether for damages or for compensation for loss of office.

[NAME]

Director

Date: _____

29

AUTHORITY TO DATE LETTER OF RESIGNATION AND RELEASE

TO: [NAME AND ADDRESS OF CHARGEE]

I, [NAME OF DIRECTOR], hereby irrevocably authorise any officer or agent of Golden Meditech Stem Cells (BVI) Limited at any time to date and submit the attached letter of resignation on my behalf.

Executed and delivered as a deed this [date]

[NAME]

Director

Witness signature: _____

Witness name: _____

30
